20-F 1 snn-20231231x20f.htm 20-F
00008459822023FYfalseSmith & Nephew plctrue0.3020.2550.5980.3010.2550.5970.3020.2550.5980.3010.2550.5970.8280.8180.8090.8270.8160.808P20YP50YP3YP7YP3YP7YP2Y00000000000.2310.2310.2310.1440.1440.14400000845982snn:NotesDue2030Member2023-01-012023-12-310000845982snn:NotesDue2029Member2023-01-012023-12-310000845982dei:AdrMember2023-01-012023-12-310000845982ifrs-full:OrdinarySharesMember2023-01-012023-12-3100008459822023-12-310000845982dei:BusinessContactMember2023-01-012023-12-3100008459822023-01-012023-12-310000845982ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember2023-01-012023-12-310000845982ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember2023-01-012023-12-310000845982ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember2023-01-012023-12-310000845982ifrs-full:CurrentMember2023-01-012023-12-310000845982snn:OtherTradingTransactionsMember2023-01-012023-12-310000845982snn:OtherTradingTransactionsMember2022-01-012022-12-310000845982snn:OtherTradingTransactionsMember2021-01-012021-12-310000845982ifrs-full:ReportableSegmentsMember2023-01-012023-12-310000845982ifrs-full:ReportableSegmentsMember2022-01-012022-12-310000845982ifrs-full:ReportableSegmentsMember2021-01-012021-12-310000845982snn:NotLaterThanTenYearsMember2023-12-310000845982ifrs-full:ForwardContractMemberifrs-full:CurrencyRiskMembercurrency:USD2023-12-310000845982ifrs-full:ForwardContractMemberifrs-full:CurrencyRiskMembercurrency:EUR2023-12-310000845982snn:SportsMedicineMember2023-01-012023-12-310000845982snn:EntMember2023-01-012023-12-310000845982snn:AdvancedWoundManagementMember2023-01-012023-12-310000845982snn:SportsMedicineMember2022-01-012022-12-310000845982snn:OrthopaedicsMember2022-01-012022-12-310000845982snn:AdvancedWoundManagementMember2022-01-012022-12-310000845982snn:DefinedBenefitPensionPlansMembercountry:USsnn:TerminationOfUsPensionPlanMember2024-01-042024-01-0400008459822019-01-012019-12-310000845982snn:DefinedBenefitPensionPlansMember2023-12-310000845982snn:RestOfWorldExcludingUnitedKingdomAndUnitedStatesOfAmericaMember2023-12-310000845982country:US2023-12-310000845982country:GB2023-12-310000845982snn:RestOfWorldExcludingUnitedKingdomAndUnitedStatesOfAmericaMember2022-12-310000845982country:US2022-12-310000845982country:GB2022-12-310000845982snn:RestOfWorldExcludingUnitedKingdomAndUnitedStatesOfAmericaMember2021-12-310000845982country:US2021-12-310000845982country:GB2021-12-310000845982snn:CashAtBankMember2023-12-310000845982snn:BankOverdraftMember2023-12-310000845982snn:CashAtBankMember2022-12-310000845982snn:BankOverdraftMember2022-12-310000845982ifrs-full:InterestRateSwapContractMember2022-12-310000845982snn:CashAtBankMember2021-12-310000845982snn:BankOverdraftMember2021-12-310000845982snn:ShortTermBorrowingMember2020-12-310000845982snn:LongTermBorrowingMember2020-12-310000845982snn:CashAtBankMember2020-12-310000845982snn:BankOverdraftMember2020-12-310000845982ifrs-full:InterestRateSwapContractMember2020-12-310000845982snn:FinancialLiabilitiesTotalMemberifrs-full:WeightedAverageMemberifrs-full:FixedInterestRateMembercurrency:USD2023-01-012023-12-310000845982snn:FinancialLiabilitiesTotalMemberifrs-full:WeightedAverageMemberifrs-full:FixedInterestRateMembercurrency:USD2022-01-012022-12-310000845982snn:DefinedBenefitPensionPlansMembersnn:OtherMemberifrs-full:Level2And3OfFairValueHierarchyMember2023-12-310000845982snn:DefinedBenefitPensionPlansMembercountry:GBifrs-full:Level2And3OfFairValueHierarchyMember2023-12-310000845982snn:DefinedBenefitPensionPlansMembersnn:OtherMemberifrs-full:Level2And3OfFairValueHierarchyMember2022-12-310000845982snn:DefinedBenefitPensionPlansMembercountry:GBifrs-full:Level2And3OfFairValueHierarchyMember2022-12-310000845982snn:DefinedBenefitPensionPlansMembersnn:OtherMemberifrs-full:Level2And3OfFairValueHierarchyMember2021-12-310000845982snn:DefinedBenefitPensionPlansMembercountry:GBifrs-full:Level2And3OfFairValueHierarchyMember2021-12-310000845982srt:ScenarioForecastMember2024-01-012024-12-310000845982snn:TreasurySharesExcludingEmployeeShareTrustMember2023-01-012023-12-310000845982snn:EmployeesShareTrustMember2023-01-012023-12-310000845982ifrs-full:TreasurySharesMember2023-01-012023-12-310000845982ifrs-full:TreasurySharesMember2021-01-012021-12-310000845982ifrs-full:InterestRateSwapContractMember2023-01-012023-12-310000845982ifrs-full:InterestRateSwapContractMember2022-01-012022-12-310000845982ifrs-full:InterestRateSwapContractMember2021-01-012021-12-310000845982snn:ShortTermBorrowingMember2023-01-012023-12-310000845982snn:CashAtBankMember2023-01-012023-12-310000845982snn:BankOverdraftMember2023-01-012023-12-310000845982ifrs-full:CurrencySwapContractMember2023-01-012023-12-310000845982snn:ShortTermBorrowingMember2022-01-012022-12-310000845982snn:CashAtBankMember2022-01-012022-12-310000845982snn:BankOverdraftMember2022-01-012022-12-310000845982ifrs-full:CurrencySwapContractMember2022-01-012022-12-310000845982snn:ShortTermBorrowingMember2021-01-012021-12-310000845982snn:CashAtBankMember2021-01-012021-12-310000845982snn:BankOverdraftMember2021-01-012021-12-310000845982ifrs-full:CurrencySwapContractMember2021-01-012021-12-310000845982ifrs-full:CurrencyRiskMembercurrency:USD2023-12-310000845982ifrs-full:CurrencyRiskMembercurrency:EUR2023-12-310000845982ifrs-full:CurrencyRiskMembercurrency:EUR2022-12-310000845982snn:ShortTermBorrowingMember2023-12-310000845982snn:LongTermBorrowingMember2023-12-310000845982snn:ShortTermBorrowingMember2022-12-310000845982snn:LongTermBorrowingMember2022-12-310000845982snn:ShortTermBorrowingMember2021-12-310000845982snn:LongTermBorrowingMember2021-12-310000845982ifrs-full:AccumulatedImpairmentMember2023-01-012023-12-310000845982ifrs-full:ForwardContractMemberifrs-full:CurrencyRiskMembercurrency:USD2023-01-012023-12-310000845982ifrs-full:ForwardContractMemberifrs-full:CurrencyRiskMembercurrency:EUR2023-01-012023-12-310000845982ifrs-full:ForwardContractMemberifrs-full:CurrencyRiskMembercurrency:USD2022-01-012022-12-310000845982ifrs-full:ForwardContractMemberifrs-full:CurrencyRiskMembercurrency:EUR2022-01-012022-12-310000845982ifrs-full:InterestRateRiskMember2023-12-310000845982ifrs-full:InterestRateRiskMember2022-12-310000845982snn:CommittedBorrowingFacilitiesMember2022-12-310000845982snn:CommittedBorrowingFacilitiesMemberifrs-full:WeightedAverageMember2023-12-312023-12-310000845982ifrs-full:ForwardContractMember2023-01-012023-12-310000845982snn:DefinedBenefitPensionPlansMembercountry:USsnn:TerminationOfUsPensionPlanMembersrt:ScenarioForecastMember2024-01-012024-12-310000845982snn:DefinedBenefitPensionPlansMemberifrs-full:BottomOfRangeMember2023-01-012023-12-310000845982snn:DefinedBenefitPensionPlansMembercountry:US2023-12-012023-12-310000845982snn:ExtremityOrthopaedicsMember2023-01-012023-12-310000845982snn:EngageSurgicalMember2023-01-012023-12-310000845982snn:DefinedBenefitPensionPlansMemberifrs-full:TopOfRangeMember2023-12-310000845982snn:DefinedBenefitPensionPlansMemberifrs-full:WhollyUnfundedDefinedBenefitPlansMembersnn:OtherMember2023-12-310000845982snn:RetirementHealthcareMemberifrs-full:WhollyUnfundedDefinedBenefitPlansMember2023-12-310000845982ifrs-full:WhollyUnfundedDefinedBenefitPlansMember2023-12-310000845982snn:DefinedBenefitPensionPlansMemberifrs-full:WhollyUnfundedDefinedBenefitPlansMembersnn:OtherMember2022-12-310000845982snn:RetirementHealthcareMemberifrs-full:WhollyUnfundedDefinedBenefitPlansMember2022-12-310000845982ifrs-full:WhollyUnfundedDefinedBenefitPlansMember2022-12-310000845982snn:DefinedBenefitPensionPlansMemberifrs-full:WhollyOrPartlyFundedDefinedBenefitPlansMembersnn:OtherMember2023-12-310000845982snn:DefinedBenefitPensionPlansMemberifrs-full:WhollyOrPartlyFundedDefinedBenefitPlansMembercountry:US2023-12-310000845982snn:DefinedBenefitPensionPlansMemberifrs-full:WhollyOrPartlyFundedDefinedBenefitPlansMembercountry:GB2023-12-310000845982snn:DefinedBenefitPensionPlansMemberifrs-full:WhollyOrPartlyFundedDefinedBenefitPlansMember2023-12-310000845982snn:DefinedBenefitPensionPlansMemberifrs-full:WhollyOrPartlyFundedDefinedBenefitPlansMembersnn:OtherMember2022-12-310000845982snn:DefinedBenefitPensionPlansMemberifrs-full:WhollyOrPartlyFundedDefinedBenefitPlansMembercountry:US2022-12-310000845982snn:DefinedBenefitPensionPlansMemberifrs-full:WhollyOrPartlyFundedDefinedBenefitPlansMembercountry:GB2022-12-310000845982snn:DefinedBenefitPensionPlansMemberifrs-full:WhollyOrPartlyFundedDefinedBenefitPlansMember2022-12-310000845982snn:AcceleratedTaxDepreciationMember2023-01-012023-12-310000845982snn:LossesAndOtherTaxAttributesMember2022-01-012022-12-310000845982snn:AcceleratedTaxDepreciationMember2022-01-012022-12-310000845982ifrs-full:BottomOfRangeMember2023-01-012023-12-310000845982snn:ExtremityOrthopaedicsMember2021-01-042021-01-040000845982snn:LongTermBorrowingMember2023-01-012023-12-310000845982snn:LongTermBorrowingMember2022-01-012022-12-310000845982snn:LongTermBorrowingMember2021-01-012021-12-310000845982snn:DefinedBenefitPensionPlansMembercountry:GB2023-06-012023-06-300000845982ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember2023-12-310000845982ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember2022-12-310000845982snn:PropertyPlantAndEquipmentOtherThanBuildingsMemberifrs-full:TopOfRangeMember2023-01-012023-12-310000845982snn:PropertyPlantAndEquipmentOtherThanBuildingsMemberifrs-full:BottomOfRangeMember2023-01-012023-12-310000845982snn:OrthopaedicInstrumentsMemberifrs-full:TopOfRangeMember2023-01-012023-12-310000845982snn:OrthopaedicInstrumentsMemberifrs-full:BottomOfRangeMember2023-01-012023-12-310000845982ifrs-full:BuildingsMemberifrs-full:TopOfRangeMember2023-01-012023-12-310000845982ifrs-full:BuildingsMemberifrs-full:BottomOfRangeMember2023-01-012023-12-310000845982snn:ProductRelatedIntangibleAssetsMemberifrs-full:TopOfRangeMember2023-01-012023-12-310000845982snn:ProductRelatedIntangibleAssetsMemberifrs-full:BottomOfRangeMember2023-01-012023-12-310000845982ifrs-full:TechnologybasedIntangibleAssetsMemberifrs-full:TopOfRangeMember2023-01-012023-12-310000845982ifrs-full:TechnologybasedIntangibleAssetsMemberifrs-full:BottomOfRangeMember2023-01-012023-12-310000845982ifrs-full:CustomerrelatedIntangibleAssetsMemberifrs-full:TopOfRangeMember2023-01-012023-12-310000845982ifrs-full:CustomerrelatedIntangibleAssetsMemberifrs-full:BottomOfRangeMember2023-01-012023-12-310000845982ifrs-full:ComputerSoftwareMemberifrs-full:TopOfRangeMember2023-01-012023-12-310000845982ifrs-full:ComputerSoftwareMemberifrs-full:BottomOfRangeMember2023-01-012023-12-3100008459822021-01-012022-12-3100008459822022-01-012023-12-310000845982ifrs-full:AssociatesMember2023-01-012023-12-310000845982ifrs-full:ContingentConsiderationMemberifrs-full:Level3OfFairValueHierarchyMember2022-01-012022-12-310000845982snn:TraumaMembersnn:OrthopaedicsMember2023-01-012023-12-310000845982snn:SportsMedicineJointRepairMembersnn:SportsMedicineAndEntMember2023-01-012023-12-310000845982snn:OtherReconstructionMembersnn:OrthopaedicsMember2023-01-012023-12-310000845982snn:KneeImplantsMembersnn:OrthopaedicsMember2023-01-012023-12-310000845982snn:HipImplantsMembersnn:OrthopaedicsMember2023-01-012023-12-310000845982snn:EstablishedMarketsMembersnn:OrthopaedicsSportsMedicineAndEntAndAdvancedWoundManagementMember2023-01-012023-12-310000845982snn:EstablishedMarketsMembersnn:OrthopaedicsSportsMedicineAndEarNoseAndThroatMember2023-01-012023-12-310000845982snn:EstablishedMarketsMembersnn:AdvancedWoundManagementMember2023-01-012023-12-310000845982snn:EmergingMarketsMembersnn:OrthopaedicsSportsMedicineAndEntAndAdvancedWoundManagementMember2023-01-012023-12-310000845982snn:EmergingMarketsMembersnn:OrthopaedicsSportsMedicineAndEarNoseAndThroatMember2023-01-012023-12-310000845982snn:EmergingMarketsMembersnn:AdvancedWoundManagementMember2023-01-012023-12-310000845982snn:EarNoseAndThroatMembersnn:SportsMedicineAndEntMember2023-01-012023-12-310000845982snn:ArthroscopicEnablingTechnologiesMembersnn:SportsMedicineAndEntMember2023-01-012023-12-310000845982snn:AdvancedWoundDevicesMembersnn:AdvancedWoundManagementMember2023-01-012023-12-310000845982snn:AdvancedWoundCareMembersnn:AdvancedWoundManagementMember2023-01-012023-12-310000845982snn:AdvancedWoundBioactivesMembersnn:AdvancedWoundManagementMember2023-01-012023-12-310000845982snn:SportsMedicineAndEntMember2023-01-012023-12-310000845982snn:OrthopaedicsSportsMedicineAndEntAndAdvancedWoundManagementMember2023-01-012023-12-310000845982snn:OrthopaedicsSportsMedicineAndEarNoseAndThroatMember2023-01-012023-12-310000845982snn:OrthopaedicsMember2023-01-012023-12-310000845982snn:AdvancedWoundManagementMember2023-01-012023-12-310000845982snn:AdvancedWoundManagementMember2023-01-012023-12-310000845982country:US2023-01-012023-12-310000845982country:GB2023-01-012023-12-310000845982country:CH2023-01-012023-12-310000845982snn:TraumaMembersnn:OrthopaedicsMember2022-01-012022-12-310000845982snn:SportsMedicineJointRepairMembersnn:SportsMedicineAndEntMember2022-01-012022-12-310000845982snn:OtherReconstructionMembersnn:OrthopaedicsMember2022-01-012022-12-310000845982snn:KneeImplantsMembersnn:OrthopaedicsMember2022-01-012022-12-310000845982snn:HipImplantsMembersnn:OrthopaedicsMember2022-01-012022-12-310000845982snn:EstablishedMarketsMembersnn:OrthopaedicsSportsMedicineAndEntAndAdvancedWoundManagementMember2022-01-012022-12-310000845982snn:EstablishedMarketsMembersnn:OrthopaedicsSportsMedicineAndEarNoseAndThroatMember2022-01-012022-12-310000845982snn:EstablishedMarketsMembersnn:AdvancedWoundManagementMember2022-01-012022-12-310000845982snn:EmergingMarketsMembersnn:OrthopaedicsSportsMedicineAndEntAndAdvancedWoundManagementMember2022-01-012022-12-310000845982snn:EmergingMarketsMembersnn:OrthopaedicsSportsMedicineAndEarNoseAndThroatMember2022-01-012022-12-310000845982snn:EmergingMarketsMembersnn:AdvancedWoundManagementMember2022-01-012022-12-310000845982snn:EarNoseAndThroatMembersnn:SportsMedicineAndEntMember2022-01-012022-12-310000845982snn:ArthroscopicEnablingTechnologiesMembersnn:SportsMedicineAndEntMember2022-01-012022-12-310000845982snn:AdvancedWoundDevicesMembersnn:AdvancedWoundManagementMember2022-01-012022-12-310000845982snn:AdvancedWoundCareMembersnn:AdvancedWoundManagementMember2022-01-012022-12-310000845982snn:AdvancedWoundBioactivesMembersnn:AdvancedWoundManagementMember2022-01-012022-12-310000845982snn:SportsMedicineAndEntMember2022-01-012022-12-310000845982snn:OrthopaedicsSportsMedicineAndEntAndAdvancedWoundManagementMember2022-01-012022-12-310000845982snn:OrthopaedicsSportsMedicineAndEarNoseAndThroatMember2022-01-012022-12-310000845982snn:OrthopaedicsMember2022-01-012022-12-310000845982snn:AdvancedWoundManagementMember2022-01-012022-12-310000845982snn:AdvancedWoundManagementMember2022-01-012022-12-310000845982country:US2022-01-012022-12-310000845982country:GB2022-01-012022-12-310000845982country:CH2022-01-012022-12-310000845982snn:TraumaMembersnn:OrthopaedicsMember2021-01-012021-12-310000845982snn:SportsMedicineJointRepairMembersnn:SportsMedicineAndEntMember2021-01-012021-12-310000845982snn:OtherReconstructionMembersnn:OrthopaedicsMember2021-01-012021-12-310000845982snn:KneeImplantsMembersnn:OrthopaedicsMember2021-01-012021-12-310000845982snn:HipImplantsMembersnn:OrthopaedicsMember2021-01-012021-12-310000845982snn:EstablishedMarketsMembersnn:OrthopaedicsSportsMedicineAndEntAndAdvancedWoundManagementMember2021-01-012021-12-310000845982snn:EstablishedMarketsMembersnn:OrthopaedicsSportsMedicineAndEarNoseAndThroatMember2021-01-012021-12-310000845982snn:EstablishedMarketsMembersnn:AdvancedWoundManagementMember2021-01-012021-12-310000845982snn:EmergingMarketsMembersnn:OrthopaedicsSportsMedicineAndEntAndAdvancedWoundManagementMember2021-01-012021-12-310000845982snn:EmergingMarketsMembersnn:OrthopaedicsSportsMedicineAndEarNoseAndThroatMember2021-01-012021-12-310000845982snn:EmergingMarketsMembersnn:AdvancedWoundManagementMember2021-01-012021-12-310000845982snn:EarNoseAndThroatMembersnn:SportsMedicineAndEntMember2021-01-012021-12-310000845982snn:ArthroscopicEnablingTechnologiesMembersnn:SportsMedicineAndEntMember2021-01-012021-12-310000845982snn:AdvancedWoundDevicesMembersnn:AdvancedWoundManagementMember2021-01-012021-12-310000845982snn:AdvancedWoundCareMembersnn:AdvancedWoundManagementMember2021-01-012021-12-310000845982snn:AdvancedWoundBioactivesMembersnn:AdvancedWoundManagementMember2021-01-012021-12-310000845982snn:SportsMedicineAndEntMember2021-01-012021-12-310000845982snn:OrthopaedicsSportsMedicineAndEntAndAdvancedWoundManagementMember2021-01-012021-12-310000845982snn:OrthopaedicsSportsMedicineAndEarNoseAndThroatMember2021-01-012021-12-310000845982snn:OrthopaedicsMember2021-01-012021-12-310000845982snn:AdvancedWoundManagementMember2021-01-012021-12-310000845982snn:AdvancedWoundManagementMember2021-01-012021-12-310000845982country:US2021-01-012021-12-310000845982country:GB2021-01-012021-12-310000845982country:CH2021-01-012021-12-310000845982snn:PrivatePlacementDebtMember2023-01-012023-12-310000845982snn:OsirisTherapeuticsMemberifrs-full:TopOfRangeMember2023-01-012023-12-310000845982snn:OsirisTherapeuticsMemberifrs-full:BottomOfRangeMember2023-01-012023-12-310000845982snn:ArthrocareMemberifrs-full:BottomOfRangeMember2023-01-012023-12-310000845982snn:HealthpointMember2023-01-012023-12-310000845982ifrs-full:TradingEquitySecuritiesMemberifrs-full:Level3OfFairValueHierarchyMember2022-01-012022-12-310000845982ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrs-full:EquityInvestmentsMember2022-01-012022-12-310000845982snn:EmployeesShareTrustMember2022-01-012022-12-310000845982ifrs-full:GrossCarryingAmountMembersnn:InstrumentsMember2023-12-310000845982ifrs-full:GrossCarryingAmountMemberifrs-full:OtherPropertyPlantAndEquipmentMember2023-12-310000845982ifrs-full:GrossCarryingAmountMemberifrs-full:LandAndBuildingsMember2023-12-310000845982ifrs-full:GrossCarryingAmountMemberifrs-full:ConstructionInProgressMember2023-12-310000845982ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembersnn:InstrumentsMember2023-12-310000845982ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:OtherPropertyPlantAndEquipmentMember2023-12-310000845982ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:LandAndBuildingsMember2023-12-310000845982snn:InstrumentsMember2023-12-310000845982ifrs-full:OtherPropertyPlantAndEquipmentMember2023-12-310000845982ifrs-full:LandMember2023-12-310000845982ifrs-full:LandAndBuildingsMember2023-12-310000845982ifrs-full:ConstructionInProgressMember2023-12-310000845982ifrs-full:GrossCarryingAmountMembersnn:InstrumentsMember2022-12-310000845982ifrs-full:GrossCarryingAmountMemberifrs-full:OtherPropertyPlantAndEquipmentMember2022-12-310000845982ifrs-full:GrossCarryingAmountMemberifrs-full:LandAndBuildingsMember2022-12-310000845982ifrs-full:GrossCarryingAmountMemberifrs-full:ConstructionInProgressMember2022-12-310000845982ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembersnn:InstrumentsMember2022-12-310000845982ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:OtherPropertyPlantAndEquipmentMember2022-12-310000845982ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:LandAndBuildingsMember2022-12-310000845982snn:InstrumentsMember2022-12-310000845982ifrs-full:OtherPropertyPlantAndEquipmentMember2022-12-310000845982ifrs-full:LandMember2022-12-310000845982ifrs-full:LandAndBuildingsMember2022-12-310000845982ifrs-full:ConstructionInProgressMember2022-12-310000845982ifrs-full:GrossCarryingAmountMembersnn:InstrumentsMember2021-12-310000845982ifrs-full:GrossCarryingAmountMemberifrs-full:OtherPropertyPlantAndEquipmentMember2021-12-310000845982ifrs-full:GrossCarryingAmountMemberifrs-full:LandAndBuildingsMember2021-12-310000845982ifrs-full:GrossCarryingAmountMemberifrs-full:ConstructionInProgressMember2021-12-310000845982ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembersnn:InstrumentsMember2021-12-310000845982ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:OtherPropertyPlantAndEquipmentMember2021-12-310000845982ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:LandAndBuildingsMember2021-12-310000845982snn:DefinedBenefitPensionPlansMembercountry:GB2023-01-012023-12-310000845982snn:DefinedBenefitPensionPlansMembercountry:US2022-01-012022-12-310000845982snn:DefinedBenefitPensionPlansMembercountry:GB2022-01-012022-12-310000845982snn:DefinedBenefitPensionPlansMembercountry:US2021-01-012021-12-310000845982snn:DefinedBenefitPensionPlansMembercountry:GB2021-01-012021-12-310000845982snn:DefinedBenefitPensionPlansMembersnn:OtherMember2021-12-310000845982ifrs-full:RestructuringProvisionMember2023-12-310000845982ifrs-full:RestructuringProvisionMember2022-12-310000845982snn:MetalOnMetalHipClaimsProvisionMember2021-12-310000845982ifrs-full:RestructuringProvisionMember2021-12-310000845982ifrs-full:LegalProceedingsProvisionMember2021-12-310000845982snn:MetalOnMetalHipClaimsProvisionMember2023-12-310000845982ifrs-full:LegalProceedingsProvisionMember2023-12-310000845982snn:MetalOnMetalHipClaimsProvisionMember2022-12-310000845982ifrs-full:LegalProceedingsProvisionMember2022-12-310000845982ifrs-full:ForwardContractMemberifrs-full:CashFlowHedgesMemberifrs-full:CurrencyRiskMember2023-01-012023-12-310000845982ifrs-full:ForwardContractMemberifrs-full:CashFlowHedgesMemberifrs-full:CurrencyRiskMember2022-01-012022-12-310000845982ifrs-full:OtherReservesMember2023-01-012023-12-310000845982ifrs-full:OtherReservesMember2022-01-012022-12-310000845982ifrs-full:OtherReservesMember2021-01-012021-12-310000845982snn:TreasurySharesExcludingEmployeeShareTrustMember2023-12-310000845982snn:EmployeesShareTrustMember2023-12-310000845982snn:TreasurySharesExcludingEmployeeShareTrustMember2022-12-310000845982snn:EmployeesShareTrustMember2022-12-310000845982snn:TreasurySharesExcludingEmployeeShareTrustMember2021-12-310000845982snn:EmployeesShareTrustMember2021-12-310000845982snn:DeferredSharesMember2020-12-310000845982snn:DeferredSharesMember2023-12-310000845982snn:DeferredSharesMember2022-12-310000845982snn:DeferredSharesMember2021-12-310000845982snn:SyndicatedRevolvingCreditFacilityMember2023-12-310000845982ifrs-full:ForwardContractMember2023-12-310000845982ifrs-full:InterestRateSwapContractMemberifrs-full:InterestRateRiskMember2022-12-310000845982ifrs-full:ForwardContractMember2022-12-310000845982snn:FinancialAssetsCashMemberifrs-full:CreditRiskMember2023-12-310000845982ifrs-full:DerivativesMemberifrs-full:CreditRiskMember2023-12-310000845982snn:FinancialAssetsCashMemberifrs-full:CreditRiskMember2022-12-310000845982ifrs-full:DerivativesMemberifrs-full:CreditRiskMember2022-12-310000845982snn:DefinedBenefitPensionPlansMembersnn:OtherMemberifrs-full:PresentValueOfDefinedBenefitObligationMember2023-12-310000845982snn:DefinedBenefitPensionPlansMembersnn:OtherMemberifrs-full:PlanAssetsMember2023-12-310000845982snn:DefinedBenefitPensionPlansMembercountry:USifrs-full:PresentValueOfDefinedBenefitObligationMember2023-12-310000845982snn:DefinedBenefitPensionPlansMembercountry:USifrs-full:PlanAssetsMember2023-12-310000845982snn:DefinedBenefitPensionPlansMembercountry:GBifrs-full:PresentValueOfDefinedBenefitObligationMember2023-12-310000845982snn:DefinedBenefitPensionPlansMembercountry:GBifrs-full:PlanAssetsMember2023-12-310000845982snn:DefinedBenefitPensionPlansMembersnn:OtherMember2023-12-310000845982ifrs-full:PresentValueOfDefinedBenefitObligationMember2023-12-310000845982ifrs-full:PlanAssetsMember2023-12-310000845982snn:DefinedBenefitPensionPlansMembersnn:OtherMemberifrs-full:PresentValueOfDefinedBenefitObligationMember2022-12-310000845982snn:DefinedBenefitPensionPlansMembersnn:OtherMemberifrs-full:PlanAssetsMember2022-12-310000845982snn:DefinedBenefitPensionPlansMembercountry:USifrs-full:PresentValueOfDefinedBenefitObligationMember2022-12-310000845982snn:DefinedBenefitPensionPlansMembercountry:USifrs-full:PlanAssetsMember2022-12-310000845982snn:DefinedBenefitPensionPlansMembercountry:GBifrs-full:PresentValueOfDefinedBenefitObligationMember2022-12-310000845982snn:DefinedBenefitPensionPlansMembercountry:GBifrs-full:PlanAssetsMember2022-12-310000845982snn:DefinedBenefitPensionPlansMembersnn:OtherMember2022-12-310000845982ifrs-full:PresentValueOfDefinedBenefitObligationMember2022-12-310000845982ifrs-full:PlanAssetsMember2022-12-310000845982ifrs-full:PresentValueOfDefinedBenefitObligationMember2021-12-310000845982ifrs-full:PlanAssetsMember2021-12-310000845982snn:AcquisitionConsiderationLiabilityMemberifrs-full:Level3OfFairValueHierarchyMember2023-12-310000845982snn:AcquisitionConsiderationLiabilityMemberifrs-full:Level3OfFairValueHierarchyMember2022-12-310000845982snn:AcquisitionConsiderationLiabilityMemberifrs-full:Level3OfFairValueHierarchyMember2021-12-310000845982ifrs-full:KeyManagementPersonnelOfEntityOrParentMember2023-01-012023-12-310000845982ifrs-full:KeyManagementPersonnelOfEntityOrParentMember2022-01-012022-12-310000845982ifrs-full:KeyManagementPersonnelOfEntityOrParentMember2021-01-012021-12-310000845982ifrs-full:SharePremiumMember2022-01-012022-12-310000845982ifrs-full:SharePremiumMember2021-01-012021-12-310000845982ifrs-full:AssociatesMember2023-12-310000845982ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember2023-12-310000845982ifrs-full:AssociatesMember2022-12-310000845982ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember2022-12-310000845982ifrs-full:GrossCarryingAmountMembersnn:ProductRelatedIntangibleAssetsMember2023-12-310000845982ifrs-full:GrossCarryingAmountMemberifrs-full:TechnologybasedIntangibleAssetsMember2023-12-310000845982ifrs-full:GrossCarryingAmountMemberifrs-full:IntangibleAssetsUnderDevelopmentMember2023-12-310000845982ifrs-full:GrossCarryingAmountMemberifrs-full:CustomerrelatedIntangibleAssetsMember2023-12-310000845982ifrs-full:GrossCarryingAmountMemberifrs-full:ComputerSoftwareMember2023-12-310000845982ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembersnn:ProductRelatedIntangibleAssetsMember2023-12-310000845982ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:TechnologybasedIntangibleAssetsMember2023-12-310000845982ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:CustomerrelatedIntangibleAssetsMember2023-12-310000845982ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:ComputerSoftwareMember2023-12-310000845982snn:ProductRelatedIntangibleAssetsMember2023-12-310000845982snn:OsirisTherapeuticsMember2023-12-310000845982snn:HealthpointMember2023-12-310000845982snn:ArthrocareMember2023-12-310000845982ifrs-full:TechnologybasedIntangibleAssetsMember2023-12-310000845982ifrs-full:IntangibleAssetsUnderDevelopmentMember2023-12-310000845982ifrs-full:CustomerrelatedIntangibleAssetsMember2023-12-310000845982ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2023-12-310000845982ifrs-full:GrossCarryingAmountMembersnn:ProductRelatedIntangibleAssetsMember2022-12-310000845982ifrs-full:GrossCarryingAmountMemberifrs-full:TechnologybasedIntangibleAssetsMember2022-12-310000845982ifrs-full:GrossCarryingAmountMemberifrs-full:IntangibleAssetsUnderDevelopmentMember2022-12-310000845982ifrs-full:GrossCarryingAmountMemberifrs-full:CustomerrelatedIntangibleAssetsMember2022-12-310000845982ifrs-full:GrossCarryingAmountMemberifrs-full:ComputerSoftwareMember2022-12-310000845982ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembersnn:ProductRelatedIntangibleAssetsMember2022-12-310000845982ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:TechnologybasedIntangibleAssetsMember2022-12-310000845982ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:CustomerrelatedIntangibleAssetsMember2022-12-310000845982ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:ComputerSoftwareMember2022-12-310000845982snn:ProductRelatedIntangibleAssetsMember2022-12-310000845982ifrs-full:TechnologybasedIntangibleAssetsMember2022-12-310000845982ifrs-full:IntangibleAssetsUnderDevelopmentMember2022-12-310000845982ifrs-full:CustomerrelatedIntangibleAssetsMember2022-12-310000845982ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-12-310000845982ifrs-full:GrossCarryingAmountMembersnn:ProductRelatedIntangibleAssetsMember2021-12-310000845982ifrs-full:GrossCarryingAmountMemberifrs-full:TechnologybasedIntangibleAssetsMember2021-12-310000845982ifrs-full:GrossCarryingAmountMemberifrs-full:IntangibleAssetsUnderDevelopmentMember2021-12-310000845982ifrs-full:GrossCarryingAmountMemberifrs-full:CustomerrelatedIntangibleAssetsMember2021-12-310000845982ifrs-full:GrossCarryingAmountMemberifrs-full:ComputerSoftwareMember2021-12-310000845982ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembersnn:ProductRelatedIntangibleAssetsMember2021-12-310000845982ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:TechnologybasedIntangibleAssetsMember2021-12-310000845982ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:CustomerrelatedIntangibleAssetsMember2021-12-310000845982ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:ComputerSoftwareMember2021-12-310000845982ifrs-full:GrossCarryingAmountMember2021-12-310000845982ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2021-12-310000845982ifrs-full:ComputerSoftwareMemberifrs-full:ConstructionInProgressMember2023-01-012023-12-310000845982ifrs-full:ComputerSoftwareMemberifrs-full:ConstructionInProgressMember2022-01-012022-12-310000845982snn:ComputerSoftwareAndIntangibleAssetsUnderDevelopmentMemberifrs-full:ConstructionInProgressMember2023-01-012023-12-310000845982snn:ComputerSoftwareAndIntangibleAssetsUnderDevelopmentMemberifrs-full:ConstructionInProgressMember2022-01-012022-12-310000845982ifrs-full:GrossCarryingAmountMemberifrs-full:TechnologybasedIntangibleAssetsMember2022-01-012022-12-310000845982snn:LossesAndOtherTaxAttributesMember2023-01-012023-12-310000845982snn:InventoryProvisionsAndOtherDifferencesMember2023-01-012023-12-310000845982snn:IntangiblesMember2023-01-012023-12-310000845982snn:IntangiblesMember2022-01-012022-12-310000845982ifrs-full:ActuarialAssumptionOfMortalityRatesMembersnn:DefinedBenefitPensionPlansMembercountry:US2023-12-310000845982ifrs-full:ActuarialAssumptionOfMortalityRatesMembersnn:DefinedBenefitPensionPlansMembercountry:GB2023-12-310000845982ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflationMembersnn:DefinedBenefitPensionPlansMembercountry:GB2023-12-310000845982ifrs-full:ActuarialAssumptionOfDiscountRatesMembersnn:DefinedBenefitPensionPlansMembercountry:US2023-12-310000845982ifrs-full:ActuarialAssumptionOfDiscountRatesMembersnn:DefinedBenefitPensionPlansMembercountry:GB2023-12-310000845982snn:RetirementBenefitObligationMember2023-01-012023-12-310000845982snn:RetirementBenefitObligationMember2022-01-012022-12-310000845982snn:OrthopaedicsMember2023-01-012023-12-310000845982snn:EngageMember2023-01-012023-12-310000845982snn:EngageMember2023-01-012023-12-310000845982ifrs-full:AssociatesMember2022-01-012022-12-310000845982snn:EngageSIntangibleAssetsMember2023-01-012023-12-310000845982snn:ImmaterialProductAssetsMember2022-01-012022-12-310000845982snn:EngageSurgicalMembersnn:ProductRelatedIntangibleAssetsMember2022-01-180000845982snn:ExtremityOrthopaedicsMembersnn:ProductRelatedIntangibleAssetsMember2021-01-040000845982snn:ExtremityOrthopaedicsMemberifrs-full:CustomerrelatedIntangibleAssetsMember2021-01-040000845982snn:EurCorporateBondMemberifrs-full:HedgesOfNetInvestmentInForeignOperationsMemberifrs-full:CurrencyRiskMember2023-12-310000845982ifrs-full:InterestRateSwapContractMemberifrs-full:FairValueHedgesMemberifrs-full:InterestRateRiskMember2022-12-310000845982ifrs-full:InterestRateSwapContractMemberifrs-full:FairValueHedgesMemberifrs-full:InterestRateRiskMember2023-12-310000845982ifrs-full:ForwardContractMemberifrs-full:CashFlowHedgesMemberifrs-full:CurrencyRiskMember2023-12-310000845982ifrs-full:ForwardContractMemberifrs-full:CashFlowHedgesMemberifrs-full:CurrencyRiskMember2022-12-310000845982ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember2023-12-310000845982ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2023-12-310000845982ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember2023-12-310000845982ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember2023-12-310000845982ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember2022-12-310000845982ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2022-12-310000845982ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember2022-12-310000845982ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember2022-12-310000845982snn:AcquisitionConsiderationLiabilityMemberifrs-full:Level3OfFairValueHierarchyMember2023-01-012023-12-310000845982snn:AcquisitionConsiderationLiabilityMemberifrs-full:Level3OfFairValueHierarchyMember2022-01-012022-12-310000845982ifrs-full:TradingEquitySecuritiesMemberifrs-full:Level3OfFairValueHierarchyMember2023-01-012023-12-310000845982ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrs-full:EquityInvestmentsMember2023-01-012023-12-310000845982snn:AcquisitionConsiderationMemberifrs-full:Level3OfFairValueHierarchyMemberifrs-full:AtFairValueMember2023-12-310000845982ifrs-full:ForwardContractMemberifrs-full:Level2OfFairValueHierarchyMemberifrs-full:AtFairValueMember2023-12-310000845982ifrs-full:CurrencySwapContractMemberifrs-full:Level2OfFairValueHierarchyMemberifrs-full:AtFairValueMember2023-12-310000845982snn:AcquisitionConsiderationMemberifrs-full:Level3OfFairValueHierarchyMemberifrs-full:AtFairValueMember2022-12-310000845982ifrs-full:InterestRateSwapContractMemberifrs-full:Level2OfFairValueHierarchyMemberifrs-full:AtFairValueMember2022-12-310000845982ifrs-full:ForwardContractMemberifrs-full:Level2OfFairValueHierarchyMemberifrs-full:AtFairValueMember2022-12-310000845982ifrs-full:CurrencySwapContractMemberifrs-full:Level2OfFairValueHierarchyMemberifrs-full:AtFairValueMember2022-12-310000845982snn:OtherFinancialLiabilitiesMembersnn:TradeAndOtherPayablesMemberifrs-full:NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember2023-12-310000845982snn:OtherFinancialLiabilitiesMembersnn:PrivatePlacementDebtNotInHedgeRelationshipMemberifrs-full:NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember2023-12-310000845982snn:OtherFinancialLiabilitiesMembersnn:CorporateBondNotInHedgeRelationshipMemberifrs-full:NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember2023-12-310000845982snn:OtherFinancialLiabilitiesMembersnn:CorporateBondInHedgeRelationshipMemberifrs-full:NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember2023-12-310000845982snn:OtherFinancialLiabilitiesMembersnn:BankOverdraftsLiabilitiesMemberifrs-full:NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember2023-12-310000845982snn:OtherFinancialLiabilitiesMembersnn:BankLoansMemberifrs-full:NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember2023-12-310000845982snn:OtherFinancialLiabilitiesMembersnn:AcquisitionConsiderationMemberifrs-full:NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember2023-12-310000845982snn:HedgingInstrumentsFairValueMemberifrs-full:ForwardContractMemberifrs-full:AtFairValueMember2023-12-310000845982snn:FinancialLiabilitiesTotalMemberifrs-full:FloatingInterestRateMembersrt:OtherCurrencyMember2023-12-310000845982snn:FinancialLiabilitiesTotalMemberifrs-full:FloatingInterestRateMembercurrency:USD2023-12-310000845982snn:FinancialLiabilitiesTotalMemberifrs-full:FixedInterestRateMembersrt:OtherCurrencyMember2023-12-310000845982snn:FinancialLiabilitiesTotalMemberifrs-full:FixedInterestRateMembercurrency:USD2023-12-310000845982snn:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrs-full:CurrencySwapContractMemberifrs-full:AtFairValueMember2023-12-310000845982ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMembersnn:AcquisitionConsiderationMemberifrs-full:AtFairValueMember2023-12-310000845982snn:TradeAndOtherPayablesMemberifrs-full:NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember2023-12-310000845982snn:PrivatePlacementDebtNotInHedgeRelationshipMemberifrs-full:NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember2023-12-310000845982snn:OtherFinancialLiabilitiesMemberifrs-full:NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember2023-12-310000845982snn:HedgingInstrumentsFairValueMemberifrs-full:AtFairValueMember2023-12-310000845982snn:FinancialLiabilitiesTotalMembersrt:OtherCurrencyMember2023-12-310000845982snn:FinancialLiabilitiesTotalMemberifrs-full:FloatingInterestRateMember2023-12-310000845982snn:FinancialLiabilitiesTotalMemberifrs-full:FixedInterestRateMember2023-12-310000845982snn:FinancialLiabilitiesTotalMembercurrency:USD2023-12-310000845982snn:FinancialLiabilitiesLongTermDebtMembersrt:OtherCurrencyMember2023-12-310000845982snn:FinancialLiabilitiesLongTermDebtMembercurrency:USD2023-12-310000845982snn:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrs-full:AtFairValueMember2023-12-310000845982snn:CorporateBondNotInHedgeRelationshipMemberifrs-full:NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember2023-12-310000845982snn:CorporateBondInHedgeRelationshipMemberifrs-full:NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember2023-12-310000845982snn:BankOverdraftsLiabilitiesMemberifrs-full:NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember2023-12-310000845982snn:BankLoansMemberifrs-full:NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember2023-12-310000845982snn:AcquisitionConsiderationMemberifrs-full:NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember2023-12-310000845982snn:AcquisitionConsiderationMemberifrs-full:AtFairValueMember2023-12-310000845982ifrs-full:ForwardContractMemberifrs-full:AtFairValueMember2023-12-310000845982ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrs-full:AtFairValueMember2023-12-310000845982ifrs-full:CurrencySwapContractMembersrt:OtherCurrencyMember2023-12-310000845982ifrs-full:CurrencySwapContractMemberifrs-full:AtFairValueMember2023-12-310000845982ifrs-full:CurrencySwapContractMembercurrency:USD2023-12-310000845982snn:PrivatePlacementDebtMember2023-12-310000845982snn:FinancialLiabilitiesTotalMember2023-12-310000845982snn:FinancialLiabilitiesLongTermDebtMember2023-12-310000845982snn:EurCorporateBondMember2023-12-310000845982snn:CorporateBondsMember2023-12-310000845982ifrs-full:CurrencySwapContractMember2023-12-310000845982snn:OtherFinancialLiabilitiesMembersnn:TradeAndOtherPayablesMemberifrs-full:NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember2022-12-310000845982snn:OtherFinancialLiabilitiesMembersnn:PrivatePlacementDebtNotInHedgeRelationshipMemberifrs-full:NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember2022-12-310000845982snn:OtherFinancialLiabilitiesMembersnn:CorporateBondNotInHedgeRelationshipMemberifrs-full:NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember2022-12-310000845982snn:OtherFinancialLiabilitiesMembersnn:CorporateBondInHedgeRelationshipMemberifrs-full:NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember2022-12-310000845982snn:OtherFinancialLiabilitiesMembersnn:BankOverdraftsLiabilitiesMemberifrs-full:NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember2022-12-310000845982snn:OtherFinancialLiabilitiesMembersnn:AcquisitionConsiderationMemberifrs-full:NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember2022-12-310000845982snn:HedgingInstrumentsFairValueMemberifrs-full:InterestRateSwapContractMemberifrs-full:AtFairValueMember2022-12-310000845982snn:HedgingInstrumentsFairValueMemberifrs-full:ForwardContractMemberifrs-full:AtFairValueMember2022-12-310000845982snn:FinancialLiabilitiesTotalMemberifrs-full:FloatingInterestRateMembersrt:OtherCurrencyMember2022-12-310000845982snn:FinancialLiabilitiesTotalMemberifrs-full:FloatingInterestRateMembercurrency:USD2022-12-310000845982snn:FinancialLiabilitiesTotalMemberifrs-full:FixedInterestRateMembersrt:OtherCurrencyMember2022-12-310000845982snn:FinancialLiabilitiesTotalMemberifrs-full:FixedInterestRateMembercurrency:USD2022-12-310000845982snn:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrs-full:CurrencySwapContractMemberifrs-full:AtFairValueMember2022-12-310000845982ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMembersnn:AcquisitionConsiderationMemberifrs-full:AtFairValueMember2022-12-310000845982snn:TradeAndOtherPayablesMemberifrs-full:NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember2022-12-310000845982snn:PrivatePlacementDebtNotInHedgeRelationshipMemberifrs-full:NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember2022-12-310000845982snn:OtherFinancialLiabilitiesMemberifrs-full:NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember2022-12-310000845982snn:HedgingInstrumentsFairValueMemberifrs-full:AtFairValueMember2022-12-310000845982snn:FinancialLiabilitiesTotalMembersrt:OtherCurrencyMember2022-12-310000845982snn:FinancialLiabilitiesTotalMemberifrs-full:FloatingInterestRateMember2022-12-310000845982snn:FinancialLiabilitiesTotalMemberifrs-full:FixedInterestRateMember2022-12-310000845982snn:FinancialLiabilitiesTotalMembercurrency:USD2022-12-310000845982snn:FinancialLiabilitiesLongTermDebtMembersrt:OtherCurrencyMember2022-12-310000845982snn:FinancialLiabilitiesLongTermDebtMembercurrency:USD2022-12-310000845982snn:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrs-full:AtFairValueMember2022-12-310000845982snn:CorporateBondNotInHedgeRelationshipMemberifrs-full:NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember2022-12-310000845982snn:CorporateBondInHedgeRelationshipMemberifrs-full:NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember2022-12-310000845982snn:BankOverdraftsLiabilitiesMemberifrs-full:NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember2022-12-310000845982snn:AcquisitionConsiderationMemberifrs-full:NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember2022-12-310000845982snn:AcquisitionConsiderationMemberifrs-full:AtFairValueMember2022-12-310000845982ifrs-full:InterestRateSwapContractMembersrt:OtherCurrencyMember2022-12-310000845982ifrs-full:InterestRateSwapContractMemberifrs-full:AtFairValueMember2022-12-310000845982ifrs-full:ForwardContractMemberifrs-full:AtFairValueMember2022-12-310000845982ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrs-full:AtFairValueMember2022-12-310000845982ifrs-full:CurrencySwapContractMembersrt:OtherCurrencyMember2022-12-310000845982ifrs-full:CurrencySwapContractMemberifrs-full:AtFairValueMember2022-12-310000845982ifrs-full:CurrencySwapContractMembercurrency:USD2022-12-310000845982snn:PrivatePlacementDebtMember2022-12-310000845982snn:FinancialLiabilitiesTotalMember2022-12-310000845982snn:FinancialLiabilitiesLongTermDebtMember2022-12-310000845982snn:EurCorporateBondMember2022-12-310000845982snn:CorporateBondsMember2022-12-310000845982ifrs-full:InterestRateSwapContractMember2022-12-310000845982ifrs-full:CurrencySwapContractMember2022-12-310000845982snn:FinancialAssetsInvestmentsMemberifrs-full:Level3OfFairValueHierarchyMemberifrs-full:AtFairValueMember2023-12-310000845982ifrs-full:InterestRateSwapContractMemberifrs-full:Level2OfFairValueHierarchyMemberifrs-full:AtFairValueMember2023-12-310000845982ifrs-full:ForwardContractMemberifrs-full:Level2OfFairValueHierarchyMemberifrs-full:AtFairValueMember2023-12-310000845982ifrs-full:CurrencySwapContractMemberifrs-full:Level2OfFairValueHierarchyMemberifrs-full:AtFairValueMember2023-12-310000845982ifrs-full:ContingentConsiderationMemberifrs-full:Level3OfFairValueHierarchyMemberifrs-full:AtFairValueMember2023-12-310000845982snn:FinancialAssetsInvestmentsMemberifrs-full:Level3OfFairValueHierarchyMemberifrs-full:AtFairValueMember2022-12-310000845982ifrs-full:ForwardContractMemberifrs-full:Level2OfFairValueHierarchyMemberifrs-full:AtFairValueMember2022-12-310000845982ifrs-full:CurrencySwapContractMemberifrs-full:Level2OfFairValueHierarchyMemberifrs-full:AtFairValueMember2022-12-310000845982ifrs-full:ContingentConsiderationMemberifrs-full:Level3OfFairValueHierarchyMemberifrs-full:AtFairValueMember2022-12-310000845982snn:HedgingInstrumentsFairValueMembersnn:TradeAndOtherReceivablesMemberifrs-full:NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember2023-12-310000845982snn:HedgingInstrumentsFairValueMemberifrs-full:InterestRateSwapContractMemberifrs-full:AtFairValueMember2023-12-310000845982snn:HedgingInstrumentsFairValueMemberifrs-full:ForwardContractMemberifrs-full:AtFairValueMember2023-12-310000845982snn:FinancialAssetsTotalMemberifrs-full:FloatingInterestRateMembersrt:OtherCurrencyMember2023-12-310000845982snn:FinancialAssetsTotalMemberifrs-full:FloatingInterestRateMembercurrency:USD2023-12-310000845982ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMembersnn:FinancialAssetsInvestmentsMemberifrs-full:AtFairValueMember2023-12-310000845982ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrs-full:ContingentConsiderationMemberifrs-full:AtFairValueMember2023-12-310000845982ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrs-full:CurrencySwapContractMemberifrs-full:AtFairValueMember2023-12-310000845982ifrs-full:FinancialAssetsAtAmortisedCostCategoryMembersnn:FinancialAssetsCashMemberifrs-full:NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember2023-12-310000845982snn:TradeAndOtherReceivablesMemberifrs-full:NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember2023-12-310000845982snn:HedgingInstrumentsFairValueMemberifrs-full:NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember2023-12-310000845982snn:HedgingInstrumentsFairValueMemberifrs-full:AtFairValueMember2023-12-310000845982snn:FinancialAssetsTotalMembersrt:OtherCurrencyMember2023-12-310000845982snn:FinancialAssetsTotalMemberifrs-full:FloatingInterestRateMember2023-12-310000845982snn:FinancialAssetsTotalMembercurrency:USD2023-12-310000845982snn:FinancialAssetsInvestmentsMemberifrs-full:AtFairValueMember2023-12-310000845982snn:FinancialAssetsCashMembersrt:OtherCurrencyMember2023-12-310000845982snn:FinancialAssetsCashMemberifrs-full:NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember2023-12-310000845982snn:FinancialAssetsCashMembercurrency:USD2023-12-310000845982ifrs-full:InterestRateSwapContractMembersrt:OtherCurrencyMember2023-12-310000845982ifrs-full:InterestRateSwapContractMemberifrs-full:AtFairValueMember2023-12-310000845982ifrs-full:ForwardContractMemberifrs-full:AtFairValueMember2023-12-310000845982ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrs-full:EquityInvestmentsMember2023-12-310000845982ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrs-full:AtFairValueMember2023-12-310000845982ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrs-full:AtFairValueMember2023-12-310000845982ifrs-full:FinancialAssetsAtAmortisedCostCategoryMemberifrs-full:NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember2023-12-310000845982ifrs-full:CurrencySwapContractMembersrt:OtherCurrencyMember2023-12-310000845982ifrs-full:CurrencySwapContractMemberifrs-full:AtFairValueMember2023-12-310000845982ifrs-full:CurrencySwapContractMembercurrency:USD2023-12-310000845982ifrs-full:ContingentConsiderationMemberifrs-full:AtFairValueMember2023-12-310000845982ifrs-full:AccumulatedImpairmentMemberifrs-full:TradeReceivablesMember2023-12-310000845982snn:FinancialAssetsTotalMember2023-12-310000845982snn:FinancialAssetsCashMember2023-12-310000845982ifrs-full:NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember2023-12-310000845982ifrs-full:InterestRateSwapContractMember2023-12-310000845982ifrs-full:CurrencySwapContractMember2023-12-310000845982ifrs-full:AtFairValueMember2023-12-310000845982snn:HedgingInstrumentsFairValueMembersnn:TradeAndOtherReceivablesMemberifrs-full:NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember2022-12-310000845982snn:HedgingInstrumentsFairValueMemberifrs-full:ForwardContractMemberifrs-full:AtFairValueMember2022-12-310000845982snn:FinancialAssetsTotalMemberifrs-full:FloatingInterestRateMembersrt:OtherCurrencyMember2022-12-310000845982snn:FinancialAssetsTotalMemberifrs-full:FloatingInterestRateMembercurrency:USD2022-12-310000845982ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMembersnn:FinancialAssetsInvestmentsMemberifrs-full:AtFairValueMember2022-12-310000845982ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrs-full:ContingentConsiderationMemberifrs-full:AtFairValueMember2022-12-310000845982ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrs-full:CurrencySwapContractMemberifrs-full:AtFairValueMember2022-12-310000845982ifrs-full:FinancialAssetsAtAmortisedCostCategoryMembersnn:FinancialAssetsCashMemberifrs-full:NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember2022-12-310000845982snn:TradeAndOtherReceivablesMemberifrs-full:NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember2022-12-310000845982snn:HedgingInstrumentsFairValueMemberifrs-full:NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember2022-12-310000845982snn:HedgingInstrumentsFairValueMemberifrs-full:AtFairValueMember2022-12-310000845982snn:FinancialAssetsTotalMembersrt:OtherCurrencyMember2022-12-310000845982snn:FinancialAssetsTotalMemberifrs-full:FloatingInterestRateMember2022-12-310000845982snn:FinancialAssetsTotalMembercurrency:USD2022-12-310000845982snn:FinancialAssetsInvestmentsMemberifrs-full:AtFairValueMember2022-12-310000845982snn:FinancialAssetsCashMembersrt:OtherCurrencyMember2022-12-310000845982snn:FinancialAssetsCashMemberifrs-full:NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember2022-12-310000845982snn:FinancialAssetsCashMembercurrency:USD2022-12-310000845982ifrs-full:ForwardContractMemberifrs-full:AtFairValueMember2022-12-310000845982ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrs-full:EquityInvestmentsMember2022-12-310000845982ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrs-full:AtFairValueMember2022-12-310000845982ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberifrs-full:AtFairValueMember2022-12-310000845982ifrs-full:FinancialAssetsAtAmortisedCostCategoryMemberifrs-full:NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember2022-12-310000845982ifrs-full:CurrencySwapContractMembersrt:OtherCurrencyMember2022-12-310000845982ifrs-full:CurrencySwapContractMemberifrs-full:AtFairValueMember2022-12-310000845982ifrs-full:CurrencySwapContractMembercurrency:USD2022-12-310000845982ifrs-full:ContingentConsiderationMemberifrs-full:AtFairValueMember2022-12-310000845982ifrs-full:AccumulatedImpairmentMemberifrs-full:TradeReceivablesMember2022-12-310000845982snn:FinancialAssetsTotalMember2022-12-310000845982snn:FinancialAssetsCashMember2022-12-310000845982ifrs-full:NotMeasuredAtFairValueInStatementOfFinancialPositionButForWhichFairValueIsDisclosedMember2022-12-310000845982ifrs-full:CurrencySwapContractMember2022-12-310000845982ifrs-full:AtFairValueMember2022-12-310000845982ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrs-full:EquityInvestmentsMember2021-12-310000845982ifrs-full:AccumulatedImpairmentMemberifrs-full:TradeReceivablesMember2021-12-310000845982snn:ResearchAndDevelopmentExpensesMember2023-01-012023-12-310000845982ifrs-full:CostOfSalesMember2023-01-012023-12-310000845982snn:ResearchAndDevelopmentExpensesMember2022-01-012022-12-310000845982ifrs-full:CostOfSalesMember2022-01-012022-12-310000845982snn:ResearchAndDevelopmentExpensesMember2021-01-012021-12-310000845982ifrs-full:CostOfSalesMember2021-01-012021-12-310000845982snn:MetalOnMetalHipClaimsProvisionMember2023-01-012023-12-310000845982snn:MetalOnMetalHipClaimsProvisionMember2021-01-012021-12-310000845982ifrs-full:TopOfRangeMember2023-12-310000845982ifrs-full:BottomOfRangeMember2023-12-310000845982snn:DefinedBenefitPensionPlansMembercountry:US2023-01-012023-12-310000845982snn:RetainedEarningsAndOtherReservesMember2023-12-310000845982ifrs-full:TreasurySharesMember2023-12-310000845982ifrs-full:SharePremiumMember2023-12-310000845982ifrs-full:RetainedEarningsMember2023-12-310000845982ifrs-full:OtherReservesMember2023-12-310000845982ifrs-full:OrdinarySharesMember2023-12-310000845982ifrs-full:IssuedCapitalMember2023-12-310000845982ifrs-full:CapitalRedemptionReserveMember2023-12-310000845982snn:RetainedEarningsAndOtherReservesMember2022-12-310000845982ifrs-full:TreasurySharesMember2022-12-310000845982ifrs-full:SharePremiumMember2022-12-310000845982ifrs-full:RetainedEarningsMember2022-12-310000845982ifrs-full:OtherReservesMember2022-12-310000845982ifrs-full:OrdinarySharesMember2022-12-310000845982ifrs-full:IssuedCapitalMember2022-12-310000845982ifrs-full:CapitalRedemptionReserveMember2022-12-310000845982snn:RetainedEarningsAndOtherReservesMember2021-12-310000845982ifrs-full:TreasurySharesMember2021-12-310000845982ifrs-full:SharePremiumMember2021-12-310000845982ifrs-full:RetainedEarningsMember2021-12-310000845982ifrs-full:OtherReservesMember2021-12-310000845982ifrs-full:OrdinarySharesMember2021-12-310000845982ifrs-full:IssuedCapitalMember2021-12-310000845982ifrs-full:CapitalRedemptionReserveMember2021-12-310000845982ifrs-full:TreasurySharesMember2020-12-310000845982ifrs-full:SharePremiumMember2020-12-310000845982ifrs-full:RetainedEarningsMember2020-12-310000845982ifrs-full:OtherReservesMember2020-12-310000845982ifrs-full:OrdinarySharesMember2020-12-310000845982ifrs-full:IssuedCapitalMember2020-12-310000845982ifrs-full:CapitalRedemptionReserveMember2020-12-310000845982ifrs-full:OrdinarySharesMembersnn:InterimDividendsMember2023-01-012023-12-310000845982ifrs-full:OrdinarySharesMembersnn:FinalDividendsMember2023-01-012023-12-310000845982ifrs-full:OrdinarySharesMembersnn:InterimDividendsMember2022-01-012022-12-310000845982ifrs-full:OrdinarySharesMembersnn:FinalDividendsMember2022-01-012022-12-310000845982ifrs-full:OrdinarySharesMembersnn:InterimDividendsMember2021-01-012021-12-310000845982ifrs-full:OrdinarySharesMembersnn:FinalDividendsMember2021-01-012021-12-310000845982ifrs-full:RetainedEarningsMember2023-01-012023-12-310000845982ifrs-full:OrdinarySharesMember2021-01-012021-12-310000845982ifrs-full:GrossCarryingAmountMemberifrs-full:TechnologybasedIntangibleAssetsMember2023-01-012023-12-310000845982snn:SportsMedicineMemberifrs-full:WeightedAverageMember2023-12-310000845982snn:OrthopaedicsMemberifrs-full:WeightedAverageMember2023-12-310000845982snn:EntMemberifrs-full:WeightedAverageMember2023-12-310000845982snn:AdvancedWoundManagementMemberifrs-full:WeightedAverageMember2023-12-310000845982snn:SportsMedicineMemberifrs-full:WeightedAverageMember2022-12-310000845982snn:OrthopaedicsMemberifrs-full:WeightedAverageMember2022-12-310000845982snn:AdvancedWoundManagementMemberifrs-full:WeightedAverageMember2022-12-310000845982snn:SportsMedicineMember2023-12-310000845982snn:EntMember2023-12-310000845982snn:AdvancedWoundManagementMember2023-12-310000845982snn:SportsMedicineMember2022-12-310000845982snn:AdvancedWoundManagementMember2022-12-310000845982ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembersnn:InstrumentsMember2023-01-012023-12-310000845982ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:OtherPropertyPlantAndEquipmentMember2023-01-012023-12-310000845982ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:LandAndBuildingsMember2023-01-012023-12-310000845982ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembersnn:InstrumentsMember2022-01-012022-12-310000845982ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:OtherPropertyPlantAndEquipmentMember2022-01-012022-12-310000845982ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:LandAndBuildingsMember2022-01-012022-12-310000845982snn:ProductRelatedIntangibleAssetsMember2023-01-012023-12-310000845982ifrs-full:TechnologybasedIntangibleAssetsMember2023-01-012023-12-310000845982ifrs-full:CustomerrelatedIntangibleAssetsMember2023-01-012023-12-310000845982snn:ProductRelatedIntangibleAssetsMember2022-01-012022-12-310000845982ifrs-full:TechnologybasedIntangibleAssetsMember2022-01-012022-12-310000845982ifrs-full:CustomerrelatedIntangibleAssetsMember2022-01-012022-12-310000845982snn:InventoryProvisionsAndOtherDifferencesMember2022-01-012022-12-310000845982snn:RetirementBenefitObligationMember2023-12-310000845982snn:LossesAndOtherTaxAttributesMember2023-12-310000845982snn:IntangiblesMember2023-12-310000845982snn:AcceleratedTaxDepreciationMember2023-12-310000845982snn:RetirementBenefitObligationMember2022-12-310000845982snn:LossesAndOtherTaxAttributesMember2022-12-310000845982snn:IntangiblesMember2022-12-310000845982snn:AcceleratedTaxDepreciationMember2022-12-310000845982snn:RetirementBenefitObligationMember2021-12-310000845982snn:LossesAndOtherTaxAttributesMember2021-12-310000845982snn:InventoryProvisionsAndOtherDifferencesMember2021-12-310000845982snn:IntangiblesMember2021-12-310000845982snn:AcceleratedTaxDepreciationMember2021-12-310000845982snn:TradingTaxLossesMember2023-12-310000845982snn:InventoryProvisionsAndOtherDifferencesMember2023-12-310000845982snn:TradingTaxLossesMember2022-12-310000845982snn:InventoryProvisionsAndOtherDifferencesMember2022-12-310000845982ifrs-full:AccumulatedImpairmentMemberifrs-full:TradeReceivablesMember2023-01-012023-12-310000845982ifrs-full:AccumulatedImpairmentMemberifrs-full:TradeReceivablesMember2022-01-012022-12-310000845982ifrs-full:RetainedEarningsMember2021-01-012021-12-310000845982ifrs-full:GrossCarryingAmountMembersnn:LaterThanOneMonthMember2023-12-310000845982ifrs-full:GrossCarryingAmountMemberifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember2023-12-310000845982ifrs-full:GrossCarryingAmountMemberifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember2023-12-310000845982ifrs-full:GrossCarryingAmountMemberifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember2023-12-310000845982ifrs-full:GrossCarryingAmountMemberifrs-full:CurrentMember2023-12-310000845982ifrs-full:AccumulatedImpairmentMembersnn:LaterThanOneMonthMember2023-12-310000845982ifrs-full:AccumulatedImpairmentMemberifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember2023-12-310000845982ifrs-full:AccumulatedImpairmentMemberifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember2023-12-310000845982ifrs-full:AccumulatedImpairmentMemberifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember2023-12-310000845982ifrs-full:AccumulatedImpairmentMemberifrs-full:CurrentMember2023-12-310000845982srt:OtherCurrencyMember2023-12-310000845982ifrs-full:GrossCarryingAmountMember2023-12-310000845982ifrs-full:AccumulatedImpairmentMember2023-12-310000845982currency:USD2023-12-310000845982currency:GBP2023-12-310000845982currency:EUR2023-12-310000845982ifrs-full:GrossCarryingAmountMembersnn:LaterThanOneMonthMember2022-12-310000845982ifrs-full:GrossCarryingAmountMemberifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember2022-12-310000845982ifrs-full:GrossCarryingAmountMemberifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember2022-12-310000845982ifrs-full:GrossCarryingAmountMemberifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember2022-12-310000845982ifrs-full:GrossCarryingAmountMemberifrs-full:CurrentMember2022-12-310000845982srt:OtherCurrencyMember2022-12-310000845982ifrs-full:GrossCarryingAmountMember2022-12-310000845982ifrs-full:AccumulatedImpairmentMember2022-12-310000845982currency:USD2022-12-310000845982currency:GBP2022-12-310000845982currency:EUR2022-12-310000845982ifrs-full:ForeignCountriesMember2023-01-012023-12-310000845982ifrs-full:CountryOfDomicileMember2023-01-012023-12-310000845982ifrs-full:ForeignCountriesMember2022-01-012022-12-310000845982ifrs-full:CountryOfDomicileMember2022-01-012022-12-310000845982ifrs-full:ForeignCountriesMember2021-01-012021-12-310000845982ifrs-full:CountryOfDomicileMember2021-01-012021-12-310000845982snn:PrivatePlacementDebtMember2023-12-310000845982snn:BioventusLlcMember2023-12-310000845982snn:BioventusLlcMember2022-12-310000845982ifrs-full:PlanAssetsMember2023-01-012023-12-310000845982ifrs-full:PlanAssetsMember2022-01-012022-12-310000845982snn:AcquisitionConsiderationMember2023-01-012023-12-310000845982snn:BioventusLlcMember2023-01-012023-12-310000845982snn:BioventusLlcMember2022-01-012022-12-310000845982snn:CartihealLtdMemberifrs-full:MajorBusinessCombinationMember2024-01-0900008459822020-01-012020-12-310000845982snn:IfrsEquityMember2023-01-012023-12-310000845982snn:IfrsDebtMember2023-01-012023-12-310000845982snn:IfrsEquityMember2022-01-012022-12-310000845982snn:IfrsDebtMember2022-01-012022-12-310000845982snn:IfrsEquityMember2021-01-012021-12-310000845982snn:IfrsDebtMember2021-01-012021-12-310000845982snn:DefinedBenefitPensionPlansMembersnn:OtherMemberifrs-full:Level1OfFairValueHierarchyMember2023-12-310000845982snn:DefinedBenefitPensionPlansMembercountry:USifrs-full:Level1OfFairValueHierarchyMember2023-12-310000845982snn:DefinedBenefitPensionPlansMembercountry:GBifrs-full:Level1OfFairValueHierarchyMember2023-12-310000845982snn:DefinedBenefitPensionPlansMembersnn:OtherMemberifrs-full:Level1OfFairValueHierarchyMember2022-12-310000845982snn:DefinedBenefitPensionPlansMembercountry:USifrs-full:Level1OfFairValueHierarchyMember2022-12-310000845982snn:DefinedBenefitPensionPlansMembercountry:GBifrs-full:Level1OfFairValueHierarchyMember2022-12-310000845982snn:DefinedBenefitPensionPlansMembersnn:OtherMemberifrs-full:Level1OfFairValueHierarchyMember2021-12-310000845982snn:DefinedBenefitPensionPlansMembercountry:USifrs-full:Level1OfFairValueHierarchyMember2021-12-310000845982snn:DefinedBenefitPensionPlansMembercountry:GBifrs-full:Level1OfFairValueHierarchyMember2021-12-3100008459822020-12-310000845982ifrs-full:ComputerSoftwareMember2023-12-310000845982ifrs-full:ComputerSoftwareMember2022-12-310000845982snn:TreasurySharesExcludingEmployeeShareTrustMember2022-01-012022-12-310000845982ifrs-full:TreasurySharesMember2022-01-012022-12-310000845982ifrs-full:RetainedEarningsMember2022-01-012022-12-310000845982ifrs-full:OrdinarySharesMember2022-01-012022-12-310000845982ifrs-full:IssuedCapitalMember2022-01-012022-12-310000845982ifrs-full:CapitalRedemptionReserveMember2022-01-012022-12-310000845982snn:FinancialLiabilitiesTotalMemberifrs-full:WeightedAverageMemberifrs-full:FixedInterestRateMembercurrency:USD2023-12-310000845982ifrs-full:WeightedAverageMemberifrs-full:FloatingInterestRateMember2023-12-310000845982snn:SeniorNotesMaturingNovember2024Member2023-12-310000845982snn:SeniorNotesMaturingJune2032Member2023-12-310000845982snn:SeniorNotesMaturingJune2030Member2023-12-310000845982snn:SeniorNotesMaturingJune2029Member2023-12-310000845982snn:SeniorNotesMaturingJune2028Member2023-12-310000845982snn:SeniorNotesMaturingJune2027Member2023-12-310000845982snn:SeniorNotesMaturingJanuary2026Member2023-12-310000845982snn:SeniorNotesMaturingJanuary2024Member2023-12-310000845982snn:CorporateBondMaturingOctober2030Member2023-12-310000845982snn:CorporateBondMaturingOctober2029Member2023-12-310000845982snn:FinancialLiabilitiesTotalMemberifrs-full:WeightedAverageMemberifrs-full:FixedInterestRateMembercurrency:USD2022-12-310000845982ifrs-full:WeightedAverageMemberifrs-full:FloatingInterestRateMember2022-12-310000845982snn:CorporateBondMaturingOctober2029Member2022-12-310000845982snn:CommittedBorrowingFacilitiesMember2023-12-310000845982ifrs-full:LaterThanFiveYearsMember2023-12-310000845982ifrs-full:LaterThanFiveYearsMember2022-12-310000845982ifrs-full:NotLaterThanOneYearMember2023-12-310000845982ifrs-full:NotLaterThanOneYearMember2022-12-3100008459822021-12-310000845982snn:RestOfWorldExcludingUnitedKingdomMember2023-01-012023-12-310000845982country:GB2023-01-012023-12-310000845982snn:RestOfWorldExcludingUnitedKingdomMember2022-01-012022-12-310000845982country:GB2022-01-012022-12-310000845982snn:RestOfWorldExcludingUnitedKingdomMember2021-01-012021-12-310000845982country:GB2021-01-012021-12-310000845982ifrs-full:TradingEquitySecuritiesMemberifrs-full:Level3OfFairValueHierarchyMember2023-12-310000845982ifrs-full:ContingentConsiderationMemberifrs-full:Level3OfFairValueHierarchyMember2023-12-310000845982ifrs-full:TradingEquitySecuritiesMemberifrs-full:Level3OfFairValueHierarchyMember2022-12-310000845982ifrs-full:ContingentConsiderationMemberifrs-full:Level3OfFairValueHierarchyMember2022-12-3100008459822022-12-310000845982ifrs-full:TradingEquitySecuritiesMemberifrs-full:Level3OfFairValueHierarchyMember2021-12-310000845982ifrs-full:ContingentConsiderationMemberifrs-full:Level3OfFairValueHierarchyMember2021-12-3100008459822023-04-012023-04-010000845982snn:OrthopaedicsMember2023-12-310000845982snn:OrthopaedicsMember2022-12-310000845982ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembersnn:ProductRelatedIntangibleAssetsMember2023-01-012023-12-310000845982ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:TechnologybasedIntangibleAssetsMember2023-01-012023-12-310000845982ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:CustomerrelatedIntangibleAssetsMember2023-01-012023-12-310000845982ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:ComputerSoftwareMember2023-01-012023-12-310000845982ifrs-full:SellingGeneralAndAdministrativeExpenseMember2023-01-012023-12-310000845982ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2023-01-012023-12-310000845982ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembersnn:ProductRelatedIntangibleAssetsMember2022-01-012022-12-310000845982ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:TechnologybasedIntangibleAssetsMember2022-01-012022-12-310000845982ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:CustomerrelatedIntangibleAssetsMember2022-01-012022-12-310000845982ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:ComputerSoftwareMember2022-01-012022-12-310000845982ifrs-full:SellingGeneralAndAdministrativeExpenseMember2022-01-012022-12-310000845982ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-01-012022-12-310000845982ifrs-full:SellingGeneralAndAdministrativeExpenseMember2021-01-012021-12-310000845982ifrs-full:OtherPropertyPlantAndEquipmentMember2023-01-012023-12-310000845982ifrs-full:LandAndBuildingsMember2023-01-012023-12-310000845982ifrs-full:GrossCarryingAmountMembersnn:InstrumentsMember2023-01-012023-12-310000845982ifrs-full:GrossCarryingAmountMemberifrs-full:OtherPropertyPlantAndEquipmentMember2023-01-012023-12-310000845982ifrs-full:GrossCarryingAmountMemberifrs-full:LandAndBuildingsMember2023-01-012023-12-310000845982ifrs-full:GrossCarryingAmountMemberifrs-full:ConstructionInProgressMember2023-01-012023-12-310000845982ifrs-full:GrossCarryingAmountMemberifrs-full:OtherPropertyPlantAndEquipmentMember2022-01-012022-12-310000845982ifrs-full:GrossCarryingAmountMemberifrs-full:LandAndBuildingsMember2022-01-012022-12-310000845982ifrs-full:GrossCarryingAmountMemberifrs-full:ConstructionInProgressMember2022-01-012022-12-310000845982ifrs-full:GrossCarryingAmountMembersnn:ProductRelatedIntangibleAssetsMember2023-01-012023-12-310000845982ifrs-full:GrossCarryingAmountMemberifrs-full:IntangibleAssetsUnderDevelopmentMember2023-01-012023-12-310000845982ifrs-full:GrossCarryingAmountMemberifrs-full:CustomerrelatedIntangibleAssetsMember2023-01-012023-12-310000845982ifrs-full:GrossCarryingAmountMemberifrs-full:ComputerSoftwareMember2023-01-012023-12-310000845982ifrs-full:GrossCarryingAmountMember2023-01-012023-12-310000845982ifrs-full:GrossCarryingAmountMemberifrs-full:IntangibleAssetsUnderDevelopmentMember2022-01-012022-12-310000845982ifrs-full:GrossCarryingAmountMemberifrs-full:CustomerrelatedIntangibleAssetsMember2022-01-012022-12-310000845982ifrs-full:GrossCarryingAmountMemberifrs-full:ComputerSoftwareMember2022-01-012022-12-310000845982ifrs-full:RestructuringProvisionMember2023-01-012023-12-310000845982ifrs-full:LegalProceedingsProvisionMember2023-01-012023-12-310000845982snn:MetalOnMetalHipClaimsProvisionMember2022-01-012022-12-310000845982ifrs-full:RestructuringProvisionMember2022-01-012022-12-310000845982ifrs-full:LegalProceedingsProvisionMember2022-01-012022-12-310000845982snn:MetalOnMetalHipClaimsProvisionMember2019-01-012019-12-310000845982ifrs-full:PresentValueOfDefinedBenefitObligationMember2023-01-012023-12-310000845982ifrs-full:PresentValueOfDefinedBenefitObligationMember2022-01-012022-12-310000845982snn:DefinedBenefitPensionPlansMembercountry:US2023-12-310000845982snn:DefinedBenefitPensionPlansMembercountry:GB2023-12-310000845982snn:DefinedBenefitPensionPlansMembercountry:US2022-12-310000845982snn:DefinedBenefitPensionPlansMembercountry:GB2022-12-310000845982snn:DefinedBenefitPensionPlansMembercountry:US2021-12-310000845982snn:DefinedBenefitPensionPlansMembercountry:GB2021-12-310000845982ifrs-full:GrossCarryingAmountMembersnn:InstrumentsMember2022-01-012022-12-310000845982ifrs-full:GrossCarryingAmountMembersnn:ProductRelatedIntangibleAssetsMember2022-01-012022-12-310000845982ifrs-full:GrossCarryingAmountMember2022-01-012022-12-310000845982snn:EngageSurgicalMember2022-01-180000845982snn:ExtremityOrthopaedicsMember2021-01-0400008459822022-01-012022-12-3100008459822021-01-012021-12-31iso4217:EURsnn:Optionssnn:segmentsnn:itemsnn:countrysnn:customeriso4217:GBPiso4217:USDxbrli:pureiso4217:CHFiso4217:USDiso4217:EURiso4217:USDiso4217:GBPiso4217:USDsnn:employeeiso4217:USDxbrli:sharesiso4217:GBPxbrli:sharesxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 20-F

 

INFORMATION FOR SHAREHOLDERS (Mark One)

REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934

or

 

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2023

or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

or

SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission file number 1-14978

 

Smith & Nephew

(Exact name of Registrant as specified in its charter)

 

England and Wales

(Jurisdiction of incorporation or organization)

Building 5, Croxley Park, Hatters Lane, Watford, Hertfordshire WD18 8YE

(Address of principal executive offices)

Helen Barraclough, +44-1923-477340, helen.barraclough@smith-nephew.com

Building 5, Croxley Park, Hatters Lane, Watford, Hertfordshire WD18 8YE

(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)

 

Securities registered or to be registered pursuant to Section 12(b) of the Act:

 

Title of each class

    

Trading Symbol

    

Name on each exchange on which registered

American Depositary Shares

Ordinary Shares of 20¢ each

2.032% Notes due 2030

4.565% Notes due 2029

SNN

SNN 30

SNLN

 

New York Stock Exchange

New York Stock Exchange*

New York Stock Exchange

New York Stock Exchange

* Not for trading, but only in connection with the first registration of American Depositary Shares, pursuant to the requirements of the Securities and Exchange Commission.

Securities registered or to be registered pursuant to Section 12(g) of the Act: None.

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None.

 

Indicate the number of outstanding shares of each of the issuer’s class of capital or common stock as of the close of the period covered by the annual report: 877,672,643 Ordinary Shares of 20¢ each

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act    Yes      No  

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934    Yes       No   

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days:    Yes       No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of “large accelerated filer, “accelerated filer,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer  

Accelerated Filer  

Non-accelerated filer   

Emerging growth company   

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 13(a) of the Exchange Act.       

† The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b) by the registered public accounting firm that prepared or issued its audit report.      

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.        

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).         

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

 U.S. GAAP

  

International Financial Reporting Standards as issued by the International Accounting Standards Board

  

Other

If “Other” has been checked in response to the previous question indicate by check mark which financial statement item the registrant has elected to follow:     Item 17       Item 18  

If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes       No  

GRAPHIC

Life Unlimited Annual Report 2023

GRAPHIC

Contents Our performance Strategic Report Our performance IFC Who we are 2 Chair’s statement 4 Chief Executive Officer’s review 8 Our marketplace 14 Our business model 16 Key Performance Indicators 18 Financial review 20 Creating value through innovation 26 Taking our innovation to market 34 Building a culture of belonging 46 Shaping a healthy and sustainable future 52 Risk report 67 Our stakeholders 82 Engaging with stakeholders 84 Governance Governance at a glance 88 Board leadership and Company purpose 90 Nomination & Governance Committee Report 102 Compliance & Culture Committee Report 111 Audit Committee Report 114 Directors’ Remuneration Report 121 Accounts Statement of Directors’ responsibilities 156 Report of Independent Registered Public Accounting Firm 157 Group income statement 172 Group statement of comprehensive income 172 Group balance sheet 173 Group cash flow statement 174 Group statement of changes in equity 175 Notes to the Group accounts 176 Company financial statements 227 Notes to the Company accounts 229 Other information Group information 235 Other information 236 Shareholder information 248 1 These non-IFRS financial measures are explained and reconciled to the most directly comparable financial measure prepared in accordance with IFRS on pages 244–248. The images used throughout the report represent the ways that Smith+Nephew is taking the limits off living and helping patients live Life Unlimited. Images used are not photographs of our patients unless expressly indicated. $5,549m Group revenue 37.5¢ Unchanged +6.4% Dividend per share Reported +7.2% Underlying1 $425m -5.4% Operating profit 7.7% -90bps Operating profit margin $970m +7.6% Trading profit1 17.5% +20bps Trading profit margin1 30.2¢ +1.3% Earnings per share (EPS) 82.8¢ +18.2% Adjusted earnings per share1 (EPSA) $829m +42.7% Cash generated from operations $635m +43.0% Trading cash flow1 $339m -1.8% R&D investment 5.9% -70bps Return on invested capital1 (ROIC)

GRAPHIC

Physical health is never just about our body. It’s our mind, feelings and ambitions. When something holds us back, it’s our whole life on hold. We’re here to change that, to use technology to take the limits off living, and help other medical professionals do the same. So that patients can stare down fear, see that anything is possible, then go on stronger. Inspired by a simple promise. Two words that bring together all we do… Life Unlimited To learn more about our purpose visit www.smith-nephew.com Smith+Nephew Annual Report 2023 1 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION

GRAPHIC

Who we are Creating value through innovation Research & Development Developing new technology through our Research & Development (R&D) programme, and acquiring exciting technologies where we can add value. Medical education The Smith+Nephew Academy network supports the safe and effective use of our products and provides opportunities to learn innovative clinical techniques. Manufacturing Building resilient manufacturing and supply chains to ensure quality and competitiveness and support new product development. Shaping a healthy and sustainable future Our ESG strategy supports our Strategy for Growth and strengthens the foundation to help us serve customers over the long term. Our ESG strategy focuses on three areas: People, Planet and Products. » People: Creating a lasting positive impact on our communities. » Planet: Aiming to reduce our impact on the environment. » Products: Innovating sustainably. Building a culture of belonging We strive to create a culture of belonging where employees can bring their full selves and best ideas, which fosters innovation, delivers business success and strengthens engagement and personal fulfilment. Our culture is based on our values of Care, Courage and Collaboration. » Care: A culture of empathy and understanding for each other, our customers and their patients. » Courage: A culture of continuous learning, innovation and accountability. » Collaboration: A culture of teamwork based on mutual trust and respect. » See pages 26–29 » See pages 30–31 » See pages 32–33 » See pages 52–66 for information on our sustainability targets and progress » See pages 46–49 for more on how we are building our culture 168 year history 14+ million patients treated with our products 100+ countries served $339 million R&D investment 18,452 employees 20 new product launches We are a leading Key facts 2023 portfolio medical technology company. We exist to restore people’s bodies and their self-belief. 2 Smith+Nephew Annual Report 2023

GRAPHIC

Taking our innovation to market We take our innovation to market through three global business units of Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. These business units are responsible for strategy and global marketing, and contain specialist sales and support teams dedicated to serving the specific requirements of our healthcare professional customers. Serving our customers through our sales force We pride ourselves on giving customers a high standard of service through our specialist sales and clinical support teams. Representatives in our surgical businesses have a detailed knowledge of the products and instruments that they sell and the surgical techniques they may be used for, and provide technical and logistical support to surgeons and hospitals. In Advanced Wound Management, sales representatives develop their knowledge of how clinicians seek to prevent and treat wounds, as well as support customers through their understanding of the economic benefits of using our products within treatment protocols. Sports Medicine & ENT Our Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. They operate in growing markets where unmet clinical needs provide opportunities for procedural and technological innovation. Advanced Wound Management Our Advanced Wound Management portfolio provides a comprehensive set of products and services to meet broad and complex clinical needs across hard to heal wounds, delivering on our mission to shape what is possible in wound care. Orthopaedics Orthopaedics includes an innovative range of hip and knee implants used to replace diseased, damaged or worn joints, robotics-assisted and digital enabling technologies and services that empower surgeons, and Trauma & Extremities products used to stabilise severe fractures and correct hard tissue deformities, as well as a shoulder replacement system. 40% of Group revenue 31% of Group revenue 29% of Group revenue » See pages 34–37 » See pages 38–41 » See page 42–45 Smith+Nephew Annual Report 2023 3 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION

GRAPHIC

Chair’s statement Encouraged by the progress made, excited by our prospects for the future “Deepak has set out a confident outlook as he leads the business in the Strategy for Growth and the second year of delivery of the 12-Point Plan.” Rupert Soames Chair Dear Fellow Shareholder, It is a great honour to write to you for the first time as Chair of Smith+Nephew, and to share my reflections on the year just gone and the journey ahead. But before I do, I want to pay tribute to my predecessor Roberto Quarta who chaired the Company with great care and diligence for nine, sometimes difficult, years. Most recently, he as Chair and Marc Owen as Senior Independent Director, have supported my induction and transition to Chair with sensitivity and skill, for which I am grateful. Since joining the Board on 26 April 2023, I have been learning about the business: its products and services; its people, customers and competitors; its strengths and weaknesses, as well as the opportunities and threats it faces. In all these things I have been supported by Deepak Nath, our Chief Executive Officer, who has deep knowledge of, and experience in, the MedTech sector. Many of our larger investors have also been generous with their time, candid in their analysis, and speak from many years’ experience of both the sector and Smith+Nephew. In addition, I had the opportunity to meet some of our smaller investors at the Annual General Meeting in April, which was a pleasure to attend and a reminder that ultimately, in all we do, there are savers and pensioners who rely on us to grow the value of their investments. Setting clear priorities In a world in which stakeholders have different, and sometimes conflicting, views on how, and to what end, companies should be run, Boards have to be resolute in discharging their responsibilities in the best interests of the Company as a whole. This means they have to have priorities, and to be clear on what their job is. 4 Smith+Nephew Annual Report 2023

GRAPHIC

The first priority of the Board is to hire and retain management who can lead Smith+Nephew to be the best business it can be; and then, watching closely, encourage, support, guide and challenge them in their work. As a Board, we are very well aware that Smith+Nephew has not performed to its full potential in recent years. The reasons for this, and more importantly, what management are doing about it, are set out in the Strategy and Operating Reviews, and I am pleased to say that in 2023 there were encouraging signs of progress. In Deepak Nath, we have an exceptionally talented CEO, and the Board is following closely the implementation of the 12-Point Plan he and his executive team developed to enable Smith+Nephew to create sustainable long-term value. Deepak has a rare combination of strategic vision and grasp of detail, and under his leadership the business has begun to gather forward momentum, including accelerating revenue growth. Joining Deepak from December 2023 is John Rogers, who will succeed Anne-Françoise Nesmes as Chief Financial Officer in the first quarter of 2024. John brings long experience as a former CFO of two FTSE 100 companies, and has also managed impressive transformations of companies’ operations. I would like to thank Anne-Françoise for her dedication and support to the business over the last three years, during which she has had to support a change of CEO and the significant impact of Covid on the business. The other priority of the Board is to serve our shareholders and wider stakeholders by governing the business effectively and in accordance with regulation and good practice, but with an emphasis on substance over form, simplicity over complexity, and transparency over opaqueness. Governance at Smith+Nephew embraces many different areas. In terms of risk management, Smith+Nephew shares a similar palette of risks to other manufacturers, but the application of medical devices, products and services in the treatment of people, the global scale of our operations, and the highly regulated environment in which we operate make monitoring of operating risk a key part of the Board’s responsibilities. In matters of corporate regulation and corporate governance, being dual-listed brings a degree of complexity. Smith+Nephew hews to the rules and regulations of both the London Stock Exchange, which is our primary listing, and the New York Stock Exchange. Our NYSE listing as a foreign private issuer brings us under the ambit of the Securities and Exchange Commission, and means that we have made the significant investment required to comply with US regulations including the applicable requirements of the Sarbanes-Oxley Act. Like many listed companies, Smith+Nephew works hard to adapt to a changing landscape of regulation and reporting requirements, all of which seem to have one result in common: significantly more lengthy Annual Reports. But whilst companies can adapt to evolving and greater reporting requirements, be it on audit or environmental or social issues, what they cannot manage is operating within a framework which does not allow them to recruit and retain the management they need to grow. Visiting our Advanced Wound Management R&D and manufacturing facility in Hull, UK 37.5¢ Dividend unchanged Smith+Nephew Annual Report 2023 5 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION

GRAPHIC

Smith+Nephew has a proud British heritage – our Company was founded in Hull in 1856 and we have grown over the last 168 years to become a truly global organisation with over 18,000 employees operating in around 100 countries. As a result of that success and global growth, the UK accounts for around 3% of our revenues and 7% of our employees, whilst over 50% of our revenues arise in the US, and nearly all of our senior operational managers, including our CEO, are US citizens, and based in the US. Pay practices differ widely around the world, and it is axiomatic and uncontroversial that companies pay their management teams in line with the norms of the country where they live and work. This approach is accepted without qualm by stakeholders for the millions of people which businesses such as Smith+Nephew employ around the world, with one exception: Executive Directors who are expected to be paid by reference to the norms of the country in which their employer has its primary listing, irrespective of where they actually live, work, and pay tax. This is unique to a listed company environment, and of course does not apply to privately-owned businesses. Currently our remuneration policies for Executive Directors are aligned to the norms of people living and working in the UK; given the small proportion of our revenues that arise in the UK, and the fact that the centre of gravity of the MedTech industry is in the US, this is not sustainable if we are to attract and retain people who live and work in the US. It is for this reason that our Chair of Remuneration, Angie Risley, and I have had extensive consultations with our largest investors in recent months and they have confirmed their broad support for our proposals to give Smith+Nephew the ability to attract and retain senior executives in the United States, if we need to do so. Our 2024 Remuneration Policy proposes a package of long-term incentive plan adjustments for US-based executives to be more closely aligned with norms in the US in terms of structure and quantum, and a comprehensive discussion of our proposals is set out on pages 121–135 of our Remuneration Report. The Board strongly believes that these proposals are in the best interests of the Company and that they will help the Board to execute on its priority to ensure the Company is led by a first-class management team. In other issues pertaining to governance and people, we are committed to fostering diversity in its broadest sense and we continue to ensure that our Board membership draws from a wide range of backgrounds and cultures. Our Board is truly multi-cultural and includes members who are from, live, or work in the US, UK, China, India, Germany and Poland. We continue to review the composition of the Board on an ongoing basis; we actively review diversity in addition to skillsets and capabilities as part of our Board succession planning process and ensure that our candidate selection process for new Board members comprises a balanced slate of candidates for consideration. We consider diversity of candidates on every appointment and selection is based on ensuring we have the best person for the role. When Anne-Françoise steps down from the Board in 2024 our Board will continue to have three experienced female Directors (Angie Risley, Katarzyna Mazur-Hofsaess and Jo Hallas), acknowledging that our percentage of female Board members will, in the short term, reduce from 33.3% to 27.3%. Our Board succession plan will seek to address this as other NEDs step down from the Board. We have announced a number of other changes to our Board this year. I would like to thank Rick Medlock and Erik Engstrom for their highly-effective service. Erik stepped down after nine years on 31 December 2023 and Rick has confirmed to the Board that he will not submit himself for re-election at our AGM in May 2024. In their place, Jez Maiden and Simon Lowth, both of whom have extensive executive and non-executive experience within large and complex global companies, have joined the Board. Until recently, Jez was CFO of Croda International and has held a number of non-executive roles including as Senior Independent Director at Travis Perkins plc. As announced, Jez will assume the role of Chair of our Audit Committee with effect from 1 March 2024. Simon is CFO of BT Group and has previously served as a non-executive director of Standard Chartered. I am delighted that our Board has been able to attract such strong candidates to continue to encourage diversity of perspective and experience on its Board. Taken in the round, I believe that your Board has the skills, diversity, strength and experience to operate effectively in the interests of all stakeholders. You can find more information on our Board and Committees and their work in our Governance Report starting on page 88 of this Annual Report. The Board also places strong emphasis on being a good corporate citizen, supporting our communities and reducing our impact on the planet and its resources. During the year we reviewed progress across our ESG strategy, and welcomed the establishment of a new governance structure and strengthened leadership in this area. More information on our progress against our sustainability targets, including our roadmap to net zero, can be found on pages 52–66. Chair’s statement continued 6 Smith+Nephew Annual Report 2023

GRAPHIC

2023 performance 2023 saw Smith+Nephew make progress both in terms of operational performance and financial results. Revenue grew at 6.4% on a reported basis which equates to 7.2% on an underlying basis.1 Trading profit margin1 was slightly ahead of the prior year, but the strong top-line growth meant that trading profit1 grew 7.6% on a reported basis. Operating profit was $425 million, with an operating profit margin of 7.7%. Cash generation from operations improved over the prior year, but was below where it should be going forward. Having considered the performance in the round, and the ongoing investments, the Board is recommending a final dividend of 23.1¢ per share. Together with the interim dividend of 14.4¢ per share, this will give a total distribution of 37.5¢ per share, unchanged from 2022. Our colleagues Before looking ahead in the Outlook, I want to pay tribute on behalf of the Board to our Smith+Nephew colleagues. Having worked in several large and global businesses during some 40 years of executive life, I think I know what good looks like when it comes to corporate culture, and I have been deeply impressed by the resilience, commitment and skill of my colleagues. They have had many dragons to wrestle with in recent years, not the least of which has been a number of leadership changes with their attendant uncertainties and distractions. Throughout they have remained focused on their purpose of helping people to take the limits off living and restore and promote health and wellbeing. I know the Board respects and is deeply grateful for their hard work, and is proud to be part of the same team. Outlook: building momentum Deepak has set out a confident outlook as he leads the business in the Strategy for Growth and the second year of delivery of the 12-Point Plan, and the Board is encouraged by the accountability shown and the progress the business has made in 2023, and excited by the prospects for the future. We look forward to welcoming shareholders to our Annual General Meeting in person in May and to updating you further on the transformation underway at Smith+Nephew. Yours sincerely, Rupert Soames, OBE Chair »See page 88 for our Governance Report »See page 121 for our Remuneration Policy 1 These non-IFRS financial measures are explained and reconciled to the most directly comparable financial measure prepared in accordance with IFRS on pages 244–248. Smith+Nephew Annual Report 2023 7 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION

GRAPHIC

Chief Executive Officer’s review Strong revenue growth and improved trading profit margin “The progress we are making is fundamental as we need to have a strong platform from which we will be able to build further shareholder value.” Deepak Nath, PhD Chief Executive Officer Dear Fellow Shareholder, In 2023 we delivered strong revenue growth and an improved trading profit margin1 as the results of our actions to transform Smith+Nephew started to come through. Our 12-Point Plan is on track, with progress beginning to translate into financial outcomes, and our innovation strategy is delivering a strong pipeline of new products that we expect to drive performance in the next few years and beyond. 2023 performance Group revenue in 2023 was $5,549 million, an increase of 7.2% on an underlying basis1 (6.4% reported). This growth was ahead of our full-year guidance published in February 2023 for underlying1 revenue growth between 5.0% and 6.0%, and reflects the strength of the portfolio, with all three business units delivering underlying1 growth above 5% for the full year. Operating profit was $425 million, with an operating profit margin of 7.7%. Trading profit1 for 2023 was up 7.6% on a reported basis to $970 million. The trading profit margin1 was 17.5%, a 20bps improvement on the prior year and in line with our full-year guidance. 1 These non-IFRS financial measures are explained and reconciled to the most directly comparable financial measure prepared in accordance with IFRS on pages 244–248. Transforming Smith+Nephew In July 2022, we announced our 12-Point Plan to fundamentally change the way Smith+Nephew operates, accelerating delivery of our Strategy for Growth and transforming to a consistently higher-growth company. The 12-Point Plan is focused on: 1. Fixing Orthopaedics, to regain momentum across hip and knee implants, robotics and trauma, and win share with our differentiated technology; 2. Improving productivity, to support trading profit margin expansion; and 3. Further accelerating growth in our already well-performing Advanced Wound Management and Sports Medicine & ENT business units. Since inception we have measured our progress across the 12-Point Plan through a set of internal KPIs to drive accountability. The 12-Point Plan is on track and starting to deliver financial outcomes. Work will continue in 2024, with further financial progress expected to follow across the year and in 2025. 8 Smith+Nephew Annual Report 2023

GRAPHIC

Fixing Orthopaedics We have made solid progress on fixing much of Orthopaedics, and laid the foundations for further improvement. Overall, 2023 full year business unit growth was 5.7% underlying1 (4.8% reported), strongly ahead of last year’s growth, which was 1.9% underlying1 (-2.0% reported). Performance has improved in Hip and Knee Implants outside of the US, and globally in Other Reconstruction (which includes robotics) and Trauma & Extremities. Recovery has been slower to come through in US Reconstruction, and especially in US Knee Implants. Product availability has been central to these variances in performance. By year end, across Orthopaedics, on the percentage of customer order lines filled (measured by line-item fill rates (LIFR)), we had closed more than 95% of the gap between the low point and our target of being in line with industry standard. Within this, in US Reconstruction there are still some areas of inconsistent product availability, which, together with slower than anticipated set deployments and some expected impact from sales force change, limited our ability to win new business. Through the 12-Point Plan we are continuing to address the factors that have undermined performance in US Reconstruction. We are making headway on inventory through better sales and operations planning, improving forecasting and bringing the mix of what we manufacture in line with demand. By the end of 2023, inventory levels for all business units were starting to come down as we expanded recent product launches, consumed raw materials and completed and deployed new instrument sets. We turned a corner in 2023, and brought Days Sales of Inventory down by 5% for the year, after several years of increase, and expect to continue this improvement in 2024 and beyond. A significant driver of the overall Orthopaedics improvements has been the new demand and supply planning process which has brought a deeper level of specificity and collaboration between our operations and commercial teams. We are also benefiting from our actions to improve logistics and redeploy implants and instrument sets from lower to higher-utilisation customers. Transform Through innovation and acquisition Accelerate Profitable growth through prioritisation and customer focus Strengthen The foundation to serve customers sustainably and simply Strategy for Growth Fixing Orthopaedics, to regain momentum across hip and knee implants, robotics and trauma, and win share with our differentiated technology Improving productivity, to support trading profit margin expansion Further accelerating growth in our well-performing Advanced Wound Management and Sports Medicine & ENT businesses, representing approximately 60% of Group revenue Delivered through our 12-Point Plan Fixing Orthopaedics Improving productivity Accelerating Sports Med and AWM Smith+Nephew Annual Report 2023 9 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION

GRAPHIC

Chief Executive Officer’s review continued We have invested in improving our commercial execution. In 2023 we repositioned our offering and undertook deeper sales training for the Orthopaedics team, and enhanced our incentive plans to better align reward with performance, sales mix, robotic placement and implant pull-through. These steps are expected to help us address the performance in Hip and Knee Implants in the US, which remains a priority. At the same time, they will also ensure we sustain the progress we have delivered elsewhere. In Trauma & Extremities, where we have successfully addressed availability of product and instrument sets for our EVOS◊ Plating system, we are focused on maintaining the improved growth dynamic delivered in the second half of 2023. Improving productivity We have made good progress on our actions to improve productivity, contributing around 160bps to our 2023 trading profit margin1. Actions have included updating and standardising pricing strategies across our portfolio and reducing days sales outstanding. We are also making procurement savings to help mitigate cost inflation and drive productivity. During 2023, we deployed an enhanced supplier selection process to identify and award business to suppliers that better align to the global business unit strategies and long-term performance metrics, and better aligned global category strategies to unlock the Smith+Nephew buying power and leverage, helping to drive volume to the most preferred suppliers and reduce cost. In line with our plan, work on manufacturing optimisation is at an earlier stage, with the benefits from network simplification and cost and asset efficiencies expected to support our mid-term margin improvement targets. The underlying work is progressing, with KPIs tracking accordingly. For instance, conversion cost, which is total direct and indirect cost to convert raw materials into finished goods as a percentage of sales, started to come down in the second half. Better aligned supply and demand process has enabled us to critically assess our manufacturing capacity. From a network perspective we are reducing excess capacity, having exited one small site in France and announced the closures of two more in China and Germany. Over the last two years we have also reduced hiring and our reliance on contingent workers. Accelerating AWM and Sports Medicine The important third pillar of the 12-Point Plan is focused on building on our consistent above-market performance from our Advanced Wound Management and Sports Medicine & ENT business units. Progress is also coming through across this workstream. Our negative pressure wound therapy business is benefiting from focused additional resource behind our sales force, delivering strong growth in 2023 across both our traditional RENASYS◊ Negative Pressure Wound Therapy System and our single-use PICO◊ Negative Pressure Wound Therapy System. We are pleased with our progress across Ambulatory Surgical Centers (ASCs), as we more than tripled the pace of cross-business unit deals between our Orthopaedics and Sports Medicine businesses in 2023. Under the 12-Point Plan we have developed a coordinated approach across these business units overseen by a dedicated strategic sales team. We are building on the strong position established by our Sports Medicine business, which is already the preferred choice for a large proportion of the ASC market, and successfully introducing our Orthopaedics portfolio. Creating value through innovation Innovation through our R&D programme is central to our higher-growth ambitions. In 2023, approaching half of our full year underlying revenue growth came from products launched in the last five years. Encouragingly, some of our key growth platforms like our robotics-enabled CORI◊ Surgical System, our EVOS◊ trauma plating platform and our REGENETEN◊ Bioinductive Implant for biological healing are not only contributing to growth today, but also have multi-year runways still ahead of them as we expand applications and launch in new markets. In 2023 we delivered a good cadence of new product launches, completing 20 with development finished on a further two ahead of launch in 2024. These included expanding CORI◊ , adding functionality and AI powered planning tools. We introduced our AETOS◊ Shoulder System, an important part of our growth plans for Trauma & Extremities which will enable Smith+Nephew to compete effectively in the $1.7 billion shoulder market, which, at around 9% CAGR, is one of the fastest growing segments in Orthopaedics. In Advanced Wound Management, we are at the early stages of rolling out the new RENASYS◊ EDGE NPWT System. RENASYS◊ EDGE brings an important new option to customers looking for enhanced intuitiveness, simplicity and durability, especially important for home-care settings. We also continued to invest behind our Sports Medicine portfolio, for instance launching REGENETEN◊ in China, India and Japan. Acquisition of CartiHeal In recent years we have successfully augmented our R&D programmes with acquisitions of exciting technologies. During the year we announced another such acquisition, CartiHeal, the developer of the CARTIHEAL◊ AGILI-C◊ Cartilage Repair Implant, a novel sports medicine technology for cartilage regeneration in the knee. CARTIHEAL◊ AGILI-C◊ is an off-the-shelf one-step treatment for osteochondral (bone and cartilage) lesions with a broader indication than existing treatments. It is indicated to treat a wide patient population, including those with lesions in knees with mild to moderate osteoarthritis, a previously unaddressed condition. Our expertise in regenerative therapy and leadership in knee repair gives me great confidence that this will be a significant value creator for Smith+Nephew over the mid-term. You can read more about our R&D programme and CARTIHEAL◊ AGILI-C◊ on pages 26–29. 1 These non-IFRS financial measures are explained and reconciled to the most directly comparable financial measure prepared in accordance with IFRS on pages 244–248. 10 Smith+Nephew Annual Report 2023

GRAPHIC

We also continued to deliver on our environmental commitments and are proud of our many achievements including our ‘AA’ MSCI ESG Rating and our recurring inclusion in leading indices, such as FTSE4Good and the ESG Index from Institutional Shareholder Services (ISS). We are on track to achieve a 70% reduction in Scope 1 and Scope 2 greenhouse gas (GHG) emissions by 2025 compared to the 2019 baseline. This year, we are reporting both our 2022 and 2023 Scope 3 GHG emissions from 13 categories and are developing our Scope 3 GHG emissions reduction roadmap. You can read about these endeavours on pages 52–66 and in our Sustainability Report on our website. I would like to use this opportunity to thank Anne-Françoise for her dedicated service since she joined in 2020 and for her commitment to ensuring a smooth transition to our new Chief Financial Officer, John Rogers. I have been immensely impressed with how John has approached his on-boarding and I look forward to working together as we continue to turn around performance and deliver the 12-Point Plan. Some years in a company are all about new strategies, transformational moves or dealing with fundamental external challenges; some years are more foundational, but nevertheless important. For Smith+Nephew, 2023 was about improving how we operate, focusing on the day-to-day processes and ultimately bringing our innovation to customers in a more reliable and simpler way. The progress we are making is fundamental as we need to have a strong platform from which we will be able to build further shareholder value and address our longer-term ambitions. Yours sincerely, Deepak Nath, PhD Chief Executive Officer A strong sense of belonging The 12-Point Plan has also been a vehicle for cultural change. The discipline we’ve driven through execution of the plan is fostering new behaviours and creating a sustainable culture marked by customer-centricity, agility and speed, execution rigour and consistently high-performing teams. As importantly, we’ve made progress in creating a workplace where each of us feels a sense of belonging. We put in place a global steering group to guide our global wellbeing strategy across physical, mental and financial wellness and conducted numerous internal inclusion events – many championed by our Employee Inclusion Groups. As teams and individuals, we donated our time and talents to our local communities, participating in many charitable events and using more than 13,000 hours of our volunteer time off in meaningful ways that advanced Life Unlimited around the world. Improve value and cash processes Scale Negative Pressure Wound Therapy Optimise procurement Drive cross-selling in ASCs Manufacturing optimisation Executing our 12-Point Plan The 12-Point Plan is on track and starting to deliver financial outcomes. Work will continue in 2024, with further financial progress expected to follow across the year and through 2025. Multiple KPIs are used to measure delivery against the two-year 12-Point Plan. c. 65% Overall progress against milestones 75% 75% 75% 50% 50% 50% Rewire Orthopaedics commercial delivery 1 point 3 point Win market share with our technology Streamline our recon portfolio 2 point 1 point 1 point 2 point 1 point 1 point Fixing Orthopaedics Improving productivity Accelerating Sports Med and AWM 75% 50% Smith+Nephew Annual Report 2023 11 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION

GRAPHIC

12 Smith+Nephew Annual Report 2023

GRAPHIC

Letting brothers enjoy their vacation together Life Unlimited 13 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION Smith+Nephew Annual Report 2023

GRAPHIC

Our marketplace Leading positions in attractive markets Smith+Nephew competes in global markets worth around $45 billion per annum. Long-term growth drivers Influencing the development of innovative treatments and the evolution of healthcare delivery. The medical technology industry is underpinned by compelling long-term growth drivers that make it an attractive market. Demographic trends, such as an ageing population and greater levels of physical activity later in life, continue to fuel demand for healthcare services. As the global population grows older, there is a natural increase in the prevalence of chronic diseases and age-related conditions, necessitating ongoing medical care. Other lifestyle-related health conditions, such as increasing prevalence of diabetes and obesity, create further demand. Advancements in medical technology are catalysts for long-term growth in healthcare. Breakthroughs in fields like artificial intelligence and biotechnology are leading to more effective and personalised healthcare solutions. This innovation enhances patient outcomes and creates new business opportunities supporting further growth. Emerging markets Increasing healthcare demand creates opportunities and challenges for healthcare providers. In emerging markets, the long-term growth drivers have been compounded by economic development including the emergence of an increasingly prosperous middle class driving demand for better healthcare services and products. As living standards improve, people seek access to higher-quality healthcare, including advanced medical treatments and medical devices. Additionally, emerging markets may have less mature healthcare infrastructure with a pressing need for investment in healthcare technology, which benefits companies offering innovative medical solutions. Emerging markets can be more receptive to novel healthcare solutions which fosters an environment where innovative and cost-effective approaches can gain rapid acceptance. Decentralised care Promoting accessible care outside traditional hospital settings. While the medical technology market has matured in recent years, changing customer and market dynamics have created new high-growth opportunities. In many countries care is becoming more decentralised, with more procedures moving to outpatient settings such as Ambulatory Surgery Centers (ASCs) in the US. This has long been a feature of the sports medicine market, but a growing percentage of orthopaedic joint replacement cases are now completed in such settings, bringing cost and time savings for healthcare providers. The trend towards outpatient care was accelerated by Covid as providers sought to keep patients out of hospitals and also tackle procedure backlogs. POLAR3◊ Total Hip Solution 14 Smith+Nephew Annual Report 2023

GRAPHIC

Seasonality Seasonality necessitates agile strategies to navigate fluctuations in demand throughout the year. There tends to be a higher volume of orthopaedic and sports medicine procedures during the winter months in our markets, when accidents and sports-related injuries are more frequent. Elective procedures tend to slow down in the summer months due to holidays. Advanced Wound Management is less impacted by seasonality due to the nature of procedures and products. At Smith+Nephew, the majority of our business is in the northern hemisphere, including approximately 50% in the US and 20% in Europe. In the US, out-of-pocket costs for health insurance plans are tied to medical expenses in a calendar year. As a result, households that have reached their annual deductible amount and/or annual out-of-pocket cap before the year’s end will find it to be cost-effective to schedule necessary procedures later in that year rather than delaying into the next year. Cost of healthcare A pressing concern globally, necessitating comprehensive strategies for sustainable healthcare delivery. Governments are focused on reducing the cost of healthcare and are sensitive to price. Medical technology companies respond through new innovation and also provide evidence supporting both the clinical and economic benefits of products. Globally, countries are focused on increasing domestic production across critical sectors, including advanced technologies and life sciences. These actions include localisation policies and export restrictions that disrupt global supply chains. Simultaneously, many countries in key emerging markets are targeting measures to lower healthcare costs and broaden accessibility, implementing price-control policies with respect to government procurement of healthcare products. In China, we saw this reflected in the introduction of volume-based procurement in some of our segments. » See pages 67–79 for more details on risks in the Risk report High regulation Stringent regulations in the medical devices industry play a crucial role in ensuring product safety, efficacy, and quality. The medical device sector is one of the world’s most heavily regulated industries providing a high cost of entry for market participants. National regulatory authorities govern the design, development, approval, manufacture, labelling, marketing and sale of healthcare products. They also review data supporting the products to ensure they are safe and perform as intended. The majority of countries require products to be authorised or registered prior to entering the market, and such authorisation or registration needs to be subsequently maintained. Regulations and industry codes govern the way the industry interacts with healthcare professionals and government officials globally, including the AdvaMed Code of Ethics and the MedTech Europe Code of Ethical Business Practice. Companies establish global compliance programmes to help employees and third-party partners comply with laws, regulations and industry codes, and often have their own codes of conduct to guide behaviour. » See page 49 for more information on our approach to compliance Smith+Nephew Annual Report 2023 15 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION

GRAPHIC

Our business model How we create value Through our business model we strive to transform outcomes for the patients we serve, for the clinicians and the healthcare systems we support, for the Company and our shareholders. Our Strategy for Growth focuses our efforts, and our purpose of Life Unlimited inspires us every single day. 1 These non-IFRS financial measures are explained and reconciled to the most directly comparable financial measure prepared in accordance with IFRS on pages 244–248. People A purpose-driven culture based on authentic values committed to doing business in the right way. R&D Innovation is at the heart of our business and we prioritise investment in new products, technologies and services. Financial strength A robust balance sheet and Capital Allocation Framework balancing investments in the future and returns today. Sustainability Addressing the long-term needs of our customers, employees, communities and stakeholders, reducing our impact on the environment. Global operations Resilient manufacturing and supply chains to ensure quality and competitiveness. What we need to create value Delivering value for stakeholders 17.5% +20bps Trading profit margin¹ 7.7% -90bps Operating profit margin $327m Dividend distribution unchanged $970m +7.6% Trading profit¹ $425m -5.4% Operating profit $5,549m +6.4% reported +7.2% underlying¹ Group revenue Investors Community $5.1m Product donations 4.20 +0.08 Gallup engagement score 97,405 Training sessions Employees Customers 20 New product launches 16 Smith+Nephew Annual Report 2023

GRAPHIC

How we create value Innovative technology We offer a broad portfolio of differentiated products and services that meet often-complex clinical needs, including digital and robotic technologies, driving procedural innovation. Product development and acquisition R&D model that provides for customer and business unit focused innovation and acquiring technologies needing further development and commercialisation. Expertise and support Our sales force supports customers and works with healthcare systems to address complex business and reimbursement requirements. Medical education Through the Smith+Nephew Academy, a network of centres and online resources, we provide medical education programmes to support the safe and effective use of our products, skills development and procedural innovation. Go to market Three global business units set product strategy and deliver global marketing to drive demand in our markets, supported by clinical evidence to demonstrate efficacy. Customer feedback Building close relationships with customers to ensure a deep understanding of unmet clinical needs and changing financial and sustainability priorities within healthcare systems. 6 2 5 3 4 1 Customer centricity Smith+Nephew Annual Report 2023 17 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION

GRAPHIC

5.9% ROIC Key Performance Indicators Measuring our progress Smith+Nephew uses a number of financial and non-financial Key Performance Indicators (KPIs) to track and evaluate performance and delivery against its Strategy for Growth and other business objectives. Those KPIs in the public domain are consolidated below. A number of other KPIs are commercially sensitive and are not published but are used internally to drive performance and growth. Revenue growth Reported revenue growth includes a foreign exchange headwind of -80bps. Revenue growth allows management and investors to measure our relative performance. We are targeting underlying revenue growth of 5%+ in the medium term. Underlying revenue growth was ahead of our guidance for 2023, with all three global business units delivering above 5% underlying growth. Profit margin Reported profit margin reflects restructuring costs, as well as acquisition and disposal-related items, amortisation and legal and other items. Profit margin allows management and investors to determine our relative performance. We are targeting at least a 20% trading profit margin in 2025. Trading profit margin was in line with our guidance for 2023, representing a 20bps improvement year-on-year. Financial Key Performance Indicators Return on invested capital1 ROIC decreased from 6.6% in 2022 to 5.9% in 2023 due to lower operating profit. ROIC allows management and investors to measure the return generated on capital invested, providing a metric for long-term value creation. Dividend per share Total distribution of 37.5¢ per share, unchanged from 2022. Dividend payments allow investors to receive a cash return on their investment in Smith+Nephew. 1 These non-IFRS financial measures are explained and reconciled to the most directly comparable financial measure prepared in accordance with IFRS on pages 244–248. 6.4% Reported revenue growth 7.7% Operating profit margin 7.2% Underlying1 revenue growth 17.5% Trading profit margin1 37.5¢ Dividend per share % % ¢ % % % 12-Point Plan Transforming Smith+Nephew In July 2022 we announced our 12-Point Plan to fundamentally change the way we operate and transform business performance. The 12-Point Plan is focused on: – Fixing Orthopaedics, to regain momentum across hip and knee implants, robotics and trauma, and win share with our differentiated technology; – Improving productivity, to support trading profit margin expansion; and – Further accelerating growth in our already well-performing Advanced Wound Management and Sports Medicine & ENT business units. »See pages 8–11 for more on our 12-Point Plan 2021 10.3 2023 7.2 2022 4.7 2021 18.0 2023 17.5 2022 17.3 2021 8.1 2023 5.9 2022 6.6 2021 14.3 2023 6.4 2022 0.1 2021 11.4 2023 7.7 2022 8.6 2021 37.5 2023 37.5 2022 37.5 c. 65% Overall progress against milestones Overall progress against milestones Multiple KPIs are used to measure delivery against the two-year 12-Point Plan. Taken as a whole, the plan is showing good progress. Further details regarding our progress across the underpinning initiatives can be found in the Chief Executive Officer’s review on pages 8–11. 18 Smith+Nephew Annual Report 2023

GRAPHIC

Non-financial Key Performance Indicators Long-term sustainability targets These KPIs allow management and investors to measure progress against our long-term sustainability targets in the three areas of People, Planet and Products. Achieve net zero Achieve net zero Scope 1 and Scope 2 greenhouse gases (GHGs) by 2040 and Scope 3 GHGs by 2045, beginning by achieving a 70% reduction in Scope 1 and Scope 2 GHGs by 2025. Scope 1 and 2 (market-based) 40% Reduction since 2019. Less waste to landfill 30% Reduction from our strategic manufacturing sites versus 2019. Product donations $5.1m Each year we donate products to support under-served communities. Please refer to page 65 for our emissions reporting methodology, materiality and scope. Employee engagement score The Gallup Global Engagement Survey allows management and investors to assess how engaged our employees are, which is a key driver of business performance. 4.20 Engagement Our Grand Mean score of 4.20 positioned us in the 83rd percentile in Gallup’s database (2022: 73rd percentile). 89% of employees participated. We adopt the industry-standard OSHA system to record incidents of occupational injury and ill health. Performance is expressed as the number of incidents per 200,000 hours worked. This KPI helps investors understand how we support the safe and effective use of our products through the provision of medical education. Quality and safety This KPI allows management and investors to verify that we are operating a safe working environment at high standards. Headline safety rate Medical education 20 New product launches This KPI helps us track the number of on-time new product launches to drive future revenue growth. We completed 20 launches in 2023 with a further two products ready for launch in 2024. Investment in innovation In 2023, more than three percentage points of our full year underlying revenue growth came from products launched in the last five years. This KPI allows management and investors to understand how much is being invested in new innovative products designed to drive future revenue growth and profit. »See pages 26–29 »See pages 30–31 for more about medical education »See page 52–66 for details of how we are meeting our sustainability commitments »See pages 48–49 for more about our employee engagement score $339m R&D investment 1 Acquisition announced This KPI tracks acquisitions that enhance our portfolio and pipeline, including technology that can change the standard of care and assets in high-growth categories. In November 2023 we entered into a definitive agreement to acquire CartiHeal, the developer of CARTIHEAL◊ AGILI-C◊ , a novel sports medicine technology for cartilage regeneration in the knee. In January 2024 we announced the completion of this transaction. Smith+Nephew paid $180 million on completion, with up to a further $150 million contingent on future financial performance. 97,405 Practitioner training sessions »See page 29 2021 0.23 2023 0.15 2022 0.22 2021 356 2023 339 2022 345 Smith+Nephew Annual Report 2023 19 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION

GRAPHIC

Financial review 2023 performance Group revenue in 2023 was $5,549 million, an increase of 6.4% on a reported basis and 7.2% on an underlying basis1 excluding a 80bps headwind from foreign exchange, slightly above the revenue guidance range of 5.0% to 6.0% for 2023 we announced previously. The operating profit was $425 million (2022: $450 million) with an operating profit margin of 7.7% (2022: 8.6%) after acquisition and disposal related items, restructuring and rationalisation costs, amortisation and impairment of acquisition intangibles and legal and other items. Trading profit1 for 2023 was $970 million (2022: $901 million) with a trading profit margin1 of 17.5% (2022: 17.3%) reflecting improvement in revenue and productivity savings across the Group. The reported profit before tax was $290 million (2022: $235 million) after adjusting for an impairment related to Engage Surgical. We acquired this business in 2022 for a maximum consideration of $135 million payable in cash. The provisional fair value consideration was $131 million and included $32 million of contingent consideration. During 2023, management evaluated the commercial viability of Engage products and concluded that they should be discontinued. A total of $109 million of Engage’s assets and liabilities were written off as a result of this action. Efficiency and 12-Point Plan progress We have made significant progress in our 12-Point Plan to fundamentally change the way we operate and transform business performance, especially our activities to fix Orthopaedics and improve productivity. This was reflected in our improved financial performance for 2023. In 2023, restructuring costs totalled $220 million, including costs related to the efficiency and productivity under the 12-Point Plan. Overall, incremental benefits of around $68 million was recognised during the year. Strengthening our foundations Dear Fellow Shareholder, The 12-Point Plan was announced in July 2022 to improve execution and drive our Strategy for Growth. The plan focuses on fixing Orthopaedics, improving productivity and accelerating growth in Advanced Wound Management and Sports Medicine through 12 initiatives, which have underpinned our improved performance in 2023. “The 12-Point Plan is beginning to translate into improved financial outcomes in 2023.” Anne-Françoise Nesmes Chief Financial Officer 20 Smith+Nephew Annual Report 2023

GRAPHIC

Group performance 2023 $ million 2022 $ million Change $ million Revenue 5,549 5,215 334 Operating profit 425 450 (25) Trading profit1 970 901 69 Profit before tax 290 235 55 Attributable profit 263 223 40 EPS 30.2¢ 25.5¢ 4.7¢ EPSA1 82.8¢ 81.8¢ 1.0¢ Non-IFRS measures The underlying increase in revenue by market reconciles to reported growth, the most directly comparable financial measure calculated in accordance with International Financial Reporting Standards (IFRS), as follows: 2023 $ million 2022 $ million Reported growth % Underlying growth % Reconciling items Acquisitions/ Disposals % Currency impact % US 2,979 2,764 7.8 7.8 – – Other Established Markets2 1,611 1,504 7.1 7.3 – (0.2) Total Established Markets 4,590 4,268 7.5 7.6 – (0.1) Emerging Markets 959 947 1.3 5.1 – (3.8) Total 5,549 5,215 6.4 7.2 – (0.8) Trading profit1 reconciles to operating profit, the most directly comparable financial measure calculated in accordance with IFRS, as follows: 2023 $ million 2023 % 2022 $ million 2022 % Operating profit 425 7.7 450 8.6 Acquisition and disposal related items 60 1.1 4 0.1 Restructuring and rationalisation costs 220 4.0 167 3.2 Amortisation and impairment of acquisition intangibles 207 3.7 205 4.0 Legal and other 58 1.0 75 1.4 Trading profit1 970 17.5 901 17.3 We expect around $275 million of restructuring costs related to the 12-Point Plan over three years. During 2023, we have been able to reduce our total production volumes, while continuing to improve product availability and instrument set delivery, ultimately enabling reductions in inventory and manufacturing capacity. We have also made progress in our productivity workstreams, with our Orthopaedics network optimisation programme, by closing two of our smaller facilities, to consolidate production into our larger sites, and reducing the size of our contingent workforce. This translates into a better underlying revenue growth and better trading margin compared to the prior year. These actions are covered in more detail in the CEO’s review in this report. EPS Basic earnings per share (‘EPS’) was up 18% to 30.2¢ and adjusted earnings per share1 (‘EPSA’) was up 1.3% to 82.8¢1, reflecting the improved trading performance. Capital allocation framework The appropriate use of capital on behalf of shareholders is important to Smith+Nephew. This approach is set out in our 2021 Capital Allocation Framework, which we used to prioritise the use of cash. We always look for great investment opportunities to add to our portfolio while providing differentiation for our customers such as the acquisition of CartiHeal (2009) Ltd (CartiHeal), the developer of CARTIHEAL◊ AGILI-C◊ that is a novel sports medicine technology for cartilage regeneration in the knee, which was announced on 22 November 2023. Upon completion on 9 January 2024, the Group paid $180 million in cash with up to a further $150 million contingent on future financial performance. We continue to make further investment in innovative medical education through the opening of a new Smith+Nephew Academy in Munich, which will serve as a central European hub for medical education and for training surgeons from across the EMEA region. See page 31 for more details. 1 These non-IFRS financial measures are explained and reconciled to the most directly comparable financial measure prepared in accordance with IFRS on pages 244–248. 2 Other Established Markets are Europe, Canada, Japan, Australia and New Zealand. Smith+Nephew Annual Report 2023 21 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION

GRAPHIC

Financial review continued 1 These non-IFRS financial measures are explained and reconciled to the most directly comparable financial measure prepared in accordance with IFRS on pages 244–248. 2 Net debt is reconciled in Note 15 to the Group accounts. and $97 million increase in deferred tax assets, partially offset by $30 million decrease in investment in associates due to the Group’s share of Bioventus’ loss and $72 million decrease in retirement benefit assets mainly due to the UK buy-in. Current assets increased by $174 million mainly due to a $190 million increase in inventories driven by strategic raw material buys to support the Group’s strategies, inflation raising the average value of inventory and increased inventory to support growth including new product launches, safety stock, or in markets where we expect growth acceleration. Whilst we acknowledge there is more work to do, this represents an improvement compared to 2022’s $361 million inventory increase, thanks to improved demand forecasting, supply planning and efficiencies as result of the 12-Point Plan. Additionally, the $36 million increase in trade and other receivables in 2023 is also an improvement compared to 2022’s $80 million increase. This improvement is a direct result of Order to Cash initiatives to improve collection as part of the 12-Point Plan. Non-current liabilities decreased by $493 million primarily due to a $405 million reclassification of borrowings to current liabilities to reflect repayments due in 2024 and remeasurement of Engage’s contingent consideration as a result of the voluntary product discontinuation. Current liabilities increased by $556 million primarily related to the reclassification from long-term debt to short-term debt and drawdown of our Revolving Credit Facility (“RCF”) in 2023. Cash flow data Cash generated from operations of $829 million is after paying out $16 million of acquisition and disposal related items, $124 million of restructuring and rationalisation expenses and $145 million for legal and other items. Trading cash flow increased by $191 million driven by better working capital movements compared to 2022. Free cash flow increased to $129 million from $56 million in the prior year because of the increase in trading cash flow. Liquidity and capital resources At 31 December 2023, the Group had access to $300 million (2022: $344 million) in cash net of bank overdrafts. The Group’s debt facilities comprise of a USD $1,000 million corporate bond, EUR corporate bond €500 million, a $1,000 million revolving credit facility and $1,030 million private placement debt. The Group had committed available facilities of $3.6 billion at 31 December 2023 of which $2.9 billion was drawn. The Group’s net debt, excluding lease liabilities, increased from $2,339 million at the beginning of 2023 to $2,577 million at the end of 2023, representing an overall increase of $238 million as a result of dividend payments and metal-on-metal settlements of $87 million. Dividends The 2022 final dividend of 23.1¢ per ordinary share, totalling $201 million, was paid on 17 May 2023. The 2023 interim dividend of 14.4¢ per ordinary share, totalling $126 million, was paid on 1 November 2023. Taxation The Group is subject to various taxes in the many countries in which the Group operates. The Group makes a significant economic contribution to the countries where it operates through taxation, either borne or collected on behalf of and paid to the relevant tax authorities, and through employment of personnel. We regard taxation as a critical element of our commitment to grow in a sustainable, responsible and socially inclusive way. We aim to submit accurate tax returns to the relevant tax authorities on a timely basis, and seek to pay the right amount of tax on the profits we make in accordance with the tax laws in all the territories in which we operate. In addition to corporate income taxes our group pays and collects other taxes including payroll (employee) taxes, sales (indirect) taxes and customs duties. During 2023, we made global tax payments of $833 million (2022: $818 million). This comprises $305 million of taxes borne by Smith+Nephew (corporate income taxes, employer social security contributions and customs duties) and $528 million of taxes collected from employees and customers on behalf of governments (employee income taxes and social security contributions and net indirect tax payable). Balance sheet data Overall goodwill and intangible assets decreased by $165 million mainly due to the Engage write-off. Goodwill decreased by $39 million as a result of Engage impairment of $84 million, which was partially offset by foreign exchange movements of $45 million. Intangible assets decreased by $126 million because of amortisation and impairment of $258 million being partially offset by additions (net of disposals) of $103 million and a transfer of $23 million from property plant and equipment and foreign currency movements of $6 million. Other non-current assets increased by $12 million due to a slight increase of $15 million in property, plant and equipment 2023 $ million 2022 $ million Change $ million Cash generated from operations 829 581 248 Trading cash flow1 635 444 191 Free cash flow1 129 56 73 2023 $ million 2022 $ million Change $ million Goodwill and intangible assets 4,102 4,267 (165) Other non-current assets 1,855 1,843 12 Current assets 4,030 3,856 174 Total assets 9,987 9,966 21 Total equity 5,217 5,259 (42) Non-current liabilities 2,499 2,992 (493) Current liabilities 2,271 1,715 556 Total liabilities 4,770 4,707 63 Total liabilities and equity 9,987 9,966 21 Net debt2 including lease liabilities 2,776 2,535 241 22 Smith+Nephew Annual Report 2023

GRAPHIC

1 These non-IFRS financial measures are explained and reconciled to the most directly comparable financial measure prepared in accordance with IFRS on pages 244–248. 2 Net debt is reconciled in Note 15 to the Group accounts. 3 ROIC is defined as: Operating profit (before amortisation and impairment of acquisition intangibles) less adjusted taxes/(Operating net operating assets + Closing net operating assets)/2. The Group refinanced its $1 billion RCF in the fourth quarter of 2023. This extends the facility maturity to 2028, with options to extend the maturity to 2030. Return on invested capital Return On Invested Capital (ROIC)1,3 is a measure of the return generated on capital invested by the Group. It encourages compounding reinvestment within the business and discipline around acquisitions. ROIC decreased from 6.6% in 2022 to 5.9% in 2023 due to lower operating profit and higher average net operating assets mainly due to an increase in short-term borrowings as a result of our capital outflow in inventory. Going concern The Directors have considered various scenarios in assessing the future financial performance and cash flows. Throughout these scenarios, which include a severe but plausible outcome, the Group continues to have headroom on its borrowing facilities and financial covenants. The Directors have a reasonable expectation that the Company and the Group are well placed to manage their business risks and to continue in operational existence for the period to 29 March 2025. Accordingly, the Directors continue to adopt the going concern basis in preparing the consolidated financial statements. Outlook For 2024, we are targeting another year of strong revenue growth and a meaningful improvement in trading profit margin. For revenue, we expect to deliver underlying revenue growth in the range of 5.0% to 6.0%. Within this, we expect continued strong growth from our Sports Medicine & ENT and Advanced Wound Management business units, and further improvement in Orthopaedics as we continue to execute on the 12-Point Plan. On a reported basis the guidance equates to a range of around 4.6% to 5.6% based on exchange rates prevailing on 21 February 2024. In terms of phasing, we expect the first quarter revenue growth rate to reflect the tough US comparator from the good start to 2023, as well as a slower quarter from Advanced Wound Bioactives following the strong fourth quarter and one less trading day year-on-year. We expect the business to return to higher growth across the remainder of the year. We expect to deliver a trading profit margin of at least 18.0%. Within this, headwinds are expected to include continuing inflation, a -70bps impact from China Volume Based Procurement (‘VBP’) within Sports Medicine Joint Repair, and around -30bps from transactional foreign exchange, plus a small impact from the acquisition of CartiHeal. We expect to more than offset these headwinds through positive operating leverage from revenue growth and productivity improvements and cost saving initiatives from the 12-Point Plan. In line with prior years, we expect to see a step up in margin in the second half of the year versus the first half of the year driven by typical seasonality. The tax rate on trading results for 2024 is forecast to be in the range of 19% to 20%, subject to any material changes to tax law or other one-off items. Our midterm targets are unchanged. The Group is focused on delivering underlying revenue growth of consistently 5%+ and expanding our trading profit margin. We continue to target at least 20% trading profit margin in 2025. While headwinds such as persistent inflation, foreign exchange movements and China VBP in Sports Medicine Joint Repair make that a demanding target, we do expect to see an increasing impact from the 12-Point Plan, including the benefits of our manufacturing optimisation programme, which are expected to flow through strongly in 2025. 2024 is a year of change for many of us, including me personally as I will leave Smith+Nephew by the end of the first quarter of 2024, after an extended transition period with John Rogers, our incoming CFO. I am very proud of what we have achieved so far, and I am confident that John and my Executive Committee colleagues will lead Smith+Nephew on to a successful 2024. Anne-Françoise Nesmes Chief Financial Officer Available debt facilities by maturity date ($m) 2025 0 0 405 2024 405 300 2026 75 75 2027 140 140 2028 1,060 700 300 60 2029 652 100 552 2030 1,095 95 1,000 2031 0 155 2032 155 EUR Bond RCF Drawn USD Bond RCF Undrawn Private placements Maturity by date Smith+Nephew Annual Report 2023 23 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION

GRAPHIC

Getting grandparents back to playing with their grandchildren Life Unlimited 24 Smith+Nephew Annual Report 2023

GRAPHIC

Smith+Nephew Annual Report 2023 25 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION

GRAPHIC

Research & Development A long history of transformative innovation Creating value through innovation JOURNEY◊ II: JOURNEY II TKA has been demonstrated to restore anatomical shape, position and motion.*1,2 This anatomical restoration can provide superior clinical outcomes and higher patient satisfaction.** 3–7 Smith+Nephew has a long and proud history of transformative innovation, dating back to our founding in 1856. In the recent past we shaped clinical practice and helped to deliver our purpose of Life Unlimited to millions of patients. In Orthopaedics, products such as our kinematic knee, JOURNEY◊ II, have brought more natural motion to joint replacement. In Sports Medicine our products have been instrumental in enabling arthroscopic repair where previously open surgery was the standard of care. And in wound care, Smith+Nephew’s PICO◊ single-use Negative Pressure Wound Management System has revolutionised the availability of this important treatment option. Over decades, we have repeatedly brought technologies to market that have disrupted established approaches and changed the standard of care.” Vasant Padmanabhan President of Research & Development and ENT $339m Invested in R&D in 2023 20 New products launched in 2023 Smith+Nephew’s innovation pipeline is a material contributor to our revenue growth, with approaching 50% of our 2023 underlying revenue growth coming from recent product launches. We expect this trend to continue as we drive innovation across our business. » For a full list of references see pages 262–264 26 Smith+Nephew Annual Report 2023

GRAPHIC

CORI◊ Digital Tensioner The CORI◊ Digital Tensioner was designed to address different demographics, making this product ergonomically suitable for female and male surgeons. This approach to innovation is helping remove barriers and limitations traditionally associated with orthopaedic surgical equipment. Addressing unmet clinical needs Today, there are still significant unmet clinical needs. These needs can be for the patient, in terms of satisfaction, clinical outcomes and reduction in complications, or for the healthcare system with costs of existing treatments or of unaddressed problems. For instance, in knee replacement, 80% of recipients state that their new knee feels ‘artificial’,8 while in Sports Medicine, the re-tear rates associated with repair of large full thickness rotator cuff tears exceeds 50%.9 In ENT, almost one in 16 children undergoing total tonsillectomies have post-procedure haemorrhages,10 and in wound care the treatment for surgical site infections costs the US healthcare system more than $3 billion per year.11 These challenges, and many others like them, inspire us to invest in developing the next generation of products and services that will continue to advance clinical practice and improve outcomes for patients and payers. We are helping to shape an innovation environment that is driven by four key trends. – Robotics and digital systems enable a degree of accuracy and personalisation of procedures that has not been possible in the past. – Biologics technology is developing rapidly and enables different types of treatments – including fully restoring tissue and function. – Procedural innovation is focused on less invasive and tissue sparing methods that can improve recovery times. – Healthcare costs require greater focus on delivering compelling value and health economic benefits. Smith+Nephew’s R&D team is focused on growth segments where we can deploy our expertise in such fast developing areas of innovation, and deliver novel solutions that address unmet clinical needs. Inspiration for new products comes from observing our customers, working with healthcare professionals on design and development, acquiring technologies needing further development and commercialisation, and our co-development partners. New products are developed using a rigorous phase-gate process starting with business case review and ending with launch readiness. We also strive to embed sustainability principles into our design and packaging. Designing a world-class user experience Users perform better when they believe they are working with best-in-class equipment. In the context of product design, devices are typically considered best-in-class when they are recognised as being developed by an industry-leading brand and exhibit a compelling and purposeful user experience. Within R&D our Human Factors team strives to bring a unique user experience to product development, encompassing a common high-quality look, feel and sound across the entire portfolio of instruments and digital systems. Their philosophy is that each product should be considered a Smith+Nephew brand ambassador, expressing excellence and encouraging ease-of-use and familiarity. Smith+Nephew Annual Report 2023 27 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION

GRAPHIC

Creating value through innovation continued Research & Development continued New products in 2023 Innovation is central to our higher-growth ambitions In 2023 we launched 20 new products, with development complete on a further two ahead of their launch in 2024. Investing in robotics and AI Our CORI◊ Surgical System is the only robotics-assisted system indicated for partial, total and revision knees. During 2023 we continued to add features and functionality. The CORI◊ Digital Tensioner is a proprietary device for soft tissue balancing in knee replacement, and the only tensioner for robotics-assisted surgery. This helps make planning more objective and eliminates inconsistencies in surgery from current manual or mechanical tools. Personalized Planning powered by AI and the RI.INSIGHTS◊ Data Visualization Platform on CORI◊ transform data into contextual intelligence by enabling surgeons to better understand how pre-operative surgical plans and intra-operative decision making link to post-operative outcomes. A new saw solution added versatility, appealing to a broader range of surgeons. CORI◊ is the only solution to offer robotics-assisted burring and saw bone-cutting options. This development was accelerated as part of our 12-Point Plan. New shoulder system In 2023 we launched our AETOS◊ Shoulder System. We acquired this technology in early 2021 and it is an important part of our growth plans for Trauma & Extremities. AETOS◊ is designed with both patient and surgeon benefits in mind. For example, the MetaStem aligns with the market trend towards minimally invasive short stem devices. Short stems are easier to implant, have improved bone preservation, and are a better fit to anatomy. AETOS◊ will enable Smith+Nephew to compete effectively in the $1.7 billion12 shoulder repair market, which, at around 9% compound annual growth rate, is one of the fastest growing segments in Orthopaedics. AETOS◊ Shoulder System CORI Surgical System 28 Smith+Nephew Annual Report 2023

GRAPHIC

Accessing external innovation through M&A Smith+Nephew has a strong track record of using bolt-on acquisitions to enhance our portfolio and R&D pipeline. This includes technology that can change the standard of care and assets in higher-growth categories. We look to acquire assets where we can use our commercial expertise and channels to drive growth, and also use our R&D expertise to develop new iterations or indications to expand the addressable market. One example is the acquisition of Rotation Medical in 2017, which included REGENETEN◊ , a novel tissue regeneration technology for rotator cuff repair. To support this acquisition we built a specialist Sports Medicine sales force which has delivered strong growth in the US and Europe, and we have started to roll out into new markets such as Japan, India and China in 2023. The acquisition of BlueBelt Technologies brought a first-generation robotics system and considerable R&D expertise which we have leveraged to create a second-generation system CORI◊ which we continued to expand with new indications and enhancements. Through the acquisition of an Extremity Orthopaedics business we added a next generation shoulder replacement platform AETOS◊ to our pipeline, completing the development ahead of its launch in 2023. In November 2023 we announced a definitive agreement to acquire CartiHeal, the developer of the CARTIHEAL◊ AGILI-C◊ Cartilage Repair Implant, a novel sports medicine technology for cartilage regeneration in the knee. CARTIHEAL◊ AGILI-C◊ is an off-the-shelf one-step treatment for osteochondral (bone and cartilage) lesions with a broader indication than existing treatments. It is indicated to treat a wide patient population, including those with lesions in knees with mild to moderate osteoarthritis, a previously unaddressed condition, as well as the approximately 700,000 patients1 that receive cartilage repair annually in the US. The acquisition was completed in January 2024. Novel cartilage regeneration – challenging standard of care The CARTIHEAL◊ AGILI-C◊ Cartilage Repair Implant is a porous, biocompatible and resorbable scaffold which promotes natural regeneration of the articular cartilage and restoration of its underlying subchondral bone. The US Food and Drug Administration (FDA) granted CARTIHEAL◊ AGILI-C◊ Breakthrough Device designation status in 2020 and Premarket Approval (PMA) in March 2022. PMA approval was granted based on the results of a two-year randomised controlled trial (N=251) that confirmed the superiority of CARTIHEAL◊ AGILI-C◊ over the current standard of care – microfracture and debridement for the treatment of knee joint surface lesions, chondral and osteochondral defects. Study inclusion criteria included patients with mild and moderate osteoarthritis. At four-year follow-up the trial continues to show significant improvement of patient reported outcome scores, low surgical reintervention, and that the difference in improvement using CARTIHEAL◊ AGILI-C◊ compared to the standard of care is statistically significant – offering potential for a new standard of care in cartilage repair. Creating a winning edge The new RENASYS◊ EDGE Negative Pressure Wound Therapy System is designed to reduce inefficiency and complexity and features an improved user interface for enhanced intuitiveness and simplicity and a durable pump built to offer virtually maintenance-free use. RENASYS◊ EDGE We have shown with REGENETEN◊ that we have the market development and commercialisation expertise to take novel technologies and successfully establish a new standard of care. AGILI-C◊ is the perfect addition to our portfolio and we look forward to leveraging our expertise to transform cartilage repair outcomes for patients.” Scott Schaffner President Sports Medicine » For a full list of references see pages 262–264 Smith+Nephew Annual Report 2023 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION 29

GRAPHIC

Creating value through innovation continued Medical education Providing opportunities to learn innovative clinical and surgical techniques Smith+Nephew is committed to educating and training healthcare professionals on the safe and effective use of our products. Every year we provide tens of thousands of surgeons and nurses with opportunities to evaluate the latest clinical evidence and learn innovative surgical techniques and the effective use of our products through our medical education programmes. Central to Smith+Nephew’s commitment to being a global leader in medical education and improving patient outcomes is providing a comprehensive accessible learning environment tailored to the needs of the healthcare professional. Through the Smith+Nephew Academy we are actively transforming the way we educate our customers around the world by surrounding them with cutting-edge technology, clinical content and scientific data. The multiple elements of the Smith+Nephew Academy offer a blended learning environment inclusive of state-of-the-art digital interactive learning, symposia, procedure-based education through hands-on experiences inclusive of Virtual Reality (VR) simulations, customised curriculum and programming specifically designed to meet the needs of the accomplished physician, resident, fellow and allied health professionals. Smith+Nephew Academy augments in-person training opportunities with a comprehensive online presence through Smith+Nephew Academy Online. We have three in-person Academies in the US in Memphis (Tennessee), Andover (Massachusetts) and Pittsburgh (Pennsylvania), as well as Academy London, Academy Singapore and, new in 2023, Academy Munich. In addition, we have smaller training facilities in the US in Phoenix (Arizona) and Austin (Texas). Our investment in S+N Academy Munich is part of a global commitment to drive innovation and learning in medical technology, creating an environment where the best healthcare providers can learn, collaborate and innovate in order to meet the needs of their patients.” Cynthia Walker Senior Vice President Medical Education 4,241 Education courses run by Smith+Nephew in 2023 97,405 Healthcare professional training sessions in 2023 30 Smith+Nephew Annual Report 2023

GRAPHIC

Academy Munich A new centre for surgical innovation and training In October 2023, we opened S+N Academy Munich, a central European hub for surgeons from across Europe, the Middle East and Africa. Surgeons and other healthcare specialists will learn the latest surgical techniques using the most advanced technology available, and practise surgical techniques using both hands-on and fully immersive digital interactive experiences. S+N Academy Munich is expected to train more than 5,000 global healthcare providers each year. Additionally, S+N Academy Munich will also serve as a hub to connect healthcare professionals with our global marketing and Research & Development teams to test and validate new technologies. RCSEng accreditation Royal College of Surgeons of England (RCSEng) Centre Accreditation has been awarded to Smith+Nephew and is the highest level of accreditation. It is seen as a kite-mark of excellence and demonstrates external validation of the Medical Education training that we provide. S+N Academy Online S+N Academy Online S+N Academy Online is the global medical education platform used by healthcare professionals and caregivers to access the latest peer-to-peer scientific, education-based best practice; intended to deliver thought leadership and content across orthopaedic reconstruction, sports medicine, ENT, trauma and extremities, and wound management. Our S+N Academy Online platform supports personalised learning journeys and educational pathways, with evolving libraries, educational resources and on-demand educational activities (such as webinars, products and recorded courses) as well as e-learning modules (including faculty-led techniques, surgical videos, expert lectures, panel discussions, clinical data, evidence literature and course information) and access to online training such as live webinars and virtual classrooms. S+N Academy Online resources are available to all registered healthcare professionals. 670 Modules available on S+N Academy Online 10,504 Healthcare professionals used S+N Academy Online in 2023 Smith+Nephew Annual Report 2023 31 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION

GRAPHIC

Creating value through innovation continued Manufacturing Smith+Nephew takes great pride in our manufacturing expertise and commitment to distributing innovative, quality products globally. Our Global Operations team supports the delivery of the Group’s strategy by ensuring that we respond efficiently to demand, new product development and changing regulatory requirements. Supporting the 12-Point Plan Global Operations is integral to the delivery of our 12-Point Plan, specifically our activities to fix Orthopaedics and improve productivity. These activities require close collaboration with our commercial teams, and have been supported by a refreshed leadership team across Orthopaedics and Global Operations with area-specific experience and track record. During 2023 we have been able to reduce our total production, while continuing to improve product availability. This in turn will ultimately enable reductions in inventory and manufacturing capacity. A significant challenge has been a misalignment between Commercial and Operations. Our previous Sales, Inventory and Operations Planning, or SIOP process, was leading to over-ordering by our commercial organisations and the creation of excess capacity. We rolled out an improved and redesigned SIOP process in 2023. This has led to improved service, both on new sets and on replenishment. We have been working to optimise our manufacturing network for a number of years. Recent landmarks in this journey have included opening a new high-technology Orthopaedics manufacturing facility in Malaysia in 2022, and we are currently building a new Advanced Wound Management facility in the UK. We are also reviewing lean methodologies across our operations to simplify processes, drive greater standardisation, and reduce scrap. With renewed focus under the 12-Point Plan we have identified further opportunities in our network for simplification to bring cost and asset efficiencies. Important steps in 2023 included announcing the closure of two smaller facilities in China and Germany to consolidate production into our larger sites. We also reduced the size of our contingent workforce. 13 Global manufacturing sites Manufacturing and distributing innovative, quality products globally By delivering on the manufacturing and procurement initiatives within the 12-Point Plan we expect to support commercial growth and drive better efficiency on both fixed and variable costs.” Paul Connolly President Global Operations 32 Smith+Nephew Annual Report 2023

GRAPHIC

The 12-Point Plan includes focus on improving productivity to support trading profit margin expansion. Areas of opportunity include driving lean methodologies across our manufacturing operations, further network optimisation and direct and indirect procurement savings. Improving procurement We are also targeting procurement savings to help mitigate cost inflation and drive productivity. We see opportunities where spend is fragmented between large numbers of suppliers, or where providers in high-cost countries are disproportionately used. During 2023 we deployed an enhanced supplier selection process to identify and award business to suppliers that better align to the global business unit strategies and long-term performance metrics, and better aligned global category strategies to unlock the Smith+Nephew buying power and leverage, helping to drive volume to the most preferred suppliers and reduce cost. We procure raw materials, components, finished products and packaging materials from suppliers globally. These include metal forgings and castings, optical and electronic sub-components, active ingredients and semi-finished goods, as well as packaging materials. During 2023 we improved supplier resilience, reducing back orders due to raw materials or components shortages to the lowest levels in more than two years. All our suppliers are subject to our Third-Party Guide to Working with Smith+Nephew, meaning they agree to conduct business on our behalf in an ethical manner that is compliant with all applicable laws, regulations and industry codes of conduct, and to manage their suppliers in accordance with the same standards. We outsource certain parts of our manufacturing processes where necessary to obtain specialised expertise or to lower cost without undue risk to our intellectual property or quality. We monitor suppliers through on-site assessments and performance audits to ensure the required levels of quality, service and delivery as well as compliance with our Third-Party Guide to Working with Smith+Nephew. Our manufacturing network We operate manufacturing facilities in countries across the globe, and have central distribution facilities in the US, Europe and Asia. Products for our Orthopaedics business unit are primarily manufactured at facilities in Memphis (US), Penang (Malaysia), Aarau (Switzerland) and Warwick (UK), as well as Tuttlingen (Germany) and Beijing (China), two facilities we are closing as described above. Sports Medicine products are primarily manufactured in the Alajuela (Costa Rica), Mansfield (US) and Oklahoma City (US) facilities. Our major manufacturing sites for Advanced Wound Management products are Hull (UK), Fort Worth (US), Columbia, Maryland (US) and Suzhou (China). Quality & Regulatory Affairs Our Quality & Regulatory Affairs function supports full product life cycle management of Smith+Nephew’s global product portfolio from design and development through manufacturing and post-market surveillance. These teams establish appropriate processes and procedures to facilitate compliance with complex global regulations and laws that govern the design, development, approval, manufacture, labelling, marketing and sale of healthcare products. The Quality & Regulatory Affairs teams directly support expansion of our global portfolio through the registration of new products and existing products in new markets, as well as ensuring compliance with regulatory reporting standards. The European Union Medical Device Regulation (EU MDR) is a significant regulatory change whereby medical devices carrying a CE mark, confirming conformity with relevant requirements, now face greater scrutiny than ever before to ensure they are effective and safe. We have made good progress with our respective submissions, with all files submitted to the Notified Bodies and 90% percent of respective product lines have received MDR certification. The Regulation allows devices certified under previous legislation (Medical Device Directive or MDD) to continue to be placed on the market in Europe until 31 December 2027 or 31 December 2028, dependent on risk classification. We closely monitor other Regulatory landscape changes. This includes changes in UK Medical Device Legislation and UKCA marking. These changes allow CE marked devices to be placed on the market in Great Britain until June 2030. Additionally, we are closely monitoring international regulatory trends that include an increased focus on cybersecurity in medical technology. 33 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION

GRAPHIC

Taking our innovation to market Orthopaedics Smith+Nephew’s Orthopaedics vision is to improve mobility and outcomes, with unique and differentiated technologies that allow patients to live a Life Unlimited. Our innovative implants seek to mimic natural movement, are manufactured using materials with a track record of longevity and performance, and are accompanied by our enabling robotic technologies. We are well positioned as the supplier of choice for surgeons across the globe. Smith+Nephew’s Orthopaedics business unit includes an innovative range of hip and knee implants used to replace diseased, damaged or worn joints, robotics-assisted enabling technologies that improve accuracy and facilitate precision during the surgical procedure, and trauma products used to stabilise fractures and correct bone deformities. In Orthopaedic Joint Reconstruction, we have a broad, clinically proven and differentiated portfolio that allows us to compete effectively across a market worth around $15.9 billion annually. This portfolio includes our proprietary OXINIUM◊ material which offers a clear advantage over competitors. In addition, our CORI◊ Surgical System is strongly positioned to take advantage of the trends towards robotic-assisted surgery and outpatient joint replacement seen across the segment. The Trauma & Extremities market is worth over $13.6 billion annually, and we are well positioned to compete effectively in this segment. The simplicity and efficiency of our complete EVOS◊ Plating System gives us an advantage in the largest segment in Trauma, and our TRIGEN◊ INTERTAN◊ Intertrochanteric Nail is backed by the clinical and economic data to position it as the standard of care for hip fracture,1,2 the second-largest segment. In Extremities, we launched our next generation shoulder implant, the AETOS◊ Shoulder System. 2023 performance Orthopaedics revenue increased 4.8% on a reported basis in 2023, including a 90bps headwind from foreign exchange. Underlying revenue growtha was 5.7%. Within this, all segments positively contributed to growth. In Knee Implants and Hip Implants our performance outside the US benefited from improved product supply and execution. Further work is required to address these challenges A leading portfolio of hip and knee implants, robotics and digital enabling technologies driving procedural innovation with Precision in Motion, and a strengthened Trauma & Extremities portfolio. Highlights Orthopaedics revenue $2,214m 2022: $2,113m Reported 4.8% Underlyinga 5.7% Orthopaedics trading profit $398m 2022: $383m 2023 Revenue 2023 Reported growth 2023 Underlying growtha Knee Implants $940m 4.7% 5.5% Hip Implants $599m 2.5% 3.8% Other Reconstruction $111m 27.8% 28.0% Trauma & Extremities $564m 3.7% 4.4% a These non-IFRS financial measures are explained and reconciled to the most directly comparable financial measure prepared in accordance with IFRS on pages 244–248. We strengthened performance across most segments in 2023, and we are clear on where we still need to improve with the necessary actions underway.” Brad Cannon President Orthopaedics & Americas We serve our markets through three global business units of Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. These business units are responsible for strategy and global marketing, and contain specialist sales and support teams dedicated to serving the specific requirements of healthcare systems. 34 Smith+Nephew Annual Report 2023

GRAPHIC

in the US. Other Reconstruction grew strongly as we expanded our CORI◊ Surgical System, and Trauma & Extremities performed well in the US where we focused on improving availability of our EVOS◊ Plating System. Trading profita grew 3.9%, although the trading profit margina of 18.0% remains below that of our other business units. Fixing Orthopaedics A major area of focus for our 12-Point Plan is to fix Orthopaedics, to regain momentum across hip and knee implants, robotics and trauma, and win share with our differentiated technology. In 2023 we made good progress improving product availability, logistics and utilisation of implants and instrument sets. We also improved commercial execution, repositioning our offering, streamlining the organisation, simplifying our commercial process and investing in deeper sales training. We also enhanced our incentive plan to better reward performance, sales mix, robotic placement and implant pull-through. Our actions and progress under the 12-Point Plan are discussed further on pages 8–11. Strategy Our Orthopaedics business unit has an innovative portfolio that allows us to compete in joint reconstruction, robotics-enabled procedures, and Trauma & Extremities markets. We are building on our strong foundation in order to sustain profitable growth. Our areas of focus include advancing innovative surgical solutions and optimising the use of working capital. Our initiatives are designed to drive growth across the Orthopaedic business unit. In joint reconstruction and robotics, we aim to accelerate growth by focusing on robotically enabled knee procedures and navigated hip arthroplasty with the CORI◊ Surgical System. Additionally, we will continue to leverage the unique material properties in OXINIUM◊ across the knee and hip platform. For Trauma & Extremities, Smith+Nephew expects to globally scale the EVOS◊ Plating System portfolio to compete more broadly in trauma centres. In addition, the 2023 launch of our AETOS◊ Total Shoulder System is expanding our footprint in the shoulder replacement market. Global market share In our Orthopaedics business unit we are one of four leading players, competing against US-based companies Stryker, Zimmer Biomet and DePuy Synthes. A Smith+Nephew 10% B Zimmer Biomet 31% C Stryker 24% D DePuy Synthesc 19% E Others 16% A Smith+Nephew 4% B DePuy Synthesc 25% C Stryker 23% D Zimmer Biomet 11% E Others 37% Trauma & Extremities $13.6bn +7% 2022: $12.7bn +3% b Data used in 2022 and 2023 estimates generated by Smith+Nephew is based on publicly available sources and internal analysis and represents an indication of market shares and sizes. c A division of Johnson & Johnson. Global market size 2023b Hip and Knee Implants $15.9bn +8% 2022: $14.8bn +4.5% Reconstruction & Robotics Knee Implants In Knee Implants, Smith+Nephew’s specialised systems include leading products for total primary replacement and revision, as well as partial and patellofemoral joint resurfacing procedures, offering surgeons and patients the benefits of many proprietary technologies. These include a unique kinematic knee, the JOURNEY◊ II Total Knee Arthroplasty system, which features OXINIUM◊ Technology and has been shown to replicate normal knee shape, position and motion.*3,4 Our LEGION◊ CONCELOC◊ Cementless Total Knee System (TKS) uses innovative 3D printed cementless technology to achieve biological fixation, bringing efficiency and versatility to the OR.5 The JOURNEY II ROX◊ Total Knee Solution, is a reverse-hybrid procedural solution which aims to provide surgeons with the normal kinematics*3,4,7–9 of JOURNEY II TKA, the cementless technology of CONCELOC◊ Advanced Porous Titanium and the wear resistance10,11 of OXINIUM◊ Technology. Hip Implants The Hip Implants portfolio is headlined by the POLAR3◊ Total Hip Solution which has among the lowest revision rates in total hip arthroplasty.*12–16 Our OR3O◊ Dual Mobility System is the first system to use the latest OXINIUM◊ DH advanced bearing technology. Dual mobility hip implants are used in primary as well as revision procedures. In addition, we offer a full breadth of stems to address surgical needs, including the ANTHOLOGY◊ Hip System. For revisions, the REDAPT◊ Revision Hip System features CONCELOC◊ Technology. Bringing innovation to India In 2023 we launched our OR3O Dual Mobility System in India for use in primary and revision hip arthroplasty. » For a full list of references see pages 262–264 A B C D E A B C D E Smith+Nephew Annual Report 2023 35 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION

GRAPHIC

Taking our innovation to market continued Orthopaedics continued Our award-winning, advanced implant material for hip and knee arthroplasty OXINIUM◊ Technology is a strong, resilient and advanced implant material that is only found in Smith+Nephew’s portfolio of joint replacement systems. OXINIUM◊ Technology has established itself as the best performing bearing with the lowest risk of revision in total hip arthroplasty (THA) at 9–18 years,13–16,33 alongside strong clinical performance in knees.33 It has been used clinically for over 20 years as part of over two million procedures. Other Reconstruction Our Other Reconstruction business includes the CORI◊ Surgical System, one of the most advanced and efficient***17 solutions. CORI◊ is a smaller,****18 portable solution capable of performing robotic-assisted knee and computer-guided hip surgery on a single platform. In robotic-assisted knee procedures, CORI◊ utilises handheld precision milling which allows surgeons to execute TKA and UKA procedures with reproducible accuracy.*****19–23 Unlike other systems, the proprietary smart mapping feature creates a 3-D image of the patient’s anatomy in surgery, eliminating time, costs, and radiation exposure23 associated with preoperative CT scans. In 2024, we will introduce the CORIOGRAPH◊ pre-op planning and modelling service that delivers a unique surgical planning solution desired by surgeons. The addition of pre-op planning will make the CORI◊ System the most versatile and flexible robotic-assisted system on the market. The proprietary software allows the CORI ◊ System to utilise our proven image-free surface mapping and image-based planning solutions for the right indications. RI.HIP◊ NAVIGATION further expands indications on the CORI◊ System, bringing a computer-guided total hip application to a platform previously dedicated to robotic-assisted knee procedures. When combined with Smith+Nephew hip implants, like the POLAR3◊ Total Hip Solution and OR3O◊ Dual Mobility System, and complementary tools to assess spinopelvic mobility (RI.HIP MODELER). RI.HIP◊ on CORI◊ delivers a comprehensive solution for navigated total hip arthroplasty. RI.HIP◊ NAVIGATION and RI.HIP◊ MODELER are designed to help maximise accuracy and reproducibility by delivering patient-specific component alignment. With the addition of a first-in-market indication in the US for robotic-assisted revision knee using the LEGION◊ Revision Knee System, the CORI◊ System is currently the only solution indicated for robotic-enabled knee procedures across the full continuum of care – partial, total, and revision knee arthroplasty. Furthermore, indications for LEGION◊ CONCELOC◊ Cementless Total Knee System and RI.HIP◊ NAVIGATION are part of CORI◊ .. Further strengthening our portfolio, we introduced the first of its kind handheld digital tensioning device for robotically-enabled total knee arthroplasty in 2023. The CORI◊ Digital Tensioner is a purpose-built device that lets surgeons measure the ligament tension in a knee prior to cutting bone.24,25 By enabling a surgeon to quantify joint laxity in the native knee and achieve an optimal ligament tensioning force, the CORI◊ Digital Tensioner helps to reduce variability when balancing the knee in surgery.24–27 Helping personalise robotics-enabled surgery with AI In 2023 we introduced two key products that close the feedback loop for our robotics and digital surgery portfolio – Personalized Planning powered by AI and RI.INSIGHTS◊ Data Visualization Platform. These solutions transform data into contextual intelligence by enabling surgeons to see how pre-operative surgical plans and intra-operative decision-making link to post-operative outcomes. Personalized Planning powered by AI, guided by RI.INSIGHTS◊ data enables the surgeon to set the initial implant placement within the total knee arthroplasty procedure based on AI-guided reference values and the surgeon’s planning preferences for specific implants and patient-specific deformities. Through the RI.INSIGHTS◊ Data Visualization Platform, surgeons can reference individual case performance and benchmark that data against an anonymised global database. The platform was designed to give surgeons a simple and effective way to link patient reported outcome measures (PROMs) to pre-operative planning and intra-operative decisions in robotically enabled knee replacements. Surgeon-specific dashboards provide the ability to analyse procedure data, such as case times, resections and alignment, and ligament tensioning data from the CORI◊ Digital Tensioner. RI.INSIGHTS◊ delivers an elegant solution to visualise data, connect PROMs, address known challenges with information access and utilisation, and transform surgical insights into actionable information. GENESIS◊ II Knee RI.INSIGHTS◊ Data Visualization Platform In 2023, we expanded the CORI◊ Surgical System’s capability in knee replacement with Personalized Planning powered by AI, guided by RI.INSIGHTS◊ data. This new addition enables surgeons to set the initial implant placement within the total knee arthroplasty procedure based on AI-guided reference values and the surgeon’s planning preferences for specific implants and patient-specific deformities. 36 Smith+Nephew Annual Report 2023

GRAPHIC

Driving procedural innovation with Precision in Motion Joint arthroplasty is dynamic, and future progress will be defined by the constant evolution of technology and its ability to accommodate unique patient circumstances, all while refining accuracy and reproducibility. Covering a broad range of indications and approaches – from primary and revision implant solutions to cutting-edge digital surgery and advanced bearing science – Precision in Motion embodies the ability of technology to: – Personalise surgery: Leveraging handheld robotic assistance, computer guided surgery and digital tensioning to help position implants based on individual patient anatomy, CORI Digital Tensioner is the first digital tensioning device with a robotic system that quantifies joint laxity prior to any bone resection and reduces variability of tensioning by 64%.24–27 – Advance efficiency: Aiming to make the complex as simple as possible by pioneering solutions to help restore joint anatomy and improve knee balance, especially in challenging cases like revision knee arthroplasty. The CORI System is the first robotic-assisted technology indicated for revision knee procedures. It has demonstrated operating room efficiency, such as a mean 56% reduction in trays28† thereby reducing sterilisation and OR time cost with an estimated savings of $1,500/ case in a single centre.29†† – Optimise performance: Combining innovations to facilitate surgeon preferences and help solve the challenges they face; such as CoCr-free modular dual mobility hip and truly unique bearing material science. Trauma & Extremities Smith+Nephew’s portfolio includes differentiated technology across the major categories of Plates and Screws, Intramedullary Nails, Hip Fracture, Limb Restoration, Extremities, and Shoulder Replacement. Leading products include the EVOS◊ Plating System which includes a wide range of clinical indications from mini and small to large fragment and periprosthetic. Designed to offer surgeons an all-inclusive, expansive plating portfolio, EVOS◊ provides the simplicity of logically organised instrumentation with advanced implant solutions that meets the demands and expectations of trauma surgeons. The portfolio also includes the TRIGEN◊ INTERTAN◊ Hip Fracture System, which is backed by many years of strong clinical evidence.2 For Extremities, SMART TSF◊ expands the capabilities of the TAYLOR SPATIAL FRAME◊ External Fixator. In 2023, we launched the AETOS◊ Shoulder System, indicated for both anatomic and reverse total shoulder arthroplasty. It is designed to restore patients’ range of motion34–37 and help minimise arthritic shoulder pain. The AETOS◊ Shoulder System is the latest solution in Smith+Nephew’s expanding Upper Extremity portfolio and complements our market-leading Sports Medicine shoulder repair and biologics solutions. The portfolio also includes the TRIGEN◊ INTERTAN◊ Hip Fracture System, which is backed by many years of strong clinical evidence.40,41 For Extremities, SMART TSF◊ expands the capabilities of the TAYLOR SPATIAL FRAME◊ External Fixator. This is our commitment. This is Precision in Motion » For a full list of references see pages 262–264 EVOS◊ Plating System Integrated solutions for fracture fixation The EVOS◊ Plating System, an evolutionary approach to simplify and unify into one plating system, offers surgeons the simplicity of one, comprehensive plating system that addresses all of their small fragment surgical needs. Smith+Nephew Annual Report 2023 37 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION

GRAPHIC

Taking our innovation to market continued Sports Medicine & ENT Smith+Nephew’s Sports Medicine & ENT business unit leads with innovative procedural solutions to elevate the standard of care in Sports Medicine & ENT. With a comprehensive offering and differentiated technologies backed by clinical evidence, we help healthcare professionals get their patients back to a Life Unlimited. Sports Medicine & ENT operates in growing markets where unmet clinical needs provide opportunities for procedural and technological innovation. Smith+Nephew holds a leadership position as a global player in the $5.8 billion annual Sports Medicine Market. Sports Medicine spans a broad patient population, including athletes. People of all ages are more active than ever before, and whenever they seek treatment for an injury or a degenerative condition, they expect a fast recovery and rapid return to activity. The surgeons who serve these patients want to treat them as efficiently and as minimally invasively as possible while ensuring the best possible outcomes. We have a rich history of product development, and our technologies, instruments and implants enable surgeons to perform minimally invasive surgery, treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip and small joints. ENT is also an attractive, growing market segment offering the opportunity to address unmet needs with differentiated procedural solutions. The positive momentum is driven by emerging therapies, changes in the point of care, mainly to the office setting, and increasing global access for ENT procedures. We offer a portfolio of technologies focused on the unmet needs of some of the most common procedures general and paediatric ENT surgeons perform today. These include tonsillectomies, epistaxis (severe nose bleeds) and tympanostomies (insertion of ear tubes). Elevating the Standard of Care Highlights Sports Medicine & ENT revenue $1,729m 2022: $1,590m Reported 8.8% Underlyinga 10.0% Sports Medicine & ENT trading profit $503m 2022: $472m 2023 Revenue 2023 Reported growth 2023 Underlying growtha Sports Medicine Joint Repair $945m 8.7% 9.9% Arthroscopic Enabling Technologies $588m 3.7% 4.7% ENT $196m 28.1% 29.8% a These non-IFRS financial measures are explained and reconciled to the most directly comparable financial measure prepared in accordance with IFRS on pages 244–248. We delivered strong growth in 2023 as we built upon our leading portfolios in Joint Repair and Arthroscopic Enabling Technologies and expanded our exciting biological healing business.” Scott Schaffner President Sports Medicine Arthroscopy solutions for the OR We are driven to design products that enable better outcomes and improved quality of care. We work with customers to ensure their arthroscopy suite is complete, robust and ready to perform – providing and supporting comprehensive technologies for visualisation, fluid management, tissue resection (COBLATION◊) and patient positioning. Our INTELLIO◊ Connected Tower Solution provides sports medicine surgeons with a complete suite of enabling technologies in the operating room (OR). It uses a centralised app to wirelessly connect and control the major components of an arthroscopy surgical tower from outside the sterile field, helping to streamline procedure support. 38 Smith+Nephew Annual Report 2023

GRAPHIC

2023 performance Sports Medicine & ENT delivered revenue growth on a reported basis of 8.8% including a 120bps headwind from foreign exchange. Underlying growtha was 10.0%. Performance was impacted as distributors reduced inventory in anticipation of volume based procurement in China. Sports Medicine Joint Repair delivered a strong performance, in line with previous years, led by the REGENETEN◊ Bioinductive Implant. Arthroscopic Enabling Technologies improved year-on-year as we benefited from improved supply. ENT grew strongly led by our tonsil and adenoid business. Business unit trading profita was up 6.6% with a trading profit margina of 29.1%. Strategy We have a strong Sports Medicine & ENT business and are well positioned for long-term leadership and delivering our vision of advancing standards of care. Our business unit is driven by the three strategic priorities – innovation, market development and commercial execution. Smith+Nephew’s Sports Medicine & ENT business is founded on procedural innovation, with differentiated technologies that shape clinical outcomes across the globe. Our portfolio continues to demonstrate strong growth across key segments, and we have an innovative pipeline in development. In line with our vision, our emphasis on market development will help shift standards of care to technologies and procedures that deliver on the promise of Life Unlimited. We are committed to investments in key areas such as clinical evidence, medical education and surgeon training for continued market development around key procedures. Our commercial initiatives reflect balanced selling across segments and regions, aligned priorities and a customer-centric, winning mentality. Global market share In Sports Medicine, Smith+Nephew holds a leading position behind Arthrex (US), and also competes against Stryker and DePuy Mitek. A Smith+Nephew 28% B Arthrex 33% C Stryker 12% D DePuy Mitekd 10% E Others 17% Global market size 2023b Sports Medicinec $5.8bn +7% 2022: $5.5bn +4% b Data used in 2022 and 2023 estimates generated by Smith+Nephew is based on publicly available sources and internal analysis and represents an indication of market shares and sizes. c Representing repair products and arthroscopic enabling technologies, and excluding ENT. d A division of Johnson & Johnson. UltraTRAC Sports Medicine advanced procedural innovation in 2023 by launching the QUADTRAC◊ Quadriceps Tendon Harvest Guide System and expanded family of ULTRABUTTON◊ Adjustable Fixation Devices for anterior cruciate ligament (ACL) reconstruction. ULTRABUTTON◊ TIB Adjustable fixation device QUADTRAC◊ Quadricepts tendon harvest guide system X-WING Graft preparation system◊ ULTRABUTTON◊ QUAD Adjustable fixation device A B C D E » For a full list of references see pages 262–264 Smith+Nephew Annual Report 2023 39 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION

GRAPHIC

Taking our innovation to market continued Sports Medicine & ENT continued Key products by segment Sports Medicine Joint Repair Our Sports Medicine Joint Repair business offers innovative procedural solutions for repairing soft tissue injuries including systems of specialised implants and instruments to facilitate arthroscopic procedures across Sports Medicine for knees, shoulders, hips and small joints. For shoulder repair, we develop products for Rotator Cuff Repair (RCR) and instability repair to help address pain and restore function. Advanced Healing Solutions for RCR include the innovative REGENETEN◊ Implant. With at least 12 published clinical studies including more than 700 patients,1,2,13–22 the REGENETEN◊ Implant has been shown to change the course of tear progression in early studies,1,3,4,6,23,24 aid return to normal activity13 and reduce re-tears versus conventional surgery.7,16,17,25–28 The HEALICOIL◊ Platform of Shoulder Anchors features an open architecture design to facilitate healing8 and is available in our REGENESORB◊ material which is designed to be absorbed and replaced by bone within 24 months.****10–12 In knee repair, arthroscopic repair techniques have become more prevalent and widely recognised for the treatment of meniscal tears in recent years.29 Our All Tears, All Repairs Meniscal Repair Portfolio provides surgeons with unsurpassed options and possibilities for meniscal repair. In November 2023 we announced a definitive agreement to acquire CartiHeal, developer of the CARTIHEAL◊ AGILI-C◊ Cartilage Repair Implant, a novel sports medicine technology for cartilage regeneration in the knee. CARTIHEAL◊ AGILI-C◊ is a porous, biocompatible and resorbable scaffold which promotes natural regeneration of the articular cartilage and restoration of its underlying subchondral bone. See page 29 for further information. We also offer a comprehensive ligament portfolio of high-quality products and thoughtful techniques to address the full spectrum of ligament pathologies and concomitant injuries. Building upon our trusted legacy of data-driven solutions, we continue to innovate in this space. In 2023 we introduced the UltraTRAC◊ QUAD ACL Reconstruction Technique which consists of the new QUADTRAC◊ Quadriceps Tendon Harvest Guide System, X-WING◊ Graft Preparation System and a family of ULTRABUTTON◊ Adjustable Fixation Devices. These technologies work together to provide an innovative procedural solution, expanding Smith+Nephew’s ability to address surgeon graft preference. Our hip preservation portfolio contains a comprehensive offering of technologies and techniques, establishing Smith+Nephew as a leader and innovator in the hip repair segment. The CAP-FIX◊ Capsular Management Family addresses all capsular management needs, from open to close. We are committed to Redefining Healing Potential in gluteus medius repairs, with the use of the REGENETEN◊ Implant.** In 2023 we launched new procedure solutions in the foot and ankle soft tissue repair segment, entering the market with focused techniques and procedural kits for ankle instability and Achilles reconstruction. Our core platform technology is designed specifically for the foot and ankle surgeon and provides a significant opportunity for growth. In addition, with the REGENETEN◊ Implant, we offer an innovative biologic solution that can be used to augment insertional or midsubstance Achilles repair.** Advanced Healing Solutions At Smith+Nephew, we are redefining healing potential with our portfolio of innovative products and materials. The REGENETEN◊ Implant supports the body’s natural healing response to promote the growth of tendon-like tissue and change the course of tear progression.**1–6 Derived from highly purified bovine Achilles tendon, it creates an environment that is conducive to healing.1,3 When used in Rotator Cuff Repair, the results of a new randomised controlled trial showed that the addition of our REGENETEN◊ Implant delivered a significant reduction in rotator cuff re-tear rates at 12 months.7 In addition, the unique open-architecture design of HEALICOIL◊ anchors reduces the amount of implanted material in the shoulder from that of solid-core anchors and may provide a biologic healing advantage.8,9 Our REGENESORB◊ material is designed to provide a jump start in bone healing and formation by full absorption and bone replacement in 24 months.****10–12 40 Smith+Nephew Annual Report 2023

GRAPHIC

Arthroscopic Enabling Technologies (AET) In Arthroscopic Enabling Technologies, our products facilitate arthroscopic surgical procedures, providing a strong foundation of platforms and associated consumables required to perform arthroscopic surgery, including visualisation, fluid management, COBLATION◊ and mechanical resection. The INTELLIO◊ Connected Tower Solution unites high-definition imaging solutions, energy-based and mechanical resection platforms, fluid management and access technologies. The LENS◊ 4K Surgical imaging system uses 4K UHD image quality and network connectivity in a 3-in-1 console for multi-speciality environments. Our WEREWOLF◊ Controller enables surgeons to remove soft tissue precisely***30 in a variety of arthroscopic procedures. With COBLATION◊ treatment, patients experienced significantly less bleeding post-operatively.*****31 The WEREWOLF FASTSEAL◊ 6.0 Hemostasis Wand is used in orthopaedic procedures for hemostasis of soft and hard tissues bringing a technology widely used in sports medicine to orthopaedic customers. Ambulatory Surgery Centers (ASCs) At Smith+Nephew, we go beyond product to deliver a comprehensive offering for ASCs. There continues to be a shift of both sports medicine and orthopaedic procedures from hospital to ASC outpatient settings. We are uniquely positioned to meet the needs of the market with procedural solutions spanning across sports medicine, hip and knee reconstruction, robotics, trauma, extremities, and post-surgical wound care. As the ASC market evolves, Smith+Nephew will continue to meet the distinct needs of this segment with procedure innovation and tailored programmes for growth. Launching the ARIS◊ COBLATION◊ Turbinate Reduction Wand The ARIS◊ COBLATION◊ Turbinate Reduction Wand utilises Smith+Nephew’s advanced COBLATION Plasma Technology to provide a minimally invasive way to reduce hypertrophic turbinates. It provides targeted hemostasis with built-in bipolar coagulation function.40 Designed for versatility, the ARIS◊ COBLATION◊ Turbinate Reduction Wand allows surgeons to vary the degree of tissue removal based on patient indication when treating hypertrophic turbinates submucosally. It offers customisation, flexibility and control for turbinate reduction procedures, accommodating various submucosal resection surgical techniques. It is designed specifically for the WEREWOLF◊ ENT Controller. Ear, Nose and Throat (ENT) In Ear, Nose and Throat, our COBLATION◊ Plasma Technology, which has been used to remove tonsils and adenoids for over 15 years,32,33 has an ability to remove tissue at low temperatures with minimal damage to surrounding tissue.32,34–38 Evidence shows that COBLATION◊ Intracapsular Tonsillectomy (CIT) procedures offer less pain, quicker recovery and a decreased risk of post-operative bleeding with similar outcomes to total tonsillectomies.39 Smith+Nephew offers a full portfolio of COBLATION◊ Wands for CIT procedures. Further expanding our portfolio, we launched the ARIS◊ COBLATION◊ Turbinate Reduction Wand in 2023. Our Tula◊ Systemprovides an in-office alternative to traditional tympanostomy using a local anaesthesia system and an automated, one-click tube delivery device.41,42 As part of our comprehensive portfolio of epistaxis (nosebleed) solutions, RAPID RHINO◊ Epistaxis Products are inflatable tamponades designed for ease of insertion and removal43 with an ultra-low profile and self-lubricating hydrocolloid fabric. In addition, we market a range of dissolvable and removable post-operative nasal dressings. ARIS wand » For a full list of references see pages 262–264 Smith+Nephew Annual Report 2023 41 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION

GRAPHIC

Taking our innovation to market continued Advanced Wound Management Smith+Nephew’s Advanced Wound Management vision is to Shape What’s Possible in Wound Care. Through our extensive portfolio, designed to meet broad and complex clinical needs, we help healthcare professionals solve the challenges of preventing and healing wounds. The global wound care market is worth around $11.4 billion globally per annum. Long-term growth has been driven by the needs of an ageing population in many markets and as we experience lifestyle-related health conditions, such as increasing prevalence of obesity, diabetes and vascular disease. These conditions are key drivers of wound prevalence which contribute to the pressure on healthcare spending. In Advanced Wound Management, we seek to help healthcare systems through innovation in products and services, to deliver accelerated healing or preventing wounds, and to do more with less, such as enabling patients to be treated faster requiring fewer resources, or moved from acute to homecare settings. We do this across our three segments of Advanced Wound Care (AWC), Advanced Wound Bioactives (AWB) and Advanced Wound Devices (AWD). 2023 performance Advanced Wound Management delivered revenue growth on a reported basis of 6.2% including a 20bps headwind from foreign exchange. Underlying growtha was 6.4%. Within this, Advanced Wound Care’s performance included growth from our major categories of foams, films and infection management. Advanced Wound Bioactives' performance was driven by strong growth from SANTYL◊ .. Advanced Wound Devices was driven by both our traditional RENASYS◊ Negative Pressure Wound Therapy System and our single-use PICO◊ Negative Pressure Wound Therapy System. Business unit trading profita was up 8.3% with a trading profit margina of 29.4%. Strategy Our vision of shaping what's possible in wound care is delivered through innovation in product with strong clinical evidence and digital tools that enable protocol compliance to ensure optimal patient outcomes. Innovation includes new product development, line extensions and acquisitions as well as digital services for both clinicians and patients. To drive ever-improving commercial execution we seek to inspire, engage and align on our global strategy across all regions and functions as efficiently as possible. Through these strategic priorities we are driving performance and supporting delivery of Smith+Nephew’s global Strategy for Growth to Strengthen, Accelerate and Transform through the 12-Point Plan. Shaping What’s Possible in Wound Care Highlights Advanced Wound Management revenue $1,606m 2022: $1,512m Reported 6.2% Underlyinga 6.4% Advanced Wound Management trading profit $472m 2022: $436m 2023 Revenue 2023 Reported growth 2023 Underlying growtha Advanced Wound Care $725m 1.8% 2.1% Advanced Wound Bioactives $553m 6.3% 6.2% Advanced Wound Devices $328m 17.0% 17.6% We are pleased with our 2023 performance, led by our Negative Pressure Wound Therapy portfolio where we focused on accelerating growth, delivering on the 12-Point Plan.” Rohit Kashyap President Advanced Wound Management & Global Commercial Operations GRAFIX◊ Placental Membranes from our skin substitute product range. a These non-IFRS financial measures are explained and reconciled to the most directly comparable financial measure prepared in accordance with IFRS on pages 244–248. 42 Smith+Nephew Annual Report 2023

GRAPHIC

A Smith+Nephew 14% B 3M 16% C Mölnlycke 10% D ConvaTec 6% E Others 54% Global market size 2023b Advanced Wound Management $11.4bn +5% 2022: $10.8bn +4% b Data used in 2022 and 2023 estimates generated by Smith+Nephew is based on publicly available sources and internal analysis and represents an indication of market shares and sizes. Global market share We operate in all three categories in wound care, and have the second largest business globally in terms of revenue. In the Advanced Wound Care segment we compete in dressings with Mölnlycke (Sweden), Coloplast (Denmark) and ConvaTec (UK). In Advanced Wound Devices, we are the primary challenger to Negative Pressure Wound Therapy incumbent 3M. In Advanced Wound Bioactives we have leadership positions in a number of our respective categories. Reducing the burden on nurses through shared-care The World Health Organisation predicts a need for nine million more nurses by 2030 for health and wellbeing.9 Chronic wounds significantly burden healthcare, consuming large healthcare budgets. With wound prevalence increasing, efficient wound care treatments are crucial.10 In 2022, Wounds International suggested that 3.5 billion nursing hours could be saved globally by 2030 with shared-care in chronic wound care and long-wear advanced foam dressings. Shared-care involves patient participation in care delivery, supported by healthcare professionals. It's effective in diabetes, stoma management and incontinence.11–14 ALLEVYN◊ LIFE Foam Dressings, supporting shared-care, are designed for extended use (up to seven days), managing exudate and providing comfort.15–22 * ALLEVYN LIFE◊ Foam Dressing DURAMAX◊ S Silicone Superabsorbent Dressing for highly exuding wounds launched in 2022. Committed to reducing environmental impact Smith+Nephew's Less Waste+More Care initiative focuses on reducing environmental impact by optimising ALLEVYN◊ Dressing packaging. This includes reducing carton, pouch and case sizes by over 20%, and making ALLEVYN◊ Dressing cartons 33% smaller and 13% lighter than competitors.23 A B C D E » For a full list of references see pages 262–264 Smith+Nephew Annual Report 2023 43 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION

GRAPHIC

Taking our innovation to market continued Advanced Wound Management continued Key products by segment Advanced Wound Care Smith+Nephew started as a wound care company and through our Advanced Wound Care business we have grown to be a leader in the segment. Today our portfolio includes products that are designed to manage exudate and infection, protect the skin and help prevent pressure injuries. In exudate management, our products provide appropriate wound fluid handling and absorption to help promote an optimal wound healing environment.24–26 Our ALLEVYN◊ LIFE Foam Dressing is uniquely differentiated, with its EXUMASK◊ change indicator and hyper-absorbent lock-away layer, with EXULOCK◊ technology for odour control and fluid lock-in.26–28 The effectiveness of the ALLEVYN Dressing range has been demonstrated across 138 publications in 19 countries on over 12,000 patients and volunteers.29 In 2023, sales of the DURAMAX◊ S Silicone Superabsorbent Dressing, launched last year, continued to grow. Our key silver-based ACTICOAT◊ Antimicrobial Barrier Dressings, DURAFIBER◊ Ag Absorbent Gelling Silver Fibrous Dressing, ALLEVYN◊ Ag Antimicrobial Foam Dressing, as well as our range of IODOSORB◊ Cadexomer Iodine products provide clinicians with a range of solutions to help patients with complex wounds, managing exudate as well as providing a barrier to bacterial penetration.30–40 We were successful in receiving US 510(k) clearance for our improved range of ALLEVYN◊ Ag Antimicrobial Foam Dressings in 2023, giving access to expanding market segments in the future. Advanced Wound Bioactives Our Advanced Wound Bioactives portfolio provides a unique approach to debridement, dermal repair and tissue substitutes with considerable evidence supporting their clinical application. Collagenase SANTYL◊ Ointment (250 units/ gram) is the only FDA-approved enzymatic debridement agent indicated for debriding both chronic dermal ulcers and severely burned areas available in the US market, with a unique mechanism of action that removes necrotic collagen and contributes to the formation of healthy collagen in chronic wounds and severely burned areas. REGRANEX◊ (becaplermin) Gel 0.01% is the only FDA-approved Platelet-Derived Growth Factor for the treatment of diabetic neuropathic ulcers, formulated to act as a first-line treatment following effective ulcer care. In our skin substitute product range, GRAFIX◊ Placental Membranes and STRAVIX◊ Umbilical Tissues retain the extracellular matrix, growth factors and native placental components to support wound closure.41–42 They are intended for application directly to acute and chronic wounds and as a surgical cover or barrier. In addition, we offer OASIS®** Matrix and OASIS MICRO products, which are naturally derived scaffolds of extracellular matrix (ECM), composed of porcine small intestinal submucosa (SIS) and indicated for the management of a wide range of acute and chronic wounds, burns and surgical interventions.43 Advanced Wound Devices In Advanced Wound Devices, our portfolio helps improve healing outcomes in chronic wounds, reduces surgical site complications and facilitates preventative care for pressure injuries. Within the negative pressure wound therapy (NPWT) category, we offer single-use and traditional (cannister-based) solutions offering customers a one-stop shop with great flexibility. The future of pressure injury prevention Hospital-acquired pressure injuries (HAPIs) are on the rise. Despite a decrease in other hospital-acquired conditions, HAPIs are up 6%.1†† Each year, complications from pressure injuries result in an estimated 60,000 deaths in the US. The average incremental cost of treating a pressure injury is $21,767. Smith+Nephew’s LEAF◊ Patient Monitoring System promotes adherence to patient turning procedures.2,3 Visual alerts in the patient room and at the nurses’ station make it easy for the whole team to see who needs to be turned and when.4 Plus, the LEAF◊ System’s Integrated Positioning Technology is the first tool that measures the quality and effectiveness of patient turning, including patient turn frequency and turn angle. Smith+Nephew's ALLEVYN◊ LIFE Dressings and SECURA◊ skincare products are designed to help prevent pressure injuries, aiding in evidence-based protocol adherence for HAPI prevention.5–8 These products showcase the Company's commitment to improved healthcare practices. 44 Smith+Nephew Annual Report 2023

GRAPHIC

Our technology takes the limits off living Smith+Nephew’s Advanced Wound Management Business Unit is also focused on utilising digitally enabled technologies and pioneering data services to provide new forms of value to our customers. We aim to help optimise clinical practice, prevent unnecessary wounds and complications, support patient care and self-management where appropriate and drive the transition to value-based business models. Building from the launch of the award-winning WOUND COMPASS◊ Clinical Support App in 2022, we are investing in a digital health portfolio that leverages the latest advancements in connectivity, artificial intelligence and data-driven health services. These technologies aim to support our customers in delivering more accessible, efficient and effective wound care for patients. PICO PICO◊ Single Use Negative Pressure Wound Therapy System (sNPWT) is cost effective and improved outcomes compared with standard care to help prevent surgical site complications in patients with surgically closed incisions. A systematic literature review and meta-analysis of 19 studies involving 4,530 patients showed a 63% reduction in the odds of developing surgical site infections with the prophylactic use of PICO◊ sNPWT compared with standard care.45 Hospital-acquired pressure injuries (HAPIs) are on the rise1 Despite a decrease in other hospital-acquired conditions, HAPIs are +6%1†† Each year, complications from pressure injuries result in an estimated 60,000 deaths in the US54 The average incremental cost of treating a pressure injury is $21,76755 Our PICO◊ range of single-use NPWT systems, with their proprietary AIRLOCK◊ Technology layer, has demonstrated significant healing outcomes for chronic wounds44*** and in the reduction of surgical site complications in closed incisions,45† in a highly portable form that allows patients to return to their daily lives.46,47 Our traditional RENASYS◊ NPWT Systems are easy to use platforms with a range of accessories to treat a wide variety of wounds and patients – across all care settings.48,49 The RENASYS◊ portfolio has been enhanced with the recent addition of EDGE, our latest innovation in NPWT designed to be clinically easy to use,50 alleviating the daily patient burden of living with a wound,51 whilst delivering higher efficiency and utility for healthcare systems.50,52,53 AWD also includes the LEAF◊ Patient Monitoring System that supports a hospital’s pressure injury prevention strategy. In 2023, we gained 510(k) clearance and introduced into the US the VERSAJET◊ III Hydrosurgery System, a surgical debridement device. » For a full list of references see pages 262–264 Smith+Nephew Annual Report 2023 45 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION

GRAPHIC

Building a culture of belonging At Smith+Nephew, we strive to create a culture of belonging where all employees can bring their full selves and best ideas. We are committed to creating a psychologically safe environment that fosters innovation, delivers business success and strengthens engagement and personal fulfilment. Inclusion and allyship Our comprehensive people strategy is focused on making Smith+Nephew a workplace that talented people want to join and stay and building a high-performing and inclusive culture where everyone feels a sense of respect and belonging. Our culture pillars of Care, Courage and Collaboration guide all we do. Creating an environment where all employees can flourish begins with attracting and retaining diverse talent, which we support through an extensive Inclusion, Diversity and Equity (IDE) programme. In 2023 we took a number of new steps to continue this journey. Our Talent Acquisition team began using ‘bias interrupters’ in their hiring practices including ensuring diverse sourcing, hiring pools and hiring panels for candidates. Bias interrupters are tweaks to basic business systems (including hiring, performance evaluations, assignments, promotions, compensation) that prevent implicit bias in the workplace, often without ever talking about bias. Supported by this, we met our gender diversity goal of 34% females in management positions and met our US ethnicity goal of 21% of those in management positions being ethnically diverse. We also established a baseline for ethnicity for the UK. Our enterprise gender ratio was 43%, exceeding industry best practice of 40%. Gender ratios 2023 We continued to increase female representation in senior roles, up to 34% in 2023 from 33% in 2022 and 31% in 2021. Total employees1 18,452 Male 57% Female 43% Senior managers and above2 1,087 Male 66% Female 34% Board of Directors 12 Male 67% Female 33% 1 Number of employees at 31 December 2023 including part-time employees and employees on leave of absence. 2 Senior managers and above includes all employees classed as Directors, Senior Directors, Vice Presidents, Executive Officers and includes all statutory directors and Directors of our subsidiary companies at 31 December 2023. By creating a workplace where our employees feel supported, included and valued for their unique strengths and perspectives, we are able to build a high-performing culture and ultimately better serve our customers and their patients.” Elga Lohler Chief HR Officer 46 Smith+Nephew Annual Report 2023

GRAPHIC

In 2023 we introduced a new workspace on our learning platform to educate our employees on allyship in the workplace. Allyship refers to actions, behaviours and practices that support, amplify and advocate with others, especially with individuals who do not belong to the same social identity group. With this, we are teaching our employees how to advocate for and elevate the experience of all their colleagues, particularly those who may be under-represented. Allyship is a strong theme within our Employee Inclusion Groups (EIGs) and will be the guiding theme for our IDE programme in 2024. Smith+Nephew’s EIGs are voluntary, employee-led groups that foster an inclusive, diverse workplace. They are aligned with our purpose, culture pillars, and business objectives and empower our employees to share their experiences, find advocacy, support and strength. To amplify their impact, in 2023 we have brought our woman-focused EIGs including the Society for Women Engineers and Women’s Inspired Network, under a combined group: The Women’s Network. Sponsored by our Group General Counsel & Company Secretary, Helen Barraclough, this group includes more than 800 members globally. Additionally, our EMPOWER EIG, which is focused on employees affected by or living with a visible or invisible disability, chronic health condition and/ or mental health difficulty, launched the Neurodiversity Network. Created and managed by our passionate neurodiverse members, the Neurodiversity Network has a wealth of tools and resources aimed at supporting neurodivergent individuals in the workplace to recognise their strengths and celebrate their unique skills and perspectives. The Neurodiversity Network also helps educate colleagues on the different types of neurodiversity, promoting the value of our neurodiverse colleagues, and raising awareness of their unique challenges. Smith+Nephew is committed to amplifying the inclusion, influence and achievements of women employees by fostering professional development, advocacy and networking. Our Women’s Network is at the centre of our efforts.” Helen Barraclough Group General Counsel & Company Secretary, Executive Sponsor Women’s Network Ethnic diversity In 2023 we met our US ethnicity goal of 21% of those in management positions being ethnically diverse. We also established a baseline for ethnicity across our UK-based management. US management1 UK management1 1 Data correct as 31 December 2023. White 76.2% Ethnically Diverse 21.4% Unknown 2.4% White 88.8% Ethnically Diverse 10.9% Unknown 0.3% +800 Members globally who are part of our EIG Women’s Network Smith+Nephew Annual Report 2023 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION 47

GRAPHIC

Building a culture of belonging continued Promoting wellbeing Wellness – physical, mental and financial – plays a critical part in enabling employees to engage and focus on delivering their objectives. In 2023 we expanded and improved our global wellness programme. Our wellbeing strategy has five components: – Embed wellness into our culture. – Raise awareness and usage of global wellness resources. – Strengthen employee engagement. – Increase employee wellness and health. – Increase employee productivity through increased engagement and overall health. Promoting wellness of body and mind Individuals whose physical and mental health needs are cared for are three times more likely to be engaged at work, according to Gallup. At Smith+Nephew, our wellness offerings care for the whole person, not just the employee. This year we’ve focused our global wellness steering group to guide our global wellbeing strategy and established a global champion network to help better understand what employees want and what is already available. During 2023, we expanded our mental health first aiders network. We now have 150 trained first aiders across 11 countries. These colleagues are trained to help identify when help is needed, the level of support required, and signpost people towards doctors, helplines or organisations that may offer counselling, professional support and treatments. Privacy is always respected, and conversations are never shared with direct managers. Our mental health champions are often just ‘someone to talk to’. Underscoring the importance of wellness, we replaced our previous Employee Assistance Plan with a new provider, Spring Health, available to all employees and their household members. The new service includes therapy sessions, coaching, a wide range of diverse providers, as well as legal assistance, financial services and referrals for child and elder care. In the US, for the first time, Smith+Nephew was one of only 50 employers recognised with a Best Employer Award for creating a healthy work culture through a well-established, progressive and measurable employee wellbeing and engagement programme. The Business Group on Health is made up of large employers interested in ensuring their wellness and benefit programmes are benchmarked and appropriate for their employees. The group supports collaborating and sharing information on vendors and best practices in wellness and benefits, including diversity, inclusion and health equity. In the US, we also won the Cigna Healthy Workforce Designation: Gold Level award for our focus on the vitality and wellbeing of our workforce and for helping employees to be healthier, more productive and engaged. At Smith+Nephew we promote flexibility in where, how and when we work. This means looking at the spaces in which we work, the ways we work and our work patterns. We believe our approach is an important differentiator, and helps our employees balance work and home life. Our Global Flexibility Principles serve as the guiding philosophy for identifying flexible work solutions that foster productivity and wellbeing while supporting our culture. While the principles are consistent globally, specific flexibility options will vary depending upon the individual, role and site/ country/region. Continuous improvement Creating a culture of belonging, where our employees are highly engaged, is a continuous journey. We measure our progress using the Gallup Q12 as the tool for our annual employee engagement survey. The Q12 survey tool focuses strongly on the role of the people leader in engaging their team. People leaders are provided with their individual survey scores and conduct team sessions where the results are discussed and actions agreed – both to improve on opportunity areas and to maintain strengths. These action plans continued throughout the year and are assessed at our annual Gallup Accountability Check-in Survey to determine whether employees are seeing improvements. In our fifth year using the survey, we again saw an improvement in our ‘grand mean’, putting Smith+Nephew in the top half of participating companies and well above the Gallup average. Since the first administration of the survey, our grand mean has increased every year and we are trending on the improvement trajectory of Gallup’s top quartile clients. Our participation rate in this year’s survey was 89%. Our most meaningful improvements were in employees feeling supported in their progress at work and being recognised for their contributions. Once again, our strongest area was connection to our purpose of Life Unlimited. We also use Gallup to measure our progress in fostering Equity and Inclusion. We made solid progress across all eight categories in 2023, and overall. In Equity our greatest improvement came in employee recognition that we encourage their progress and development. In Inclusion we improved most significantly in the category recognising that Smith+Nephew is committed to building the strengths of each employee. Smith+Nephew supports a culture of wellbeing that provides benefits, resources and programmes for employees across the globe to provide an opportunity to improve their overall wellbeing so that they can bring their best self to work each day. Physical Financial Social Emotional 48 Smith+Nephew Annual Report 2023

GRAPHIC

Achieving results with responsibility Our global compliance programme helps our business to comply with applicable laws, regulations and industry code requirements in the markets in which we operate. Our comprehensive programme includes policies, guidance, role-based training, monitoring and validation processes supported by data analytics and reporting channels. Our compliance teams work closely with business partners to ensure that our programme evolves in parallel with business changes and emerging risks in the sector. Data privacy is an integral part of our programme and regulation in this area continues to increase. We are committed to helping our employees and third-party partners to do business in the right way through simplification of compliance programme requirements and by embedding key compliance controls into business processes. We regularly review our global policies and use an interactive tool and other resources to guide employees to make decisions that comply both with the law and our Code of Conduct. Our business models require that we work closely with third-party partners, and in many countries these partners sell products on our behalf. We have a well-established risk-based third party compliance programme which includes ongoing due diligence, training and oversight of these partners. An ethical employer Creating an environment where employees feel safe and that fosters innovation means building trust by operating ethically and compliantly. We have multiple levels of ethics and compliance oversight, including a Board Compliance & Culture Committee, to ensure managers, employees and business partners act with integrity. Data privacy has now been fully integrated into the compliance governance framework. We ensure appropriate oversight of significant interactions with healthcare professionals or government officials, and we comply with all national and state transparency reporting laws which require reporting of physician compensation. All employees have a responsibility to report violations of our Code. This may be done via their manager, directly to Compliance, HR or Legal functions, or through an externally managed reporting channel where anonymous reports may be made. At Smith+Nephew, we recruit, employ and promote employees on the sole basis of the qualifications and abilities needed for the work to be performed. We do not tolerate discrimination on any grounds and provide equal opportunity based on merit. Smith+Nephew gives individuals with disabilities fair consideration for all vacancies against the requirements of the role. Where possible, for any employee who has a disability or who becomes disabled while working for us, we make reasonable adjustments and provide appropriate training to ensure that they are supported in their career. We are committed to providing equal opportunities in recruitment, promotion and career development for all employees, including those with disabilities. We do not use any form of forced, compulsory or child labour. Smith+Nephew supports the Universal Declaration of Human Rights of the United Nations, respecting the human rights, dignity and privacy of individuals and their right to freedom of association, freedom of expression and the right to be heard. As a global medical technology business, we recognise our responsibility to take a robust approach to preventing slavery and human trafficking. Smith+Nephew is committed to preventing such activities in all of its corporate operations and in its supply chains. We comply with applicable laws and regulations globally in terms of our interactions with labour unions. +0.19 +0.10 +0.08 +0.07 +0.08 +0.04 -0.04 +0.32 +0.12 +0.07 +0.05 +0.04 2019 2020 2021 2022 2023 GrandMean Change (Average from Baseline) Smith+Nephew Gallup clients average Top 25% Gallup clients Smith+Nephew’s culture trajectory is well above average Source: Gallup In 2023, Smith+Nephew conducted its fifth administration of our Global Employee Survey using the Gallup Q12 engagement tool. We saw a significant uptick in engagement from year one (2019) to year two (2020) following the launch of our purpose, culture pillars and brand refresh. Smith+Nephew’s engagement trajectory (in orange) has remained well above the Gallup average (grey) and is tracking towards the top quartile of the Gallup database (blue). » Our Code of Conduct and Business Principles and Modern Slavery Statements are available at www.smith-nephew.com Smith+Nephew Annual Report 2023 49 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION

GRAPHIC

Giving friends back their freedom to enjoy the slopes Life Unlimited 50 Smith+Nephew Annual Report 2023

GRAPHIC

Smith+Nephew Annual Report 2023 51 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION

GRAPHIC

Protecting the future Through our Strategy for Growth we are working to strengthen the foundation of our business to serve customers sustainably and simply, to accelerate profitable growth through prioritisation and customer focus, and to transform our business through innovation. Our Strategy for Growth is underpinned by our Capital Allocation Framework, which has as one of its priorities investing in innovation and our ESG agenda. You can read more about our Strategy for Growth on pages 8–11, and our Capital Allocation Framework on page 21. We strive to deliver our ESG strategy in the communities where we live and work through the application of our values: – We demonstrate Care by respecting our global resources and striving to protect the safety and wellbeing of our employees. – We demonstrate Courage by setting ambitious goals to increase our volunteerism, reducing waste and greenhouse gas emissions, and by operating responsibly and sustainably. – We demonstrate Collaboration by working together with our partners who share our commitment and contributing to our communities through individual and team volunteerism. Our ESG strategy supports these value drivers by helping us to address the requirements of our stakeholders, creating a lasting positive difference to our communities, and protecting our environment. Our ESG strategy, inspired by the United Nations’ Sustainable Development Goals (SDGs), takes into account the social, environmental and economic aspects of our business and reflects the fact that sustainability and financial performance are closely linked. As a profit-seeking business, we aim to meet our economic objectives whilst at the same time managing the social and environmental impacts of our business activities. Our ESG strategy focuses on three areas: People, Planet and Products. Our objectives and progress against these are summarised on pages 54–59. Shaping a healthy and sustainable future Our ESG strategy is built on our purpose – Life Unlimited, our Strategy for Growth and our culture of Care, Courage and Collaboration. Our ESG and sustainability programme is intended to drive business value for our stakeholders, while inspiring our employees and empowering our teams to make a positive impact on society and the planet.” Katya Hantel Vice President ESG People Creating a lasting positive impact on our communities Planet Aiming to reduce our impact on the environment Products Innovating sustainably 52 Smith+Nephew Annual Report 2023

GRAPHIC

Our stakeholders’ priorities Through our ESG strategy we are addressing the needs and expectations of our stakeholders. Customers and suppliers Building ESG principles into the delivery of healthcare is of growing importance to our customers. Increasingly, customers require us to provide details of our ESG strategy and objectives. Customers place increasing importance on these responses when making contract decisions. Our Third Party Guide to Working with Smith+Nephew requires our suppliers to conduct business in a way which fits with the values and ethics of Smith+Nephew and provides our customers with further insight into how we work with suppliers to drive our ESG strategy. Employees Employees are looking for companies with strong values and cultures, that operate with integrity, transparency and accountability, and offer satisfying career opportunities for all. Living our values and being a force for positive change is part of our ESG strategy. Investors Investors are prioritising investments based on corporate ESG programmes and outputs. Our ESG programme provides evidence of our progress in these areas. Governments and regulators ESG regulation is increasing at pace globally. Our ESG strategy and governance focuses on ensuring compliance with existing and emerging regulation on sustainability matters. Our Compliance & Culture Committee reviews, tracks and monitors our compliance and progress towards our ESG objectives aligned with applicable regulations and our Strategy for Growth. Our senior management engage with industry bodies and interest groups such as AdvaMed, MedTech Europe and similar organisations on ESG matters which have the potential to impact our organisation. Environment and communities The communities where we are located want to see support for local education, health and volunteering programmes from businesses which operate there. Our ESG strategy prioritises giving back to local communities, for example through employee volunteering programmes. More information on our ESG activities can be found in our 2023 Sustainability Report, available on our website. www.smith-nephew.com Stakeholders want to understand the impact of our ESG strategy on People, Planet and Products to understand how we are driving and implementing strategy to reduce our impact on the planet and its resources and enabling us to innovate sustainably. ESG governance In January 2023, we streamlined the governance and operational structure around the delivery of our ESG strategy. We established the ESG Operating Committee to implement and execute our ESG strategy across all business areas, reporting directly to the Executive Committee. The Executive Committee will continue to formulate and drive our ESG strategy with oversight from the Board and its Committees. The Board reviews the ESG strategy, key risks and opportunities and progress on a regular basis and three Board Committees review its implementation: Compliance & Culture Committee, Audit Committee and Remuneration Committee. For further information on our governance see the Governance Report from page 88 and our Task Force on Climate-related Financial Disclosures (TCFD) reporting on pages 60–64. Our ESG strategy focuses on three areas: People, Planet and Products. Within these three areas, we have developed comprehensive objectives to help us deliver on our sustainability ambitions. Each year we measure and report progress against these objectives. During 2023, we adjusted several of our objectives to better reflect the challenges we face and to ensure they remain meaningful. We are proud of our many achievements over the years, including our ‘AA’ MSCI ESG Rating and our recurring inclusion in leading indices, such as FTSE4Good, the ESG Index from Institutional Shareholder Services (ISS) and the Dow Jones Sustainability Index. This year, we are reporting both our 2022 and 2023 Scope 3 greenhouse gas (GHG) emissions from 13 categories and are developing our Scope 3 GHG emissions reduction roadmap and strategy for the short to medium term. Climate change During 2023, we have continued to consider the potential impact of climate change on our business operations. Our physical assets and supply chains are vulnerable to weather and climate change, for example through sea-level rise, more frequent extreme weather events and more severe extreme weather events. Patients are vulnerable to a potential rise in infectious disease propagation. Governments and corporations alike are under increasing pressure to mitigate the expected effects of climate change, potentially resulting in infrastructure projects which would require large capital outlays and further increase pressure on healthcare payments. In 2021, we made a commitment to achieve net zero Scope 1 and Scope 2 GHG emissions by 2040 and net zero Scope 3 GHG emissions by 2045, beginning by achieving a 70% reduction in Scope 1 and Scope 2 GHG emissions by 2025. We are on track to achieve a 70% reduction in Scope 1 and Scope 2 GHG emissions by 2025 compared to the 2019 baseline. We aim to minimise the disruption to our manufacturing and distribution network. We understand how important it is to balance environmental initiatives with business activities, and strive to reduce emissions through new technology development, renewable energy use and other measures. Smith+Nephew Annual Report 2023 53 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION

GRAPHIC

Shaping a healthy and sustainable future continued People Creating a lasting positive impact on our communities Our objectives Our progress in 2023 Volunteering We are committed to living our culture in our communities by providing 8 hours of paid volunteer time to all employees and enabling at least 50 community/charity events across our sites each year from 2023 to 2030. 95 Events in first year Giving Between 2020 and 2030, donate $125 million in products to underserved communities. $5.1m ($16.2m since 2020) Inclusion Empower and promote the inclusion of all. 4,200+ Supporters across our seven Global Employee Inclusion Groups and sub-groups Our facilities in Memphis (US) and Malaysia sourced renewable electricity for the 2023 calendar year. In the final three months of 2023, we started procuring green energy at all our UK sites. This is set to continue through 2024. Our reporting against the TCFD framework and the Sustainability Accounting Standards Board (SASB) framework for our sector of Medical Equipment and Supplies can be found on pages 60–64 and 258–259 respectively. The Compliance & Culture Committee and the Audit Committee received updates on TCFD and SASB reporting during 2023. As part of our Enterprise Risk Management process, we have a sustainability risk register and a business resilience process review built into our review of our Principal Risks (see pages 69–77). Our Principal Risks capture our physical and transitional climate-related risks in our Enterprise Risk Management process. Climate change is an element of our Global Supply Chain Principal Risk, as increasingly frequent climate events increase the likelihood and impact of disruptions to our supply chain. Delivering on our sustainability ambitions In 2023, we continued to focus on our three priority areas: People, Planet and Products. Within these areas we have refined our objectives so that we can measure and report clearly on our progress. With an emphasis on increasing participation in EIGs and Life Councils, eight hours of paid volunteer time continues to be available to and promoted for uptake by all employees. In addition, in 2023, we focused on site-wide and community engagement activities, enabling us to combine individual efforts and maximise our impact through organised events. We reviewed and refined our packaging objective in light of industry and customer engagement, expanding its scope to include broader themes. In 2024 and beyond, we will continue to review and adapt our strategy and objectives to ensure they are current and that we make meaningful progress. » Read our TCFD reporting on pages 60–64 54 Smith+Nephew Annual Report 2023

GRAPHIC

People are at the heart of our purpose – Life Unlimited Putting people first will help us to achieve our vision of a world where healthcare professionals are able to help restore health to patients, wherever they are. We prioritise people in three ways: First, we help improve patients’ wellbeing and empower the healthcare professionals who treat them. Second, we engage with the communities where we operate, encouraging our people to volunteer in local communities, offering paid volunteer time and matching employee charitable donations. And third, we support our own employees’ wellbeing by ensuring their work environment is healthy and safe. We also continue to build employee wellness programmes that enable healthy life choices. Our giving activities during the year totalled donations of $5.2 million. These consisted of $5.1 million in product donations and $88,000 from matching employee gifts to qualified charities. Since 2020, our product donation strategies have been held back by the impacts of Covid; however, we are seeing the return of medical missions and continue to support, as needed. Celebrating our partnership with IHP – helping thousands in need For over 20 years Smith+Nephew has partnered with International Health Partners (IHP) to donate products to help treat people in need in over 30 countries worldwide. Most recently, we donated more than 40,000 products from our Advanced Wound Management portfolio to Ukraine, where medical supplies are desperately needed. To celebrate their impact across the world, in 2023 IHP held an event in London for all their valued partners and supporters, which Smith+Nephew attended. The infographic shows some of the places that our support has helped through our partnership with IHP. 95 volunteer events in 2023. $5.1m of product donations in 2023. 2013 Democratic Republic of the Congo, Sierra Leone, Zimbabwe 2014 Gambia, Gaza, Honduras, Philippines, Sri Lanka. Turkey, West Bank 2015 Haiti, Iraq 2016 Afghanistan, Gambia, Haiti, Honduras, Iraq, Jamaica, Nicaragua, Ukraine 2017 Iraq, Nicaragua 2018 El Salvador, Iraq, Sierra Leone 2019 Benin, Myanmar, Nicaragua 2020 Lebanon 2021 Jamaica 2022 Ukraine 2023 Ukraine Employee engagement is important to us and is measured by the Gallup Global Engagement Survey (see pages 48–49). In 2023, we combined the four Employee Inclusion Groups focused on women into one group. » See pages 48–49 Smith+Nephew Annual Report 2023 55 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION

GRAPHIC

Planet Aiming to reduce our impact on the environment We recognise the need to protect our planet and help mitigate against the impacts of climate change. In response, we manage resources efficiently, reduce our emissions where possible and are mindful of the impact our decisions have on the environment. In 2023, as the impacts of the global pandemic started to recede, many colleagues chose to adopt remote or hybrid working. Accordingly, some offices continued to see lower occupancy levels and we are adapting to those situations. Our ESG strategy extends upstream to our suppliers and downstream to our customers. This means that we want to work with partners who are making efforts to reduce their own environmental impacts. We are also working to deliver products and services that have less impact on the environment and are taking steps to better understand the extended footprints of our top-selling products. This helps us focus our resources where they will produce the most positive impact. To help achieve improvements in this area, we are collaborating with our key suppliers where there are more opportunities. We are mindful of the importance of biodiversity, particularly in some of the countries in which we operate including Costa Rica and Malaysia. The impact on local biodiversity is one of our considerations when we approve capital expenditure within our Global Operations business. Reducing our GHG emissions Our approach to cutting emissions is three-fold: tackling energy efficiency, generating our own renewable energy on-site and sourcing lower-carbon energy through green tariffs and procuring renewable energy certificates. To achieve this, we are evaluating new ideas and investing in technological solutions at many of our sites. Our aim is to achieve net zero status in line with our objectives. During 2023, we calculated both our 2022 and 2023 Scope 3 GHG emissions for 13 categories, and are beginning to develop a roadmap for reduction. See page 66 for more details. Shaping a healthy and sustainable future continued Our objectives Our progress in 2023 Progress since 2019 baseline Net zero Achieve net zero Scope 1 and Scope 2 GHG emissions by 2040 and Scope 3 GHG emissions by 2045, beginning by achieving a 70% reduction in Scope 1 and Scope 2 GHG emissions by 2025. A carbon reduction roadmap for Scopes 1 and 2 through 2025 has been developed and a roadmap for Scope 3 is being developed. We have calculated our Scope 3 GHG emissions data for 2022 and 2023. Scopes 1 and 2 (total) 40,266 tonnes CO2e emitted (market-based)1 Our manufacturing sites in Malaysia and Suzhou are generating on-site renewable energy. Scopes 1 and 2 (total) 40% reduction CO2e emitted (market-based)1 Emissions have been reduced by undertaking energy efficiency projects, on-site renewables and procurement of renewable energy and purchase of RECs. Scope 3 1.3 million tonnes CO2e emitted in 2023 Scope 3 Now reporting 13 categories, up from 8 in 2021. Waste Achieve zero waste to landfill2 at our manufacturing facilities in Memphis and Malaysia by 2025 and at all our strategic manufacturing facilities by 2030. Our Malaysia facility has achieved zero waste to landfill. 849 tonnes sent to landfill from Memphis manufacturing facilities, representing 38% of total waste from those facilities. 1,411 tonnes sent to landfill from the Group.1 32% reduction Less waste was sent to landfill from Memphis manufacturing facilities during 2023 compared to 2019. 30% reduction Less waste was sent to landfill from all our strategic manufacturing facilities during 2023 compared to 2019. 1 Data and more details are available in the 2023 Sustainability Report on pages 59–60. 2 We define zero waste to landfill as a landfill diversion rate of 90% or greater. 56 Smith+Nephew Annual Report 2023

GRAPHIC

2025 Begin by achieving a 70% reduction in Scope 1 and Scope 2 GHG emissions by 2025. 2040 Achieve net zero Scope 1 and Scope 2 GHG emissions by 2040. 2045 Achieve net zero Scope 3 GHG emissions by 2045. Our net zero targets What we have completed in 2023 – Conducted a detailed analysis of our energy usage data. – Actioned our carbon reduction roadmap. – Measured and reported our 2022 and 2023 Scope 3 GHG emissions from 13 categories, an increase from 8 categories reported for 2021. – Sourced renewable electricity for our manufacturing facility in Memphis (US) and started to generate renewable electricity from solar photovoltaic panels in Malaysia and Suzhou (China). What we are currently doing – Preparing a carbon reduction roadmap to reduce Scope 3 GHG emissions. – Sourcing renewable energy opportunities at all our strategic manufacturing sites. – Converting our European and UK leased car fleet to electric vehicles (EVs). – Expanding our supplier engagement through CDP. – Promoting a salary sacrifice scheme in the UK to enable employees to drive EVs. Roadmap to net zero What we expect to do next – Implement renewable electricity at all our strategic manufacturing sites by 2025. – Convert our remaining global leased car fleet to electric vehicles. – Actively engage with our suppliers and encourage them to set their own net zero targets. We encourage all our employees and supply chain partners to take responsibility for minimising their energy use. We make efforts to motivate staff to actively care about the environment, providing them with guidance and access to information to enable them to make a real difference. To identify and reduce our Scope 3 GHG emissions, we are working with our suppliers to identify opportunities and then build our roadmap for emissions reduction. We continued to source renewable wind energy for all our locations in Memphis (US). We also sourced hydroelectric energy for our manufacturing location in Malaysia. These were both achieved through the purchase of renewable energy certificates (RECs). From October 2023, all our UK sites began sourcing renewable energy through the UK Green Tariff. We have installed solar photovoltaic panels at our Suzhou and Penang sites. Both systems began operating in early 2023 and combined the two solar-powered systems reduced our Scope 2 GHG emissions by over 2,000 tonnes of CO2e in 2023. Sourcing renewable energy reduces our market-based GHG emissions, i.e. the emissions from the electricity we purchase. Our roadmap to net zero is outlined below. These are our current actions, which will be updated in the coming years as our plans develop. In accordance with the California Voluntary Carbon Market Disclosures Act (AB1305), detailed information is available on pages 36–39 of the 2023 Sustainability Report. Net zero In line with the Paris Agreement, which aims to hold the increase in the global average temperature to well below 2°C above pre-industrial levels, and pursue efforts to limit the temperature increase to 1.5°C above pre-industrial levels, we are committed to net zero. ‘Net zero’ means that the activities within a company’s value chain result in no net impact on the climate from GHGs. It is in our roadmap to achieve net zero Scope 1 and Scope 2 GHG emissions by 2040 and Scope 3 GHG emissions by 2045, for more details see the table below and page 36 of the 2023 Sustainability Report. We are on track to achieve a 70% reduction in Scope 1 and Scope 2 GHG emissions by 2025 compared to a 2019 baseline. Highlights 3.5 GWh We are now generating renewable energy in China and Malaysia in 2023. 2000 tCO2e GHG emissions prevented from going into the atmosphere by these projects. Smith+Nephew Annual Report 2023 57 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION

GRAPHIC

Shaping a healthy and sustainable future continued Products Innovating sustainably We aim to develop products with sustainable attributes, increase access to care, improve our environmental impact and reduce costs. Along with our customers and other stakeholders, we are focused on the environmental footprint of our products and services. Manufacturing and supplying safe and effective products is at the heart of our business. Our people, processes and technology are structured to support progress towards the objective of innovating sustainably. We are applying sustainability attributes to both our new products and their packaging to support delivery of our ESG objectives and those of our customers. We have integrated sustainability as a specific topic in our New Product Development phase review process to drive consideration of sustainability and efficiency in our product design, specifically: 1) material and energy usage during production; 2) reduced product footprint for shipping/ transportation; and 3) recyclability of waste products (e.g. packaging). Our customers are increasingly requesting information on the chemical components and recyclability of our products and packaging. Our focus on products will assist our customers in reaching their sustainability goals. Packaging sustainability to minimise environmental impact, both for new products and our existing portfolio, continues to be a key area of opportunity, as does moving to digital Instructions For Use (IFU). Our 2022 initiative to reduce packaging dimensions for our foam dressings has continued in 2023 and is resulting in reduced volumes of packaging materials being used and lower GHG emissions. By 2025, we aim to have completed a focused risk-based due diligence of our Tier 1 suppliers, including a risk-based analysis of sub-tier suppliers. Supplier risk criteria include country, commodity and spend, and we have updated our global process for managing Corporate Social Responsibility (CSR) supplier risk. In 2023, we completed internal screening due diligence with 100% of our Tier 1 suppliers with additional due diligence with identified potential high-risk Tier 1 suppliers. Our objectives Our progress in 2023 New products Include sustainability review in New Product Development (NPD) for all new products and product acquisitions. Sustainability is now embedded into our NPD phase review process, ensuring that we discuss, consider and implement sustainability when we design new products. Packaging We are committed to reducing our packaging and designing with reusable, recyclable and/or renewable resources which are sustainably sourced. We have refined and updated our packaging objective. We have continued to improve sustainable sourcing, including our ‘regionalisation strategy’ to purchase more packaging materials from local suppliers. We continue to use our electronic Instructions For Use platform, minimising paper instructions issued where possible. Supply chain By 2025, complete a focused risk-based due diligence of our Tier 1 suppliers, including risk-based analysis of sub-tier suppliers, to assure compliance with our sustainability requirements. We have completed due diligence and assessments of all Tier 1 suppliers according to our risk-based procedure. We have continued our supplier on-site audit programme for suppliers identified through risk-based analysis. On-site audits include worker interviews and practical assessment of the implementation of supplier policies and procedures to assure compliance with modern slavery, human trafficking, HSE and sustainability requirements. 58 Smith+Nephew Annual Report 2023

GRAPHIC

RENASYS◊ EDGE The future starts now The RENASYS◊ EDGE Negative Pressure Wound Therapy System has been designed with healthcare professionals and patients in mind. RENASYS◊ EDGE features years of innovation built into a format that is more easily portable and has a smaller footprint compared to RENASYS◊ TOUCH and RENASYS◊ GO products.1 The size and weight of the device is designed to allow patients to continue with their daily lives and supports patient privacy.2 RENASYS◊ EDGE incorporates an intuitive, user-friendly interface for easy to learn operation and troubleshooting.3 Our step-by-step user interface guidance is aimed at supporting clinicians’ training and increasing their confidence with therapy application.3 RENASYS◊ EDGE offers a short, user-friendly and time-efficient on-board guide for cleaning in between patient use.3,4 The modularised design enables easy and low-cost repair.4 RENASYS◊ EDGE is sturdy, reliable and durable, with the aim of minimising the need for device returns.5 34 kWh energy saved compared to RENASYS◊ TOUCH over its lifetime, enough to charge a mobile phone over 2,800 times.7 3× RENASYS◊ EDGE more energy efficient than RENASYS◊ TOUCH.6 13 kg C02 emissions saved compared to RENASYS◊ TOUCH over its lifetime.8 RENASYS◊ TOUCH See page 264 for references. Smith+Nephew Annual Report 2023 59 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION

GRAPHIC

TCFD reporting Pages 60–64 set out Smith+Nephew’s disclosures which are consistent with the recommendations of the Task Force on Climate-related Financial Disclosures (TCFD) framework. By this we mean the four TCFD recommendations and the 11 recommended disclosures set out in Figure 6 of Section B of the report entitled ‘Implementing the Recommendations of the Task Force on Climate-related Financial Disclosures’ published in October 2021 by the TCFD. Governance The way in which we evaluate, manage and embed sustainability within our business and culture is directly linked to our Strategy for Growth through a focus on People, Planet and Products. Oversight of our ESG strategy is one of the Matters Reserved to the Board. The Board reviews the ESG strategy, key risks and opportunities, and progress on a regular basis and approves the Sustainability Report annually, and reviews and approves the ESG, TCFD and SASB reporting in the Annual Report. Three Board Committees are also closely involved in reviewing the elements of sustainability that impact the key areas of our business. All Committees receive regular updates on ESG strategy, implementation, objectives and targets, and climate-related financial risks and opportunities. The Committee Chairs report to the Board at each Board meeting: – The Compliance & Culture Committee, chaired by Marc Owen, assesses how we implement our ESG strategy in the core areas of People, Planet and Products, encompassing the Group’s impact on employees, the environment, the local communities in which it operates, customers, suppliers and other key stakeholders. The Compliance & Culture Committee also tracks progress of the delivery on ESG objectives and metrics, including a regular review of our net zero emissions progress at each Committee meeting. – The Audit Committee, chaired by Rick Medlock, is responsible for ensuring oversight of the process by which risks relating to the Group and its operations are managed and reported. The Audit Committee assesses the extent to which climate change and other ESG risks are likely to have a material impact upon our financial statements by reviewing the possible impact of different scenarios related to climate change. The Audit Committee also has oversight of the TCFD reporting in the Annual Report. – The Remuneration Committee, chaired by Angie Risley, is responsible for ensuring that the Remuneration Policy and related incentive schemes incorporate ESG targets and metrics where appropriate to do so. Executive Committee: – Driven by the Chief Executive Officer, determination and management of ESG strategy, with the President Global Operations and Vice President ESG accountable for leading on implementation. – Ensures that ESG risks and opportunities are included in decision making as part of each project, initiative and the 12-Point Plan. ESG Operating Committee: – Established in January 2023. – Supports the Executive Committee in the execution and delivery of the ESG strategy. – Membership includes Global Operations, ESG, Global Manufacturing, Research & Development, Global Procurement, Public Policy & Government Affairs, Finance and Human Resources. Board: – Oversight of ESG strategy and risk management programme. Remuneration Committee: – Oversight and review of ESG metrics within Remuneration Policy, and compensation and incentive plans generally. – Approval of ESG percentage and measures within short-term and long-term incentive plans. In 2023, the Committee approved 5% of the Annual Bonus Plan for Executive Directors would be dependent on the achievement of ESG objectives and in 2024, 5% of the Annual Bonus Plan and 10% of the Performance Share Plan for Executive Directors and Executive Officers are dependent on the achievement of ESG objectives. Audit Committee: – Oversight of the risk management process and reviewing its operating effectiveness. – Receives regular updates on ESG and climate-related financial risks and opportunities. – Assesses whether climate change has a material impact on our financial statements. – Ensures the Company reports in line with the recommendations of the TCFD framework. Compliance & Culture Committee: – Oversight of ESG policy and performance versus targets, with reviews undertaken at each committee meeting. – Receives regular updates on ESG and climate-related risks and opportunities, people and culture objectives including IDE and ethics, compliance, quality and regulatory matters. Shaping a healthy and sustainable future continued 60 Smith+Nephew Annual Report 2023

GRAPHIC

Our Chief Executive Officer sets strategy together with the Executive Committee, and the President Global Operations and the Vice President ESG are responsible for the implementation and report at least quarterly on our progress to the Board, its Committees and our Executive Committee. In January 2023, we streamlined the governance and operational structure around the delivery of our ESG strategy. We established the ESG Operating Committee to implement and execute our ESG strategy across all business areas, reporting directly into the Executive Committee which will continue to formulate and drive our ESG strategy with oversight from the Board and its Committees. Smith+Nephew leaders consider ESG risks and opportunities in their decision making. For example, when evaluating options for our new manufacturing site in Melton, UK, an analysis of ESG requirements and risks is being undertaken as part of the project and decision making. Where appropriate, papers submitted to the Board by management for review include an analysis of ESG issues and opportunities to enable the Board to consider these factors in decision making and to ensure effective Board oversight on ESG strategy, risks and opportunities. Detailed information on our ESG risks can be found in our Sustainability Report. Strategy Our ESG strategy is built on our purpose – Life Unlimited, our Strategy for Growth and our culture of Care, Courage and Collaboration. Our ESG strategy, which was developed by our Sustainability Council in 2019 and approved by the Board, is inspired by the United Nations’ Sustainable Development Goals. Our strategy reflects the importance of social, environmental and economic aspects of sustainable development. Our Principal Risks capture our physical and transitional climate-related risks in our Enterprise Risk Management (ERM) process. Climate-related risk Potential impact Timeframe Actions taken by management Commercial execution Inability to satisfy customers’ sustainability requirements and expectations. Decline in customer demand. Lower prices to remain competitive. Medium (3-7 years) and long term (>7 years) Continued new product launches and monitoring of innovation pipeline. Legal and compliance Failure to identify existing or new legal or regulatory requirements including sanctions programmes and ESG matters which result in non-compliance with applicable laws and regulations. Fines and sanctions. Short (<3 years), medium (3-7 years) and long term (>7 years) The ESG Operating Committee assesses new and enhanced regulations, reporting requirements and works cross-functionally to ensure compliance. Failure to meet the needs of stakeholders relating to increased focus on and regulation of ESG reporting requirements. Decline in customer demand. Medium (3-7 years) and long term (>7 years) Monitoring new regulatory and enforcement trends. Carbon taxes. Increased pricing of GHG emissions. Medium (3-7 years) and long term (>7 years) Net zero targets set for Scope 1, 2 and 3 GHG emissions. New product innovation, design & development including intellectual property Sustainability in new products. Decline in customer demand. Medium (3-7 years) and long term (>7 years) Sustainability criteria built into new product development processes. Pricing and reimbursement Limited ability to pass on the cost of sustainability improvements. Higher input costs. Medium (3-7 years) and long term (>7 years) Optimise portfolio mix and promote differentiated products. Quality and regulatory Failure to meet stakeholder expectations with regard to increasing ESG regulations and reporting requirements. Decline in customer demand. Medium (3-7 years) and long term (>7 years) Monitoring regulatory changes and understand interpretation of legislation. Transition risks Smith+Nephew Annual Report 2023 61 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION

GRAPHIC

Scenario modelling Implication and mitigation Potential severity without mitigation Potential severity with mitigation Global temperature rise Based on the Intergovernmental Panel on Climate Change's sixth assessment report, we modelled the following scenarios out to 2030 and 2050: – Low: Limit warming to 2°C (IPCC scenario SSP1-2.6) – Medium: Limit warming to 3°C (IPCC scenario SSP2-4.5) – High: Limit warming to 4°C (IPCC scenario SSP 3-7.0) Extreme heat increases the demand for cooling and can overwhelm power grid infrastructures. Existing defences and business continuity plans are expected to mitigate any near-term impacts and the longer-term impact is being closely monitored by the ESG and operations teams. High Medium Sea-level rise We modelled the following scenarios out to 2030 and 2050: – Sea-level rise up to 5 metres – Distance from nearest coastline Rising sea levels impact manufacturing sites at coastal locations. Existing flood defences and business continuity plans are expected to mitigate any near-term impacts and the longer-term impact on the Group’s manufacturing footprint is an area of focus being considered in our manufacturing strategy. For example, the announced relocation of our Advanced Wound Management facility mitigates against the impact of sea-level rise and accordingly reduces the potential impact. Medium Low Extreme weather We modelled the following extreme weather scenarios out to 2030 and 2050: – Precipitation – Wind – Drought Heavy precipitation events will make flooding more probable, strong winds can damage roofs and compromise the building envelope, and more intense or prolonged droughts can lead to diminishing water resources and potentially more severe wildfires. Existing weather defences and business continuity plans are expected to mitigate any near-term impacts and the longer-term impacts are considered in our manufacturing strategy. Medium Low Physical risks Shaping a healthy and sustainable future continued TCFD reporting continued 62 Smith+Nephew Annual Report 2023

GRAPHIC

We address climate-related risk primarily through business strategies in our global operations functions including facilities, health and safety, business continuity and global supply chain management. Severe weather patterns as a result of climate change may cause damage to manufacturing or distribution facilities, potentially impacting our ability to meet customer demand over the long term. Refer to the risk management section on page 64 and the Risk report on page 67 for more details on our risk management process. Climate-related opportunities Climate-related opportunities are identified and addressed through our ESG strategy and programmes. Through this process we have identified a number of climate-related opportunities relating to energy sourcing, energy efficiency, on-site renewable energy generation, engagement through the CDP Supply Chain programme and packaging reduction initiatives. In 2020, all our locations in Memphis (US) began sourcing electricity from renewable wind energy via the procurement of renewable energy certificates (RECs) and this has continued through 2023. We completed construction of our Malaysia facility in 2021 and photovoltaic panels started generating renewable energy on-site at the beginning of 2023. Similarly, at our facility in Suzhou (China), solar photovoltaic panels commenced generating on-site renewable energy in early 2023. All UK sites have sourced a green tariff for the supply of electricity from renewable sources from October 2023. In 2021, we aligned with the recommendations of the Intergovernmental Panel on Climate Change and published our commitment to achieve net zero Scope 1 and Scope 2 GHG emissions by 2040 and Scope 3 GHG emissions by 2045, beginning by achieving a 70% reduction in Scope 1 and Scope 2 GHG emissions by 2025. We understand how important it is to balance environmental initiatives with business activities and strive to reduce emissions through new technology. We have conducted a review of our current state and captured related business risks in our risk register. Energy efficiency audits have been carried out at sites in the UK and Germany in 2023 with the recommendations added to improvement action plans. The new UK site at Melton, on the outskirts of Hull, will be designed to high ESG standards with a focus on energy and resource efficiency. The site aims to generate on-site renewable energy. Scenario analysis The scenario analysis undertaken in 2023 was supported by a third party and included more than 30 locations. The modelling focused on the material impacts on our business and was based on our current business activities and assumed no mitigation. As outlined on pages 61–62, our physical and transition risks are captured in our ERM process. Refer to our Risk report on page 67 for further details. Based on the modelling undertaken, the highest potential impact (without mitigation) is in relation to global temperature rise. The potential impact of sea-level rise has decreased from the prior year modelling with the announced plans to build a new Advanced Wound Management facility at Melton, on the outskirts of Hull, which sits at a higher elevation and is further inland than the current facility. The Group closely monitors climate-related physical risks and is taking mitigating measures such that the net impact to the business with these measures in place is not expected to be material. Smith+Nephew Annual Report 2023 63 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION

GRAPHIC

Risk management Climate-related risks are managed through our comprehensive risk governance framework. At the top of our structure, the Board sets our risk appetite and monitors the application of our risk framework, including strategy, execution and outputs of risk reviews by the business and the Group Risk team. The Board cascades our risk appetite throughout our organisation through the Executive Committee, the risk owner community and our management group. A formal ‘bottom-up’ exercise ensures that risks are escalated back through the process to our Board and are reflected in our Principal Risks as appropriate. Refer to pages 67–77 for more detail. Climate-related risks We identify climate-related risks based on short-, medium- and long-term horizons. We consider short term to be within one to three years (in line with our annual budget and three-year plan cycles), medium term to be within three to seven years (in line with scenario modelling to 2030 and typical product life cycles) and long term to be greater than seven years. Short-term risks are captured in our financial planning process; medium- and long-term risks are captured within our global footprint planning process. Our annual and three-year financial planning, and our capital expenditure planning processes require climate-related risk information and specific ESG considerations. We maintain a separate sustainability risk register where risk owners consider how ESG and climate risks affect our Principal Risks. These are managed through our ERM process. Detailed information on our ERM process can be found on pages 67–68 of the Annual Report and in our Sustainability Report. Metrics and targets We have published an annual Sustainability Report since 2001 detailing progress against our global objectives. We have objectives in each of our priority areas: People, Planet and Products. Our key climate-related metrics are greenhouse gas emissions and waste to landfill. Our key objectives in relation to these metrics are net zero greenhouse gas emissions by 2045 and zero waste to landfill at our strategic manufacturing facilities by 2030. Detailed information about our objectives and progress made against those objectives can be found on pages 54–59 of the Annual Report and in our Sustainability Report. In 2023, the Remuneration Committee approved 5% of the Annual Bonus Plan for Executive Directors would be dependent on the achievement of ESG objectives linked to our ESG strategy and in 2024, 5% of the Annual Bonus Plan and 10% of the Performance Share Plan for Executive Directors and Executive Officers are dependent on the achievement of ESG objectives. We have mapped our Scope 1 and Scope 2 GHG emissions, and during 2022 we also began to map our Scope 3 GHG emissions in order to meet our objective of reducing total life cycle GHG emissions to net zero by 2045. In 2021, we also established interim carbon reduction objectives for 2025. See our 2023 Sustainability Report for details on our Scope 1 and Scope 2 net zero roadmap. In 2022, we published our 2021 baseline Scope 3 GHG emissions, including data from eight of the 15 categories. In 2023, we reported both our 2022 and 2023 Scope 3 GHG emissions from 13 of the 15 categories. We have carbon reduction roadmaps for our Scope 1 and Scope 2 GHG emissions to show our pathway to meet our objectives. Our Scope 1, 2 and 3 GHG emissions data are provided on page 66 of the Annual Report with more detailed information also available in our Sustainability Report. In 2023, our combined Scope 1 and market-based Scope 2 GHG emissions reduced by 40% compared to our 2019 baseline year. We sent 30% less waste to landfill from our strategic manufacturing facilities compared to 2019. In January 2023, we launched a salary sacrifice scheme to make electric vehicles available to all employees in the UK. With electric vehicle chargers in place at the majority of our UK offices and manufacturing facilities, all employees are being encouraged to commute with more consideration for the environment. This initiative will help to lower our GHG emissions arising from employee commuting. Shaping a healthy and sustainable future continued TCFD reporting continued 64 Smith+Nephew Annual Report 2023

GRAPHIC

Our focus is on the areas of largest environmental impact, including manufacturing sites, warehouses, R&D sites and offices. Smaller locations representing less than 2% of our overall emissions are not included. Acquisitions completed before 2023 are included in the data, with more recent ones excluded. This is in line with our established policy for the integration of acquired assets. Our GHG emissions reporting represents our core business operations and facilities that fall within the scope of our consolidated financial statements. Primary data from energy suppliers has been used wherever possible. We report our emissions in three scopes: – Scope 1: Direct sources of emissions which mainly comprise the fuels we use on-site, such as gas and heating oil, and fugitive emissions arising mainly from the losses of refrigerant gases. We have included UK vehicle emissions from leased cars since 2020. In 2023, we widened this to include 14 European countries in our leased vehicle reporting. – Scope 2: Indirect sources of emissions such as purchased electricity and steam we use at our sites. – Scope 3: Indirect value chain emissions that arise as a result of activities from assets or processes not owned or controlled by Smith+Nephew; these can be further divided into upstream and downstream emissions and fall into 15 defined categories. During 2023, we have data available for 13 categories. We have also targeted the use of online ‘real-time’ data to monitor energy usage to make savings. We have a programme to replace older inefficient equipment with highly efficient equipment, such as compressors, chillers, pumps, fans and motors. This year we also continued to convert our company car fleet in Europe to electric vehicles where appropriate. In Memphis during 2023, we continued to purchase RECs through Green Flex, a voluntary renewable energy programme. Certified by Green-e Energy, North America’s leading certification programme for renewable energy, Green Flex RECs are based on wind power generated in the Midwest US. Purchasing RECs gives buyers the right to renewable energy and also makes it possible to track ownership of it. Our participation in this scheme underscores our commitment to supporting renewable energy and helps to reduce our market-based carbon emissions footprint. We also sourced hydroelectric energy for our manufacturing location in Malaysia through the purchase of RECs. From October 2023, all our UK sites began sourcing renewable power. Our sites in Suzhou and Penang are now generating electricity on-site using solar PVs. CO2e reporting methodology, materiality and scope We report the carbon footprint of our Scope 1, Scope 2 and Scope 3 GHG emissions in tonnes of CO2 equivalent from our business operations for the year ended 31 December 2023. We are including UK-specific energy and emissions data to satisfy the Streamlined Energy and Carbon Reporting (SECR) requirements. Location-based emissions are calculated in compliance with the WRI/WBCSD GHG Protocol Corporate Accounting and Reporting Standard and have been calculated using carbon conversion factors published by the UK Government Department for Energy Security & Net Zero and the Department for Environment, Food & Rural Affairs (Defra) for 2023. We have applied the emission factors most relevant to the source data, including Defra 2023 (for UK locations), IEA 2021 (for overseas locations) and for the US we have used the most recently available US EPA ‘Emissions & Generation Resource Integrated Database’ (eGRID) for the regions in which we operate. All other emission factors for gas, oil, steam and fugitive emissions are taken from Defra 2023. In line with dual-reporting we also report market-based emissions. These are contractual or supplier-specific emission factors that can be applied when procuring low-carbon energy or siting facilities in areas with lower emissions but also recognising that this might be higher than the grid average in some cases. Where market-based factors were not available, we have used ‘Residual Mix’ data for the EU locations and IEA data for all other countries, except for the remaining US locations where the eGRID factors were applied. Smith+Nephew Annual Report 2023 65 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION

GRAPHIC

Shaping a healthy and sustainable future continued CO2e reporting methodology, materiality and scope continued Reporting our Scope 3 emissions During 2023, we have worked with our global energy partner to measure our 2022 and 2023 Scope 3 GHG emissions using a recognised protocol, CEDA (Comprehensive Environmental Data Archive). Our calculation of our 2023 Scope 3 GHG emissions was 1.3 million tonnes of carbon dioxide equivalent from the 13 categories that we measured. Our data quality has improved, through improved analysis and reporting within each emissions category for Scope 3 and by extending the number of categories that we have reported. We also conducted our first global commuting survey. Our Scope 3 GHG emissions assessment was made using the best available 2023 data. As expected, in line with our peer group, purchased goods and services contributes the most significant proportion of our Scope 3 GHG emissions, over 83%. Further details are available in the 2023 Sustainability Report on page 38. In 2024, we intend to prepare an emissions transition plan which will cover all three emission scopes. 2023 2022 2019 (baseline year) UK Global (excluding UK) Total UK Global (excluding UK) Total UK Global (excluding UK) Total CO2e emissions (tonnes) from: Direct emissions (Scope 1)1 5,682 10,219 15,9012 5,563 6,605 12,1683 4,747 5,141 9,8883 Indirect emissions (Scope 2) (location-based) 3,997 55,015 59,0122 3,856 57,961 61,8173 4,911 62,413 67,3243 Total (location-based) 9,679 65,234 74,9132 9,419 64,566 73,9853 9,658 67,554 77,2123 Indirect emissions (Scope 2) (market-based) 3,800 20,565 24,3652 5,205 31,474 36,6793 5,072 52,080 57,1523 Total (market-based) 9,482 30,784 40,2662 10,768 38,079 48,8473 9,819 57,221 67,0403 Energy consumption to calculate Scope 1+2 emissions (GWh)1 48 195 243 49 188 237 45 168 213 Intensity ratio (location-based): CO2e (t) per $m sales revenue 13.6 14.2 15.1 CO2e (t) per full-time employee 3.9 3.9 4.3 Intensity ratio (market-based): CO2e (t) per $m sales revenue 7.3 9.4 13.1 CO2e (t) per full-time employee 2.1 2.6 3.7 Other indirect emissions (Scope 3)4 1,276,079 1,385,356 1 UK-only vehicle data included in Energy and Scope 1 GHG emissions since 2020. A total of 14 European countries were included in 2023 vehicle data. 2 Data and more details are available in the 2023 Sustainability Report on pages 59–60. 3 Data and more details are available in the 2023 Sustainability Report on pages 60–61. 4 Measurement of 2022 and 2023 Scope 3 GHG emissions from the 13 categories measured. Refer to ‘Reporting our Scope 3 emissions’ above for more details. 2023 data includes recent acquisitions completed and new site openings during 2022. Revenue: 2023: $5.5bn; 2022: $5.2bn; 2019: $5.1bn. Average full-time employee data: 2023: 19,081; 2022: 19,094; 2019: 18,030. » www.smith-nephew.com/sustainability 66 Smith+Nephew Annual Report 2023

GRAPHIC

Risk report Like all businesses, we face risks and uncertainties. Smith+Nephew has developed an enterprise risk management framework, together with supporting policies and procedures, to support risk management and value creation. Our risk management process Successful identification and management of existing and emerging risks is critical to the achievement of strategic objectives and to the long-term success of any business. Risk management is therefore an integral component of our corporate governance. As in previous years, our Enterprise Risk Management (ERM) process is based on a holistic approach to risk management. Our belief is that the strategic and operational benefits of proactively managing risk are achieved when ERM is aligned with the strategic and operational goals of the organisation. Our process and governance structure achieve this. 2023 has seen a further maturing of risk management. Our quarterly Risk Champion workshops focused on topics such as Business Continuity and Business Change, Pricing and Reimbursement, Cybersecurity, and external risk trends and developments. This increased awareness of external and internal risks and management actions across the Group. We enhanced our reporting dashboards to share regular ERM insights with Risk Champions and our executive management. Executive Committee risk owners report and discuss Principal Risk trends from an operational perspective in monthly Executive Committee meetings. We further enhanced the annual top-down Executive Committee risk assessment process to ensure it considers a wide range of external and internal themes, trends and benchmarking information. The Group Risk Team also enhanced their quality checks to improve alignment between top-down and bottom-up processes. Emerging risks Executive Committee risk owners continue to scan the horizon for new and emerging risks and these are discussed and considered in the top-down risk discussion. Emerging risks that were identified this year include: – Our customers, investors and other internal and external stakeholders are increasingly focused on our approach to Environmental, Social and Governance (ESG) matters and how we embed ESG considerations into all areas of our business. In 2023, we have responded to this increased interest by enhancing our ESG governance structure, ensuring that ESG considerations are taken into account in decision-making processes and are reflected within each of our Principal Risks as appropriate. – Advances in Artificial Intelligence (AI), machine learning, robotics, and other technologies create opportunities for the Group when used within a clear governance framework. These technologies can help us to innovate to meet unmet patient needs and earn and retain market share through improved productivity and customer service. The use of AI technology should be implemented with clear guidance on usage and risk management in order to mitigate the risk of employees or third parties inadvertently disclosing proprietary information or confidential or sensitive data. As many AI tools are limited by the information within the data sets that they are trained on, human oversight is required in order to manage risk and avoid outputs that are inherently biased or untrue. The Group has an internal policy that defines the governance and controls required to ensure the use of AI is appropriate, transparent, and properly implemented and monitored. 1. Risk identification 2. Gross (inherent) risk assessment 3. Current control identification 4. Net (residual) risk assessment 5. Risk response planning 6. Risk reporting 7. Monitoring and review Our risk management process Smith+Nephew Annual Report 2023 67 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION

GRAPHIC

Risk report continued 2024 Risk Management Plan Our work will continue to evolve in 2024 with a particular focus on strengthening cross-functional risk management in alignment with the 12-Point Plan. This will include deep-dive sessions into specific risks with cross-functional teams. We will work with the new head of sustainability to further develop the risk register in this area. The Group Risk team will also continue to influence decision making through effective challenge to risk owners and Risk Champions in the quarterly review process. Our risk governance framework At the very top of our structure is our Board with responsibility for oversight of risk management, setting our risk appetite and monitoring the application of our risk framework including strategy, execution, and outputs of risk reviews by the business and Group Risk team. The Board cascades our risk appetite throughout our organisation through the Executive Committee, risk owner community and our management Group. A formal ‘bottom-up’ risk management exercise ensures that risks are escalated back through the process to our Board and are reflected in our Principal Risks as appropriate. Providing guidance and rigour across this process is our Executive Committee and the Group Risk team. At the third line of defence is our Internal Audit function, providing an annual opinion on the effectiveness of our Risk Management process to the Executive Committee, chaired by the Chief Executive Officer, and then to the Board and its Committees. Business Area Risk Champions – Carry out day-to-day risk management activities. – Identify and assess risk. – Implement strategy and mitigating actions to treat risk within Business Area. – Lead regular risk register updates. Executive Committee – Identifies and ensures the management of risks that would prevent the Company from achieving our strategic objectives. – Appoints Business Area Risk Champions who are accountable for applying the Enterprise Risk Management Policy and Framework to produce the risk deliverables. – Reviews external/ internal environment for emerging risks. – Reviews risk register updates from Business Area Risk Champions. – Identifies significant risks and assesses effectiveness of mitigating actions. Board of Directors and Board Committees – The Board is responsible for oversight of risk management, for our annual strategic risk review and for determining the risk appetite the organisation is willing to take in achieving its strategic objectives. – The Board monitors risks through Board processes (Strategy Review, Disclosures, M&A, Investments, Disposals) and Committees (Audit and Compliance & Culture). – The Audit Committee is responsible for ensuring oversight of the process by which risks relating to the Company and its operations are managed and for reviewing the operating effectiveness of the Group’s Risk Management process. Group Risk Team – Manages all aspects of the Group’s approach to Enterprise Risk Management including design and implementation of processes, tools, and systems to identify, assess, measure, manage, monitor, and report risks. – Facilitates implementation and co-ordination through Business Area Risk Champions. – Provides resources and training to support process. – Reports regularly on risk to the Executive Committee. – Prepares Board and Group Risk Committee reports. Internal Audit – Provides independent assurance to the Board and Audit Committee on the effectiveness of the Group’s Risk Management process. – Provides annual assessment of effectiveness of Enterprise Risk Management. Group Risk Team Internal Audit Board of Directors and Board Committees Executive Committee Business Area Risk management life cycle Annual improvement and refinement of our risk management process ensures that it remains aligned with strategy and operations. Our Risk Management Policy, sponsored by our Chief Executive Officer, is driven by an Enterprise Risk Management Manual and the Group Risk team providing training to Business Area Risk Champions. As in prior years, risks continue to be managed through a ‘top-down’ and ‘bottom-up’ process, with regular oversight from the Executive Committee and quarterly reports to the Board Committees. An overview of our risk management life cycle is illustrated below. 68 Smith+Nephew Annual Report 2023

GRAPHIC

Increased risk Reduced risk No change Our Strategy for Growth 1Strengthen the foundation to serve customers sustainably and simply 2 Accelerate profitable growth through prioritisation and customer focus 3 Transform our business through innovation and acquisition » See pages 8–11 for further information on our Strategy for Growth A Audit Committee N Nomination & Governance Committee R Remuneration Committee C Compliance & Culture Committee B Board Compliance and Reputation – Legal and Compliance. – Quality and Regulatory. External – Political and Economic. Financial – Foreign Exchange. – Pricing and Reimbursement. Operational – Cybersecurity. – Global Supply Chain. – Mergers and Acquisitions. – New Product Innovation, Design & Development including Intellectual Property. – Strategy and Commercial Execution. People – Talent Management. 2023 Principal Risks We assess our Principal Risks in terms of their potential impact on our ability to deliver our business strategy. We have grouped our Principal Risks into five categories: Compliance and Reputation, External, Financial, Operational and People. The Principal Risks are presented in alphabetical order according to their grouping below. Risk grouping Risk change from 2022 Risk oversight Risk key 1 2 3 Smith+Nephew Annual Report 2023 69 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION

GRAPHIC

Quality and regulatory Examples of risks – Transition to EU MDR impacts ability to meet customer demand. – Time required by Notified Bodies to review product submissions and site quality systems’ certification time for new products impacts ability to meet customer demand. – Defects in design or manufacturing of products supplied to, and sold by, the Group could lead to product recalls or product removal or result in loss of life or major injury. – Significant non-compliance with policy, regulations or standards governing products and operations regarding registration, design, manufacturing, distribution, sales or marketing. – Failure to obtain proper approvals for products or processes. – Stringent local requirements for clinical data across various markets globally. – Failure to meet stakeholder expectations with regard to increasing sustainability regulations and reporting requirements. Actions taken by management – The Quality departments within each Business Unit regularly monitor activities to comply with new requirements, including EU MDR. – Regular engagement with Notified Bodies, MHRA and regulatory representatives to monitor regulatory changes and understand interpretation of legislation. – Comprehensive and documented product quality processes and controls from design to customer distribution in place, with the addition of cybersecurity to new product development projects for relevant products. – Standardised monitoring and compliance with quality management practices through our Global Quality and Regulatory Affairs organisation. – Incident management teams in place to provide a timely response in the event of an incident relating to patient safety. – Governance framework in place for reporting, investigating and responding to instances of product safety and complaints. – Local clinical evidence requirements are included in global new product development projects. Global regulatory bodies continue to increase their expectations of manufacturers and distributors of medical devices not only in respect of quality and regulation of products but also in respect of sustainability requirements. Our products are used in the human body and therefore patient safety is of paramount importance. The European Medical Device Regulation (EU MDR), and multiple other global regulations and changes in standards have increased the focus on clinical and technical evidence, supplier controls and product performance transparency. Our customers and other stakeholders also require us to explain our approach to and demonstrate compliance with increasing sustainability regulations and reporting requirements. Legal and compliance Examples of risks – Failure to act in an ethical manner consistent with our Code of Conduct and Business Principles. – Violation of anti-corruption or healthcare laws, breach by employee or third-party representative. – Misuse or loss of personal information of patients, employees, research subjects, consumers or customers results in violations of data privacy laws, including General Data Protection Regulations. – The development, manufacture and sale of medical devices entail risk of product liability claims or recalls. – Failure to identify changes in or new legal or regulatory requirements including sanctions programmes and ESG matters which result in non-compliance with applicable laws and regulations. – Failure to meet needs of stakeholders relating to increased focus on and regulation of ESG reporting requirements. Actions taken by management – Board Compliance & Culture Committee oversees our ethical and compliance practices. – Global compliance programme, policies and procedures in place and regularly updated. – Annually all employees required to undertake training and certify compliance with our Code of Conduct and Business Principles. – Group monitoring and auditing programmes in place. – Launched enhanced confidential independent reporting channels for employees and third parties to report concerns. – Trade compliance programme, policies and procedures. – Appointed a new head of ESG – The ESG Operating Committee assesses new and enhanced regulations and reporting requirements and works cross-functionally to ensure compliance. – Monitoring new regulatory and enforcement trends. We are committed to doing business with integrity and believe that ‘doing the right thing’ is part of our mandate to operate. We operate in multiple countries and regulatory authorities in each jurisdiction enforce an increasingly complex pattern of laws and regulations that govern the design, development, approval, manufacture, labelling, marketing, sale and operation of both traditional and digital healthcare products and services. Operating across this complex and dynamic legal and compliance environment, which includes regulations on bribery, corruption, privacy, sustainability and trade compliance, increases the risk of fines, penalties, and reputational damage. We mitigate this through policies, procedures, training and practices designed to prevent and detect violations of law, regulations and industry codes. We conduct risk-based oversight to monitor compliance with our Code of Conduct and associated policies. Oversight Link to Strategy 1. Strengthen 2. Accelerate Change from 2022 3. Transform Oversight Link to Strategy 1. Strengthen 2. Accelerate Change from 2022 Risk report continued 2023 Principal Risks continued Compliance and reputation risks C C 1 2 3 1 2 3 70 Smith+Nephew Annual Report 2023

GRAPHIC

Political and economic Examples of risks – Global or regional recession and increasing macroeconomic controls impact on customer financial strength. – Global political and economic uncertainty and conflict, including in Ukraine and the Middle East. – Failure to meet the sustainability targets and public policy changes. – Failure to pivot on business strategy in light of increased sanction programmes globally. – Market access rights. – Increases in import and labour costs. – Increases in tariffs and restrictions on global trade. – Inflationary pressures impacting raw materials, freight, salaries and wages. – Potential for significant tax rate changes and/or base broadening measures in key jurisdictions where we operate including OECD proposals and US tax reform. – Failure to comply with current tax laws. – Transfer pricing policy not correctly implemented or monitored. – Changing legislation in the US and other key markets may require changes to our operating model. Actions taken by management – Built sustainability strategy on our purpose, business strategy, and culture pillars, and tracked and benchmarked targets within the industry. – Our ESG Operating Committee implements and operationalises ESG strategy and provides data and metrics to monitor implementation. – Continued engagement with governments, administrations, and regulatory bodies to enhance education and advocacy efforts with policymakers. – Global trade compliance programme, policies and procedures. – Business continuity plans developed with alternative source options identified for critical suppliers and increased safety inventory levels for critical products affected by the conflict in Ukraine and disruptions of travel through the Red Sea and Suez Canal. – Actively participate in trade associations to enhance education and advocacy efforts with policymakers. – Ongoing engagement and monitoring/ lobbying on localisation initiatives. – The Group Tax team continually monitors developments in tax legislation and obtain external advice where relevant. – The Group Tax team, supported by external advisers, works closely with the business to implement agreed processes and procedures. – Seeking appropriate independent third-party advice when required. We operate a global business and are exposed to the effects of political and economic risks, changes in the regulatory and competitive landscape, trade policies and trade compliance requirements, war, political upheaval, changes in government policy regarding healthcare priorities and sustainability expectations, increasing inflationary pressure and tax rates, preference for local suppliers, import quotas, economic sanctions and terrorist activities. Oversight Link to Strategy 1. Strengthen 2. Accelerate Change from 2022 External risks B 1 2 3 Smith+Nephew Annual Report 2023 71 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION

GRAPHIC

Pricing and reimbursement Examples of risks – Reduced reimbursement levels and increasing pricing pressures. – Systemic challenge on number of elective procedures. – Lack of compelling health economics data to support reimbursement requests. – Unilateral price controls/reductions imposed on medical devices. – Price-driven tendering/ procurement processes. – Volume-based procurement in China and other markets. – Limited access to non-clinical decision makers. – Limited ability to pass on increased costs such as raw materials, freight, sustainability improvements and the cost of compliance with regulations to our customers. Actions taken by management – Our 12-Point Plan includes an initiative which focuses on pricing strategy and execution in order to mitigate some of the impact of inflation. – Developed innovative economic product and service solutions for both Established and Emerging Markets. – Incorporated health economic components into the design and development of new products. – Sales training to improve capability to communicate the clinical and economic value proposition to non-clinical decision makers. – Implementing innovative contracting models designed to lessen the risk of adoption and coverage for healthcare providers and payers. – Increased engagement with payer bodies to influence reimbursement mechanisms to reward innovation. – Optimise portfolio mix and promote differentiated products. – Consideration of price increases. Our success depends on our ability to sell our products profitably, despite increasing inflation and costs associated with improving the sustainability of our products, pricing pressures from customers and the availability of and access to adequate government funding and reimbursement to meet increasing demands for our products arising from patient demographic trends. The prices we charge are therefore impacted by budgetary constraints and our ability to persuade customers and governments of the economic value of our products, based on clinical data, cost, patient outcomes and comparative effectiveness. Market developments such as China volume-based procurement, consolidation of customers into buying groups, inflation, increasing professionalisation of procurement departments and the commoditisation of entire product groups, continue to challenge prices. We mitigate this through price increases to counteract the impact of inflation where possible, portfolio mix and promotion of differentiated products, including a compelling clinical and economic value proposition. Foreign exchange Examples of risks – Risk of adverse trading margins due to fluctuating foreign currency exchange rates between our main manufacturing operations (the US, UK, Costa Rica, Malaysia and China) and where our products are sold. Actions taken by management – A foreign exchange hedging programme is operated and is overseen centrally by the Group Treasury team. – The Finance and Banking Committee monitors ongoing treasury matters including foreign exchange exposure. We operate a global business and are therefore exposed to exchange rate volatility. Volatility in foreign currency exchange rates can impact our results and it may not be possible to fully mitigate against them. Oversight Link to Strategy 1. Strengthen Change from 2022 Oversight Link to Strategy 1. Strengthen 2. Accelerate Change from 2022 Risk report continued 2023 Principal Risks continued Financial risks A B 1 2 3 1 2 3 72 Smith+Nephew Annual Report 2023

GRAPHIC

Cybersecurity Examples of risks – Loss of confidential or sensitive information, intellectual property and/or data privacy breach. – Inadequate consideration of cybersecurity in the design of new products, systems and/or processes. – Disruption to business operations due to a significant cybersecurity incident. – Increased government focus on cybersecurity and changes in regulatory environment. – Increasing demand for cybersecurity expertise could impact our ability to attract and retain cybersecurity talent. – Disruption to the business due to critical system infrastructure and applications being unavailable. Actions taken by management – Ensured every user has access to and is using a secure Virtual Private Network (VPN) when connecting to Smith+Nephew networks to safeguard remote working. – Continued security awareness activities including email communications, intranet posts, visuals, videos and more email phishing training activities. – Multi-factor authentication tools reduce the likelihood of remote attacks. – Security information and event management (SIEM) in place to provide real-time analysis of security alerts generated by applications and network hardware. – Regular penetration testing and frequent vulnerability scanning undertaken. – Endpoint protection and intrusion detection/prevention implemented. – Security governance structure in place including a Security & Privacy Steering Committee. – Monitor developments from governments and raise changes and developments with Global IT Security. – Cybersecurity Maturity Programme monitored by the Audit Committee. – IT disaster recovery policy in place. We depend on a wide variety of information systems, programmes and technology to run our business effectively. We also develop and sell certain digitally enabled products that connect to proprietary and third-party networks and/or the internet. Our systems and the systems of the entities we acquire may be vulnerable to a cyber-attack, theft of intellectual property, malicious intrusion, data privacy breaches or other significant disruption. We have a layered security approach in place to prevent, detect and respond, to minimise the risk and disruption of any intrusions and to monitor our systems on an ongoing basis for current or potential threats. Oversight Link to Strategy 1. Strengthen 3. Transform Change from 2022 Operational risks A 1 2 3 Smith+Nephew Annual Report 2023 73 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION

GRAPHIC

Risk report continued 2023 Principal Risks continued Global supply chain Examples of risks – Disruption to manufacturing at a single source facility (lack of manufacturing redundancy), including from natural disaster. – Manufacturing and supply chain capacity not adequate to support growth. – Constrained supplier sterilisation capacity due to increased regulation and enforcement. – Risks associated with the transition of warehouse and distribution activities to external supplier impacting inbound and outbound logistics. – Supplier failure impacts ability to meet customer demand (single source supplier). – Inadequate sales and operational planning impacts ability to meet customer demand for product. – Excess inventory due to incorrect demand forecasts, inaccurate demand signals and unexpected changes in demand. – Failure of suppliers and distribution partners to achieve and maintain regulatory compliance. – Increasing costs of raw materials and freight. – Increasing salary and wage costs for manufacturing and distribution employees and contractors. – Severe weather patterns, global temperature rise and sea-level rise caused by climate change or natural disaster causes damage to manufacturing or distribution facilities, impacting ability to meet customer demand. – Disruption to the business due to critical system infrastructure and applications being unavailable. – Critical material shortages leading to supply challenges. – Increased freight cycle times due to conflict in the Middle East, resulting in disruptions of travel through the Red Sea and Suez Canal. – Labour attrition and delays in backfilling. – Failure to transform to achieve our sustainability targets. Actions taken by management – Our 12-Point Plan includes initiatives to improve product availability and inventory, enhance procurement and management of transportation costs, focus on lean manufacturing and quality and optimise our manufacturing network. – Delivering Global Operations transformation programme to optimise manufacturing and distribution centres and reduce single source limitations. – Global Operations project management governance and toolkits to support successful execution of transformation programmes. – Risk-based review programmes undertaken for critical suppliers. – Business continuity plans developed with alternative source options identified for critical suppliers and increased safety inventory levels for critical products. – Implemented an enhanced Sales Inventory and Operations (SI&OP) process to improve demand and supply planning. – Executive oversight of sales and operational planning. – Increased co-ordination between commercial, supply chain and logistics to improve forecast accuracy. – Comprehensive product quality processes in place from design to customer supply. – Supplier contract agreements achieve and manage regulatory compliance. – Initiatives to improve manufacturing efficiency and reduce overhead costs. – IT disaster recovery policy in place. – Leadership taskforce established to resolve cumulative impact of global supply chain events. – Global, regional, and local crisis management governance in place. – Emergency and incident management and business recovery plans in place at major facilities and for key products and key suppliers. – Appointed a new head of ESG. – An ESG Operating Committee implements and operationalises ESG strategy and provides data and metrics to monitor implementation. – Investment in flood defences at our operations in Hull and building of a new R&D and manufacturing facility for Advanced Wound Management in Melton West. Our ability to make, distribute and sell medical products to customers in over 100 countries involves complex manufacturing and supply chain processes. Increased outsourcing, sophisticated materials, and the speed of technological change in an already complex manufacturing process leads to greater potential for disruption in our supply chain. Lack of availability of raw materials and components compound supply and business disruption. Capacity constraints and the regulatory environment, including the increased focus on global regulation of sustainability, increase our exposure to supply chain disturbance. Increasingly frequent climate events increase the likelihood and impact of disruptions to our supply chain. Increased inflationary pressure on production, freight and warehousing and distribution costs increases our risk of failing to achieve accelerated profitable growth. Our business depends on our ability to plan for and be resilient in the face of events that threaten one or more of our key locations. Damage caused by environmental and climate change factors, including natural disasters and severe weather, can and do threaten our critical sites. Oversight Link to Strategy 1. Strengthen 2. Accelerate Change from 2022 Operational risks continued B 1 2 3 74 Smith+Nephew Annual Report 2023

GRAPHIC

New product innovation, design & development including intellectual property Examples of risks – Failure to develop, partner or acquire a competitively differentiated innovation. – Insufficient long-term planning to respond to competitor and disruptive entries into the marketplace. – Inadequate innovation due to low Research & Development (R&D) investment, R&D skills gap or ineffective product development execution. – Loss of market share due to critical gaps in product portfolio not filled. – Loss of proprietary data due to natural disasters or failure of Product Lifecycle Management (PLM) systems. – Competitors may assert patents or other intellectual property rights against the Group or fail to respect the Group’s intellectual property rights. – Failure to ensure sustainability in new products. Actions taken by management – Our 12-Point Plan includes an initiative to reposition our knee and hip portfolio. – Continued product and technology acquisitions and product launches and effective implementation of new product launches. – Global R&D organisation and governance framework providing strategic direction for allocation of R&D investment across all businesses. Clear stage-gate process to continually evaluate R&D investment decisions and development of new products. – Cross-functional New Product Design and R&D processes focused on identifying new products and potentially disruptive technologies and solutions. – Replacing global Product Lifecycle Management systems. – Monitored external market trends and collated customer insights to develop product strategies. – Ongoing monitoring of competitor patent portfolios post product launch. – Ongoing intellectual property training for business counterparts. – Sustainability criteria built into new product development processes. Our product innovation pipeline is becoming broader in scope and increasingly complex, as we focus our efforts on procedure innovation using digital technologies such as connectivity, machine learning, and artificial intelligence. Our focus on high growth and profitable markets requires us to better understand unmet customer needs, drivers of surgical efficiency and patient outcomes, and new country/ regional regulations including requirements related to cybersecurity and sustainability. Our innovation pipeline needs to be sufficiently differentiated from our competition in order for us to deliver our commercial ambition. If Smith+Nephew fails to protect and enforce its intellectual property rights successfully, its competitive position could suffer, which could impact profitable, sustainable growth. Mergers and acquisitions Examples of risks – Failure to identify appropriate acquisitions. – Failure to conduct effective acquisition due diligence. – Failure to integrate newly acquired businesses effectively, including integration with Group standards, policies and financial controls. – Failure to deliver on plans to achieve the acquisition business case. Actions taken by management – Acquisition activity aligned with corporate strategy and prioritised towards products, business units and markets identified to have the greatest long-term potential. – Clearly defined investment appraisal process based on range of valuation metrics including return on invested capital, in accordance with Capital Allocation Framework and comprehensive post-acquisition review programme. – Detailed and comprehensive cross-functional due diligence undertaken prior to acquisitions by experienced internal and external experts (including the integration management office). – Compliance and other risks included as part of due diligence reviews, integration plans and reporting for acquisitions. – Integration committee review, approval of integration plans and monitoring of ongoing process. – Board has annual post-deal review session. As the Group grows to meet the needs of our customers and patients, we recognise that we are not able to develop all the products and services required using internal resources and therefore need to undertake mergers and acquisitions in order to expand our offering and to complement our existing business. In other areas, we may divest businesses or products which are no longer core to our activities. It is crucial for our long-term success that we make the right choices around acquisitions and divestments. Failure to identify appropriate acquisition targets, to conduct adequate due diligence or to integrate them successfully or to deliver on the acquisition business case would have an adverse impact on our competitive position and profitability. Oversight Link to Strategy 3. Transform Change from 2022 Oversight Link to Strategy 3. Transform Change from 2022 B B 1 2 3 1 2 3 Smith+Nephew Annual Report 2023 75 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION

GRAPHIC

Risk report continued 2023 Principal Risks continued Strategy and commercial execution Examples of risks – Failure to execute our strategy adequately from high-level ambition to specific actions to make the ambition a reality. – Multiple change initiatives, including those within our 12-Point Plan could distract management from delivering business-as-usual objectives. – Inability to keep pace with significant product innovation and technical advances to develop commercially viable products. – Failure to engage effectively with our key stakeholders to meet their evolving needs leading to loss of customers. – Failure to manage distributors effectively leading to stocking and compliance issues. – Inability to satisfy customers’ sustainability requirements and expectations. – Limited healthcare professional access to medical education. – Failure to achieve potential from acquisitions due to integration challenges. – Failure to effectively implement core elements of business change prevents our projects and programmes achieving the intended benefits and disrupts existing business activities. Actions taken by management – Dedicated Acceleration Office and Executive Steering Committee led by our CEO to monitor the successful delivery of the 12-Point Plan. – Changed our commercial operating model from a franchise and regions model to business unit model. – Executive oversight of changes to our commercial operating model. – Strategic planning process clearly linked to business and Group risk. – Continued new product launches and monitoring of innovation pipeline. – Implemented an enhanced Sales Inventory and Operations (SI&OP) process to improve demand and supply planning. – Enhanced accessible digital sales information and training modules for sales staff. – Enhanced Virtual Medical Education platforms and opening of the Smith+Nephew Academies in Singapore and Munich. – Integration committee to review/ approve integration plans and monitor ongoing processes. – Our 12-Point Plan includes an initiative to reposition our knee and hip portfolio. – Continued product and technology acquisitions and product launches and effective implementation of new product launches. – Project management governance, toolkits and project steering committee oversight to support successful execution of programme and projects. The long-term success of our business depends on setting the right strategic priorities such as the 12-Point Plan and our three-year strategic plan and executing on our plans to deliver priority initiatives in highly competitive markets. This requires effective communication and engagement both internally on a cross-functional basis (for example, in order to drive procedure-based selling models) and with our customers, suppliers and other stakeholders. We must also successfully embed the right governance structures, accountability and capabilities across the Group and ensure we adjust and refine strategic priorities and business models when necessary. The pace and scope of our business change initiatives may increase execution risk for the change programmes as well as for our business-as-usual activities. Failure to set and execute on priorities and drive cross-functional accountability within our business will impact our ability to continue to grow our business profitably and sustainably and to serve our customers. Oversight Link to Strategy 1. Strengthen 2. Accelerate Change from 2022 3. Transform Operational risks continued B 1 2 3 76 Smith+Nephew Annual Report 2023

GRAPHIC

Talent management Examples of risks – Loss of key talent, high attrition and lack of appropriate succession planning in context of required skillsets for future business needs. – In the event that the Company’s remuneration strategies, quantum and structure particularly in terms of long term incentives for US executives are not adequately addressed to better align to local market norms, the Company may not be able to effectively compete for, attract and retain talent, which may impact management stability, internal talent pipeline development and the ability for management to drive value creation. – Loss of competitive advantage due to an inability to attract and retain top talent. – Loss of intellectual capital due to poor retention of talent. – Failure to attract talented and capable candidates. – Increased talent movement globally due to shifting personal work-life balance priorities. – Increased salaries globally. Actions taken by management – Our 2024 Remuneration Policy proposes a package of long-term incentive plan adjustments for US executives to be more closely aligned with norms in the US in terms of structure and quantum. Our draft Remuneration Policy and a comprehensive discussion of our proposals is set out on pages 126–135 of our Remuneration Report. – Talent planning and people development processes well established across the Group. – Talent and succession planning discussed annually by the Board and regularly by the Executive Committee and Nomination & Governance Committee. – Identification of high-value roles and ensuring that these roles are filled with our high-performance individuals with strong succession plans in place. – Developed strategic skills resourcing plan by functional areas. – Provided employees with access to tools and resources to manage their emotional, physical, and mental wellness. – Enhanced Inclusion, Diversity and Equity (IDE) policy, including establishment of Employee Inclusion Groups (EIGs) and IDE Inclusion Council in order to foster culture of belonging within the organisation and promote engagement, attraction and retention of top talent. – Ongoing segmentation of specific job roles and applying focused rewards to ensure we are competitive and attractive to candidates. In the current market, recruitment and retention of top talent and minimising attrition is a critical risk which requires a strong engagement process. We recognise that people leadership, effective succession planning and the ability to engage, retain and attract talent is a key lever of success for our business. Failure to do so places our ability to execute the Group strategy and to be effective in the chosen market/discipline at risk. People Oversight B Link to Strategy 1. Strengthen 2. Accelerate Change from 2022 1 2 3 Smith+Nephew Annual Report 2023 77 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION

GRAPHIC

Risk report continued Our Viability Statement How we assess our prospects During the year, the Board has carried out a robust assessment of the Principal Risks affecting the Company, particularly those which could threaten the business model. These risks, and the actions being taken to manage or mitigate them, are explained in detail on pages 67–77 of this Annual Report. In reaching our Viability Statement conclusion, we have undertaken the following process: – The Audit Committee reviewed the Risk Management process at their meetings in February, April, July and December, receiving presentations from the Group Risk team, explaining the processes followed by management in identifying and managing risk throughout the business. – In July and September 2023, the Executive Committee met to review the 2023 Principal Risks (the top-down risk review process). The Executive Committee was asked to consider the significant risks which they believed could seriously impact the profitability and prospects of the Group and the Principal Risks that would threaten its business model, future performance, solvency or liquidity. – All Executive Committee members nominated the Risk Champions and have worked with them to prepare risk registers. The Risk Champions nominated by the Executive Committee are senior employees and in risk management. – Using the outputs from the Business Area ‘bottom-up’ risk identification completed in September 2023 and following ‘top-down’ discussions with the Executive Committee, the most significant risks affecting our organisation were presented to the Executive Committee for approval in November as the draft 2023 Principal Risks facing the Company and again in January 2024 as final disclosures. – The Executive Committee decided to streamline the 12 Principal Risks from 2022 into 11 Principal Risks with amendments to the descriptions within each Principal Risk to reflect the macro and internal factors to be taken into account in 2023. – In assessing our TCFD risks we concluded that climate-related risks are not significant in our viability horizon of three years. Nonetheless, the impact of extreme weather events have been considered in our operational risk scenarios. – All relevant executives have attested alignment to the Group’s Enterprise Risk Management Process as part of the annual certification on governance, risk, and compliance. – The Board debated and agreed the risk appetite for each of the Principal Risks in February 2023. – Final Principal Risks were presented to the Audit Committee and the Board in February 2023 for their consideration and approval. – Throughout the year, a number of reviews into different risks were conducted by the Board, the Audit Committee and the Compliance & Culture Committee looking into the nature of the risks and how they were mitigated. Assessment period The Board have determined that the three-year period to December 2026 is an appropriate period over which to provide its Viability Statement. This period is aligned to the Group’s Strategic Planning process and reflects the Board’s best estimate of the future viability of the business. Scenario testing To test the viability of the Company, we have undertaken a robust scenario assessment of the Principal Risks, which could threaten the viability or existence of the Group. These have been modelled as follows: – In carrying out scenario modelling of the Principal Risks on the following page we have also evaluated the impact of a severe but plausible combination of these risks occurring over the three-year period. We have considered and discussed a report setting out the terms of our current financing arrangements and potential capacity for additional financing should this be required in the event of one of the scenarios modelled occurring. – We are satisfied that we have robust mitigating actions in place as detailed on pages 67–77 of this Annual Report. We recognise, however, that the long-term viability of the Group could also be impacted by other, as yet unforeseen, risks or that the mitigating actions we have put in place could turn out to be less effective than intended. Viability Statement Having assessed the Principal Risks, the Board has determined that we have a reasonable expectation that the Group will be able to continue in operation and meet its liabilities as they fall due over a period of three years from 1 January 2024. In our long-term planning we consider horizons of between five and 10 years. However, as most of our efforts are focused on the coming three years, we have chosen this period when considering our viability. Our conclusion is based on the Strategic Plan reviewed and approved by the Board in December 2023. We will continue to evaluate any additional risks which might impact the business model. By order of the Board, on 26 February 2024. Helen Barraclough Company Secretary 78 Smith+Nephew Annual Report 2023

GRAPHIC

2023 Scenarios modelled Scenario 1: Global economic downturn Significant global economic recession, leading to sustained lower healthcare spending across both public and private systems. Action taken: We have modelled 10% lower revenue throughout 2024 and 5% lower revenue throughout 2025. Reduced reimbursement levels and increasing pricing pressures. Action taken: We have modelled annual price erosion of 1% impacting all product lines, along with a full drop through impact on profit in each of the periods 2024–2026. Link to strategy – Accelerate profitable growth through prioritisation and customer focus. Link to Principal Risks – Global supply chain. – Strategy and commercial execution. – Political and economic. – Pricing and reimbursement. Scenario 2: Operational risk Inability to keep pace with significant product, innovation, and technical advances to develop commercially viable products, losing significant market share to the competition. Action taken: We have modelled 1% lower growth than planned for a key product range in the US, along with a full drop through impact on profit in each of the periods 2024–2026. Disruption to a Global Distribution Centre (GDC) preventing our ability to supply our customers with all products from the applicable GDC for one quarter. Action taken: We have modelled an inability to supply products from one of our GDCs for one quarter of 2025. Key supplier disruption – resulting in our inability to manufacture and supply a few key products for a full year. Action taken: We have modelled an interruption to receiving goods from a key supplier for a period of one year in 2025. Increases in raw materials, freight and labour costs. Action taken: We have modelled an increase in our input costs by an additional 5% in each of the periods 2024–2026, due to continued inflationary pressures. Product liability claim. Action taken: We have modelled a group of product liability claims resulting in a settlement agreement requiring cash payment in each of the periods 2024–2026, without any insurance coverage. Link to strategy – Strengthen the foundation to serve customers sustainably and simply. – Transform our business through innovation and acquisition. Link to Principal Risks – Strategy and commercial execution. – New product innovation, design & development including intellectual property. – Global supply chain. – Legal and compliance. – Political and economic. – Talent management. Scenario 3: Foreign exchange, legal, regulatory and compliance risks Data privacy failure – giving rise to a significant fine or loss. Action taken: We have modelled a one-off significant fine from regulator of 2% of revenue or loss resulting from a data privacy issue in 2025. Failure to obtain proper regulatory approvals for products or processes impacting our ability to sell products. Action taken: We have modelled the complete loss of revenue from a key product effective in mid-2024 for two years, and returning to lower volumes in mid-2026. Risk of adverse trading margins due to fluctuating foreign currency exchange rates across our markets. Action taken: We have modelled a reduction in profitability in 2025 and 2026 due to a weakening in other currencies relative to the US Dollar by 5%. Link to strategy – Strengthen the foundation to serve customers sustainably and simply. Link to Principal Risks – Legal and compliance. – Quality and regulatory. – Foreign exchange. Scenario 4: Cybersecurity Disruption to business operations due to a significant cybersecurity incident. Action taken: We have modelled one of our key regions being unable to invoice also affecting shipping and tracking of deliveries for one month due to a disruption to our IT infrastructure in 2024. Link to strategy – Strengthen the foundation to serve customers sustainably and simply. Link to Principal Risks – Cybersecurity. Scenario 5: Mergers and acquisitions Failure to integrate newly acquired business effectively to achieve expected growth. Action taken: We have modelled a scenario of zero growth in a recently acquired business in 2024. Link to strategy – Transform our business through innovation and acquisition. Link to Principal Risks – Mergers and acquisitions. Smith+Nephew Annual Report 2023 79 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION

GRAPHIC

80 Smith+Nephew Annual Report 2023

GRAPHIC

Enabling those moments that bring balance together Life Unlimited Smith+Nephew Annual Report 2023 81 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION

GRAPHIC

Our stakeholders Section 172 statement We are a leading portfolio medical technology company and Our Purpose is Life Unlimited – we exist to restore people’s bodies and their self-belief. » See pages 13–17 for more on Life Unlimited We live our Purpose through our culture pillars of Care, Courage and Collaboration to use technology to take the limits off living, and help other medical professionals do the same. » See pages 46–49 for more on our culture Our ambition is to transform into a structurally higher growth company through our Strategy for Growth: Strengthen the foundations in commercial and manufacturing to enable us to serve customers sustainably and simply, and deliver the best from our core portfolio. Accelerate our growth profitably through robust prioritisation of resources and investment, and with continuing customer focus. Transform ourselves for higher long-term growth, through investment in innovation and acquisitions. » Read more in the Chief Executive Officer’s Review pages 8–11, and the Governance report on the Board activities on pages 100–101. In accordance with section 172 of the Companies Act 2006 and the UK Corporate Governance Code 2018, the Board considers the potential impact on the Company’s key stakeholders and takes their views and interests into account when making decisions. The pages referenced in each of the sections below form part of this statement and provide examples of our approach to stakeholder engagement and how the Board considers their views and the impact of decisions on key stakeholder groups. The Board is committed to taking a long-term view in order to deliver sustainable value creation for shareholders and other stakeholders. The Board understands the importance of ensuring that the views and interests of all stakeholders are considered in the delivery and oversight of the Company’s strategy and culture. Although members of the Board engage directly with stakeholders as part of site visits or employee engagement meetings, engagement with stakeholders mostly takes place at an operational level and the Board forms its views through reports and information presented to it by management. Management are asked to outline and present the potential impacts on stakeholders to the Board where appropriate during the review, discussion and decision making process. Employees Our Employees are crucial to the success of our business. Creating a culture of belonging and an environment that fosters innovation, delivers business success and strengthens engagement and development is core to everything we do. » See page 84 82 Smith+Nephew Annual Report 2023

GRAPHIC

Investors Our Investors are the owners of our business. The Board seeks to engage and understand their perspectives on performance, value, risk and governance. Our Investor presentations are available to download on our website: www.smith-nephew.com. » See page 85 Customers and suppliers Healthcare Professionals and patients are at the centre of everything we do. Working in partnership with our suppliers ensures we have the right resources to support our growth and that those who partner with us are committed to doing business in a way which is consistent with our values. » See page 87 Governments and regulators We focus on product safety, compliance and doing business the right way in order to achieve the full potential of our portfolio. We engage through industry bodies and similar organisations with focus on key issues impacting our organisation and the MedTech industry more broadly. » See page 86 Environment and communities People, Planet and Products are at the heart of our ESG strategy aiming to create a positive impact on our communities, reducing the impact on our environment and enabling us to innovate sustainably. » See page 86 Our Stakeholders Smith+Nephew Annual Report 2023 83 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION

GRAPHIC

Focus for 2024 – Management have taken actions to continue to focus on communicating on innovation, linking strategy and commitments, talent development and ESG/IDE strategic initiatives in global webcasts, leadership team meetings and through internal communications and the Company intranet S+N Life. – Board members will follow up on the outcomes and impact of the actions taken to address the 2023 employee feedback from Board listening sessions. – The Chair and Non-Executive Directors will be provided with additional opportunities to visit certain key Company sites as part of their induction. – The 2024 Board Listening Sessions have been amplified to include additional Non-Executive Directors to enable the Board to hear from a broader group of employees. The 2024 sessions will focus on several key topics including the new Global Business Unit model, new leaders, remuneration, 12-Point Plan initiatives within Operations and the ways in which corporate functions enable success. – Induction and refresher sessions will continue to be developed and delivered programmatically to Non-Executive Directors depending on their areas of interest. – Continue to report on and review workforce equity initiatives and programmes to support the wider workforce. – Two full board sessions planned for 2024 focusing on talent, retention and succession planning for senior leaders. » See pages 46–49 for People » See pages 111–113 for Compliance & Culture Committee Engaging with our stakeholders The Board has oversight of the initiatives being undertaken to strengthen, accelerate and transform the Company in line with our Strategy for Growth, driving the creation of value whilst ensuring we are doing business in the right way. Engagement with our stakeholders, including employees, investors, customers and suppliers, governments and regulators and our local communities provides valuable feedback and insight for the Board into what matters to stakeholders most, and helps to foster greater understanding of the impact of decisions on each of our key stakeholder groups. In matters brought to the Board for discussion and approval, the Board considers the likely consequences and impact on stakeholders in the longer term, and carefully considers their interests as part of the decision-making process in the interests of the Company as a whole. Employees 2023 Outcome/impact – The Board received valuable feedback from the 2023 listening sessions with employees wanting to hear more from management on innovation, the link from our strategy to our Commitments and culture, talent development and ESG and IDE initiatives. – The site visit to Costa Rica provided an opportunity for direct engagement with EIGs and leadership teams in Operations and GBS functions which enable the Board to measure and monitor the Culture of the organisation. – Feedback from the Chair and new Non-Executive Directors has been positive on the breadth and depth of the induction programme. Please see page 107 for our Q&A with Jez Maiden. – The review programmes relating to compensation adjustment for markets materially impacted by high inflation have continued and have been reported to the Remuneration Committee and CCC. – Board listening sessions, site visits and succession planning reviews have provided confidence for the Board that the Company is focusing its efforts on developing a strong internal talent pipeline and visibility on succession planning for high value roles within the Company. Areas of interest – Purpose, Strategy and Culture. – Leadership and succession planning. – Talent, retention and development. – Employee wellbeing and cost of living. – Inclusion, Diversity and Equity (IDE). How we engage – Direct engagement through Board/employee listening sessions. A number of Non-Executive Directors lead these sessions in order to understand more about the Company culture, employee engagement and IDE. – Meeting with employees informally during visits to our sites and during our Board meetings. – Board Inductions enable the Board to hear directly from employees on Purpose, Strategy and Culture. – The Remuneration Committee and the Compliance & Culture Committee (CCC) receive updates at each meeting on the activities of our Employee Inclusion Groups (EIGs), and initiatives relating to IDE, wellbeing and community together with the initiatives relating to ongoing review of programmes to support the wider workforce. – The Board and its Committees are provided with updates on leadership and talent development and succession planning for senior executives. Engaging with our stakeholders 84 Smith+Nephew Annual Report 2023

GRAPHIC

Focus for 2024 – Continued focus and support from the Board on strategy, performance and operational excellence to support delivery of value creation for investors. – Continued engagement by the Chair and Board on remuneration matters in order to ensure that the Company remains competitive in key markets to attract and retain talent. – Continue to seek opportunities for direct Board engagement with Investors on key topics of investor focus. – Continued engagement by the Chair and Board with Investors on key matters throughout the year which feed through to the Board agenda. » See pages 248–256 for Shareholder information Investors Areas of interest – Strategy and Performance. – Capital Allocation and Dividend. – Leadership and Succession planning. – Remuneration. – Sustainability and ESG. How we engage – Chair engagement with investors, groups and teams covering strategy and operational excellence, remuneration, succession planning and ESG matters. – Senior Independent Director engages with investors and governance teams on topics of investor interest including Board composition, diversity and ESG matters. – Our Chief Executive Officer and our Chief Financial Officer engage regularly with investors as part of an ongoing dialogue throughout the year. – US Executive Director Remuneration Consultation. – Meet the Management Day enabled direct engagement with investors for members of the Board. – The Board receives analyst reports, reviews the share register and receives reports on investor meetings and investor perceptions of the Company through external advisor sessions. 2023 Outcome/impact – The Chair and management received consistent feedback from investors to reiterate investor perspectives and expectations on performance improvement, value creation and cost management. The Board and senior management have addressed the feedback provided to the extent possible through investor communications and other engagement. – The Meet the Management event was attended by Non-Executive Directors either virtually or in person, which provided further context and insight into investor areas of focus such as operational excellence, cost management, improvement in inventory and cash and talent retention, which in turn shape Board agendas and discussions. – Engagement on US Executive Director Remuneration proposals shaped the proposed 2024 Remuneration Policy (see pages 126–135). I have had the opportunity to meet some of our larger investors who have been generous with their time and speak from many years’ experience of both the sector and Smith + Nephew. I also had the opportunity to meet some of our smaller investors at the AGM in April 2023 which was a pleasure to attend and a reminder that ultimately, in all we do, there are savers and pensioners who rely on us to grow the value of their investments.” Rupert Soames Chair Smith+Nephew Annual Report 2023 85 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION

GRAPHIC

Focus for 2024 – The Board and the CCC will continue to receive reports on product safety, compliance with applicable laws and regulations and will receive updates on Company interactions with governments and regulators as appropriate. – The Chief Executive Officer and senior leadership will continue to engage and participate in discussions with industry bodies in order to advocate for and amplify issues which are of importance to the organisation and the MedTech industry more broadly. » See page 33 for Quality & Regulatory Governments and regulators Areas of interest – Product safety. – Compliance with applicable legal and regulatory requirements. – Promotion of fair competition. – Social and economic concerns. How we engage – Updates are provided on our Global Compliance programme with applicable metrics and monitoring at each CCC meeting. – The Board and CCC receive updates on product quality and regulatory matters and compliance with applicable laws and regulations. – The Chief Executive Officer and other senior leaders engage through industry bodies such as AdvaMed, Medtech Europe and similar organisations in order to advocate for and provide perspectives on core issues which are of critical importance to the MedTech industry. – The Chief Executive Officer and senior management meet with governments and regulators, as applicable. 2023 Outcome/impact – The Chief Executive Officer and other senior leaders participated in a number of industry meetings and interest groups in order to drive issues of critical importance to both the organisation and the MedTech industry. – The CCC received reports on product and regulatory audits which provide comfort and confidence that product safety is being managed and maintained effectively. – The CCC and Board also receive updates from the Group General Counsel under legal privilege relating to any material legal matters of which the Board should be aware. Focus for 2024 – Board site visits and induction programmes will continue to include further information and on key areas of focus within ESG for the Company. – The Board will continue to engage with EIGs as appropriate on site visits and report on Board listening sessions. – The CCC will continue to track progress against key objectives and metrics in terms of transition plan and other objectives. – The Audit Committee will continue to review key disclosures and reporting obligations around sustainability risks. – The Remuneration Committee will continue to review key elements of ESG metrics for remuneration purposes. – Board members and the Company Secretary will continue to attend industry discussions on ESG matters of importance to the Company. » See pages 111–113 for Compliance & Culture Committee Environment and communities Areas of interest – Investment and innovation in local communities. – Understanding how the Company’s business impacts local communities and global business. How we engage – The Board approves the ESG Strategy annually and receives updates on core ESG initiatives at each meeting as appropriate. – Updates on performance and progress on key environment and social metrics are provided at each CCC meeting. – Updates on reporting and disclosures are included at each Audit Committee meeting. – Remuneration Committee determines ESG metrics for remuneration purposes liaising closely with the CCC to ensure that metrics are quantifiable and measurable. – The Chair, Chief Executive Officer and Company Secretary attend industry roundtable and panel discussions on ESG matters which impact the Company. 2023 Outcome/impact – At the Costa Rica site visit, the Board received detailed presentations on the environmental and community initiatives being undertaken by our employees locally and had direct engagement with members of our EIGs. – Proposed Remuneration Policy for 2024 includes ESG metrics for both short-term and long-term incentive plans. Engaging with our stakeholders continued 86 Smith+Nephew Annual Report 2023

GRAPHIC

Focus for 2024 – Continued focus at Board level on innovation pipeline and product portfolio to meet customer requirements. – Continued focus from the Board and its Committees on risk management and ensuring product quality, compliance with applicable laws and regulations and doing business the right way. – The Board will monitor ongoing network transformation initiatives and supply chain focus on excellence and productivity. – The Board and CCC will continue to focus on customer requirements in the area of People, Planet and Products. – See also Sustainability Report for further details on how we plan to continue to consider areas of importance to our customers. » See pages 111–113 for Compliance & Culture Committee Report Customers and suppliers 2023 Outcome/impact – Please see pages 26–29 on innovation highlighting initiatives designed to support unmet customer needs. – The Board and CCC received regular reports on quality audits as part of ongoing monitoring. – The CCC continues to monitor company response to new regulations impacting our products, quality and regulatory matters and FDA and other regulatory engagement and reports to the Board at each Board meeting. – Monitoring of supply chain and procurement matters is reviewed regularly by the Board with a focus on outcomes of the 12-Point Plan initiatives and metrics. – Please also see pages 9 and 45–47 of our Sustainability Report which highlight our customer and supplier focus. – Board review of our Sustainability Strategy ensures a clear link to stakeholders and issues of importance to customers. – The Board and CCC receive reports at each meeting on sustainability matters which take into account the views and requirements of our customers and in turn how we engage with our suppliers to reflect customer approach. Areas of interest – Innovation and improved outcomes. – Ensuring product quality, compliant with regulations and doing business the right way. – Partnering with suppliers to ensure business is done the right way. – ESG. How we engage – The Board reviews the portfolio strategy throughout the year, together with acquisition pipeline for key assets to accelerate innovation and respond to customer and patient unmet needs. – The Board and CCC are provided with updates on product quality, regulatory matters and complaints and legal, compliance and ethical matters. – We continue to work with our suppliers and explain our expectations in our Third-Party Guide to our Code of Conduct. – Our customers continue to focus on ensuring that ESG and sustainability are taken into account in our decision making aligned with their own policies and procedures. Further information about our relationship with other stakeholders, including the local communities in which we operate and the impact of climate change on our business, can be found in the Sustainability Report on pages 9 and 33. The Strategic Report comprising pages IFC–81 was approved by the Board on 26 February 2024. Deepak Nath, PhD Chief Executive Officer Smith+Nephew Annual Report 2023 87 STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION

GRAPHIC

Governance at a glance 1. Board leadership and Company purpose The Board’s primary focus is the long-term success of the Company. It ensures the right resources and culture are in place to deliver on its objectives, and is responsible for effective engagement with stakeholders. 2. Division of responsibilities The Board ensures a diverse balance of Executive and Non-Executive Directors with clear definition of their respective roles and responsibilities. Statement of Compliance The Board is committed to the highest standards of corporate governance. We comply with the provisions and principles of the UK Corporate Governance Code 2018 (2018 Code). The Company’s American Depositary Shares and bonds are listed on the New York Stock Exchange (NYSE) and we are therefore subject to the rules of the NYSE as well as to US securities laws and the rules of the Securities and Exchange Commission (SEC) applicable to foreign private issuers. We comply with the requirements of the NYSE and SEC and have no significant differences to report between the US and UK corporate governance standards. We explain in this ‘Governance’ section how we comply with and have applied the 2018 Code during the year. The 2018 Code can be found at www.frc.org.uk/getattachment/88bd8c45-50ea-4841-95b0-d2f4f48069a2/2018-UK-Corporate-Governance-Code-FINAL.pdf. We also explain how we have complied with the Financial Conduct Authority’s (FCA) Listing Rules and Disclosure & Transparency Rules (DTRs) throughout the year. In a world in which stakeholders have different, and sometimes conflicting, views on how, and to what end, companies should be run, Boards have to be resolute in discharging their responsibilities in the best interests of the Company as a whole.” Rupert Soames, OBE Chair »See pages 96–99 Board meeting attendance »See pages 84–87 and 90–95 Key Activities – Purpose and culture – Strategy and innovation – Operations and commercial excellence – Stakeholders – Risk and internal controls Board Audit Nomination & Governance Compliance & Culture Remuneration 94% 100% 88% 95% 96% This section provides an overview of our corporate governance structure, our policies and practices, as well as the key activities undertaken by the Board and its Committees to ensure effective leadership and the implementation of strong corporate governance at Smith+Nephew. 88 Smith+Nephew Annual Report 2023

GRAPHIC

3. Composition, succession and evaluation The Board maintains an appropriate balance of skills, experience and knowledge to ensure that it can discharge its responsibilities. The evaluation of Board performance and succession plans are crucial to ensure that the Board operates effectively. 5. Remuneration The Remuneration Committee designs policies and practices to support strategy and stability thereby promoting the long-term sustainable success of the Company. In doing so, it ensures these align with the remuneration and related policies across the Group’s workforce. 4. Audit, risk and internal control and Compliance and Culture The Audit Committee’s assurance that the financial reporting is fair, balanced and understandable is important for stakeholders to determine the Company’s performance. The Compliance & Culture Committee assists the Board in monitoring ethics and compliance, quality and regulatory, culture and sustainability matters across the Group. Board ethnicity Board tenure »See pages 121–154 »See pages 111–120 »See pages 102–110 Deepak Nath $4,658,252 Anne-Françoise Nesmes $2,059,946 Total remuneration 33.33% female 66.67% male Board gender diversity White British or other White (including minority-white groups) 9 Asian/Asian British 2 Not specified/prefer not to say 1 0-2 yrs 5 3-5 yrs 4 6+ yrs 3 Deepak Nath Anne-Françoise Nesmes Single figure remuneration Deepak Nath Anne-Françoise Nesmes Salary $1,512,726 $785,673 Pension & Benefits $65,000 $109,735 Bonus $1,997,124 $1,010,184 LTI Nil $154,354 Forfeited Incentives $1,083,402 Nil Employee engagement CEO Financial International Healthcare/Medical Devices Emerging Markets Cybersecurity ESG UK Governance Remuneration 67% 58% 42% 92% 58% 67% 58% 67% 58% 58% Board experience STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION Smith+Nephew Annual Report 2023 89

GRAPHIC

Rupert Soames Chair Appointed as an Independent Non-Executive Director in April 2023 and as Chair in September 2023 Board leadership and Company purpose Board of Directors Key skills and competencies: Rupert has extensive global leadership experience, a proven track record of delivering shareholder value and a deep understanding of UK corporate governance. Current external appointments: – Chair of the Confederation of British Industry. Previous experience: Rupert stepped down in December 2022 after nine years as Group Chief Executive from Serco Group plc, the specialist services business in Health, Defence, Transport and Immigration. Previously, he was Chief Executive Officer of Aggreko plc for 11 years and prior to that Chief Executive of Misys plc’s Banking and Securities Division. Rupert was Senior Independent Director and a member of the Audit, Remuneration and Nomination Committees for both DS Smith and Electrocomponents plc (now RS Group). Nationality: British Anne-Françoise Nesmes Chief Financial Officer Appointed Chief Financial Officer in July 2020 and stepping down from the Board in Q1 2024 Key skills and competencies: Anne-Françoise has worked as a senior finance executive in global FTSE listed companies for many years, which alongside a strong business acumen and deep sector knowledge provides her with the experience required to be part of the Smith+Nephew leadership team. She demonstrates a high competency for delivering operational excellence across different geographic markets and leading large teams who are responsible for significant budgets. She has an impressive and diverse background and her ability to translate financial insights into results helps guide Smith+Nephew. Current external appointments: – Senior Independent Director and Chair of the Audit Committee at Compass Group plc. Previous experience: Anne-Françoise joined GlaxoSmithKline plc in 1997 where she worked for 16 years, holding multiple senior finance roles including Senior Vice President, Global Vaccines. Anne-Françoise served as Chief Financial Officer for Dechra Pharmaceuticals plc in 2013 where she successfully implemented financial strategies to support the growth of the business. She was Chief Financial Officer of Merlin Entertainments Limited (formerly Merlin Entertainments plc) from 2016 to 2020, leaving after successfully completing the transaction to take the company private. Nationality: British/French Key skills and competencies: Marc is a proven leader with an astute strategic vision, capable of building significant international healthcare businesses. He has strong commercial healthcare expertise. Marc is responsible for ESG through his role as Chair of the CCC. Current external appointments: None. Previous experience: Marc commenced his healthcare and technology career at McKinsey & Company where he progressed to senior partner and eventually a founding partner of McKinsey’s Business Technology Office. In 2001, Marc joined McKesson Corporation and served as Executive Vice President and member of their Executive Committee. He delivered strategic objectives and led over 40 acquisitions and divestments over a 10-year period. In late 2011, he headed McKesson Speciality Health, which operates over 130 cancer centres across the US and provides market intelligence, supply chain services, patient access to therapy, provider and patient engagement and clinical trial support. In 2014, he was appointed Chair of the European Management Board at Celesio AG. He retired in March 2017 once he had improved operations, set the strategy and recruited his successor. Nationality: British/American Marc Owen Senior Independent Director Appointed Independent Non-Executive Director in October 2017 and Senior Independent Director in September 2022 N R Committee key Committee Chair Member of the Audit Committee Member of the Remuneration Committee Member of the Nomination & Governance Committee Member of the Compliance & Culture Committee C A R N C Deepak Nath Chief Executive Officer Appointed Chief Executive Officer in April 2022 Key skills and competencies: Deepak brings global leadership and risk-management expertise and has a track record of driving growth at major healthcare companies through delivering a significant improvement in execution and building a strong results-focused culture. Current external appointments: None. Previous experience: He began his career as a scientist in computational physics at Lawrence Livermore National Laboratory and holds a BSc and MSc in Mechanical Engineering and a PhD in Theoretical Mechanics from the University of California, Berkeley. Prior to joining Siemens Healthineers, he held roles at both Amgen and McKinsey and spent 10 years at Abbott Laboratories, Inc. culminating in his appointment as President of Abbott Vascular. At Siemens Healthineers (2018–2022) he was President of the Diagnostics business responsible for $6 billion of revenue and 15,000 employees. Nationality: American A C N 90 Smith+Nephew Annual Report 2023

GRAPHIC

Erik Engstrom Independent Non-Executive Director Appointed Independent Non-Executive Director in January 2015. Stepped down from the Board on 31 December 2023 Key skills and competencies: Erik has successfully reshaped RELX Group’s business in terms of portfolio and geographies. He brings a deep understanding of how technology can be used to transform a business and insight into the development of new commercial models that deliver attractive economics. His experience as a Chief Executive Officer of a global company gives him valuable insights as a member of our Audit and Nomination & Governance Committees. Current external appointments: – Chief Executive Officer of RELX Group. Previous experience: Erik commenced his career at McKinsey & Company and then worked in publishing, latterly as President and Chief Operating Officer of Random House Inc. and as President and Chief Executive Officer of Bantam Doubleday Dell, North America. In 2001, he moved on to be a partner at General Atlantic Partners, a private equity investment firm. Between 2004 and 2009, he was Chief Executive Officer of Elsevier, the division specialising in scientific and medical information and then from 2009 Chief Executive Officer of RELX Group, the division specialising in scientific and medical information and then from 2009 Chief Executive Officer of RELX Group. Nationality: Swedish Jo Hallas Independent Non-Executive Director Appointed Independent Non-Executive Director in February 2022 Key skills and competencies: Jo has extensive international experience focused on business transformation through both organic and acquisitive growth in global industrial and consumer sectors. She brings valuable expertise which will help Smith+Nephew build upon and achieve our strategic ambitions. Current external appointments: None. Previous experience: Jo commenced her career at Procter & Gamble based in Germany, the US, Thailand and the Netherlands. She then joined Bosch where she held a business unit leadership role in their Power Tools division followed by Invensys in 2009 where she ran their global heating controls business unit including launching its first smart home offer. She then moved to Spectris plc, where she had responsibility for a portfolio of global industrial technology businesses, as well as for the Group’s digital strategy. From April 2019 to April 2023, Jo served as Chief Executive Officer for Tyman plc where she made sustainability a core foundation of the group’s strategy. Jo was also previously Chair of the Remuneration Committee for Norcros plc. Nationality: British John Ma Independent Non-Executive Director Appointed Independent Non-Executive Director in February 2021 Key skills and competencies: John has an impressive track record in medical device businesses and his contribution provides value as Smith+Nephew continues to develop innovative ways to grow and serve our markets with a focus towards Asia Pacific regions. He is an established healthcare leader and has strong experience of driving market entry and growth within emerging markets. Current external appointments: – Founder, Chair and Chief Executive of Ronovo Surgical. Previous experience: In 2000, John joined GE Healthcare and became Vice President and General Manager of their Global Product Company in China. John has also held a number of senior positions as President of Asia Pacific regions at Pentair Inc., Vice President of Express Scripts Inc., and Global Partner of Fosun Group. He initially joined Fosun Pharma to lead their medical device business and in 2014 became President of Fosun Healthcare Holdings. He served as a key member of their healthcare investment committee which went on to establish a global presence across the US, Europe, Israel and China. In 2017, John joined Intuitive Surgical as their Senior Vice President of Strategic Growth Initiatives. He has previously served as a NED for both Haier Electronics Group and Clinical Innovations LLC. Nationality: American Katarzyna Mazur-Hofsaess Independent Non-Executive Director Appointed Independent Non-Executive Director in November 2020 Key skills and competencies: Katarzyna demonstrates a true passion for customer focus and maintains an impressive track record in senior leadership within the MedTech industry. She is a qualified medical doctor (PhD) and has a wealth of experience in medical devices and orthopaedic sectors. Her Chief Executive Officer experience of a global company and valuable industry knowledge will help drive innovation and ensure the continued development of Smith+Nephew. Current external appointments: – Chief Executive Officer, Care Enablement (MedTech segment), at Fresenius Medical Care AG and a member of the Management Board. Previous experience: Katarzyna commenced her corporate career at Roche in Poland, was later recruited by Abbott Laboratories to manage their diabetes care division in Poland and became Country General Manager. Her career progressed to General Manager of Molecular Diagnostics Division for EMEA and eventually to Divisional Vice President Abbott Diagnostics for Europe. In 2010, she became President EMEA region at Zimmer, following the Biomet acquisition and led the integration in the region and served as President EMEA for Zimmer Biomet, leading orthopaedic company. In 2018, she joined Fresenius Medical Care, the renal company, as CEO EMEA and Member of the Management Board. Effective January 2022, Katarzyna took over responsibility for the globally operating Care Enablement segment in which Fresenius Medical Care AG has consolidated its €5.5 billion healthcare products business into one MedTech organization. Her responsibility includes research and development, quality and regulatory, manufacturing, supply chain and commercial operations. Nationality: German/Polish A N A C C STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION Smith+Nephew Annual Report 2023 91

GRAPHIC

A R Board leadership and Company purpose continued Board of Directors continued Angie Risley Independent Non-Executive Director Appointed Independent Non-Executive Director in September 2017 Bob White Independent Non-Executive Director Appointed Independent Non-Executive Director in May 2020 Key skills and competencies: Angie has gained experience in a wide range of sectors, including a regulated environment. This diversity of experience is welcomed by the Board and the Remuneration Committee. Angie is also an additional resource and sounding board for Smith+Nephew’s own internal Human Resources function. Current external appointments: – Non-Executive Director and Chair of the Remuneration Committee at InterContinental Hotels Group plc. Previous experience: From 2007 to 2013 Angie was the Group HR Director for Lloyds Banking Group and was Group HR Director of Sainsbury plc and a member of their Operating Board from January 2013 to May 2023. Over the years, Angie has been a member of the Low Pay Commission and has held a number of Non-Executive Directorships with Biffa plc, Arriva and Serco Group plc. At Serco Group plc she was the Chair of the Remuneration Committee. Previously she has attended Remuneration Committees of Whitbread plc and Lloyds Bank. Nationality: British Key skills and competencies: Bob is an experienced leader with more than 25 years’ worth of industry relevant experience. He is an influential and well-known figure in the medical technology sector and has an impressive track record in delivering growth and fostering innovation. He brings valuable global medical technology insight to the Board, which will prove fundamental in helping to shape and develop the future strategic direction of Smith+Nephew healthcare expertise. Current external appointments: None Previous experience: Bob has held a number of senior Vice President positions throughout his career, most recently as Executive Vice President and President at Medtronic plc. He was also senior Vice President at Chemdex Corporation, Accelrys Inc., SourceOne Healthcare Technologies, Inc., GE Healthcare and Covidien as President for Emerging Markets and President for Respiratory and Monitoring Solutions. He then became Senior Vice President and President of Medtronic Asia Pacific, having led the integration of Covidien Asia Pacific when it was acquired by Medtronic plc in 2015. Nationality: American C R Rick Medlock Independent Non-Executive Director Appointed Independent Non-Executive Director in April 2020. Stepping down as Chair of the Audit Committee on 1 March 2024 and will not submit for re-election at the AGM Jez Maiden Independent Non-Executive Director Appointed Independent Non-Executive Director in September 2023 and as a member of the Audit and Remuneration Committee. Will become Chair of the Audit Committee from 1 March 2024 Key skills and competencies: Rick has extensive experience and a deep understanding of technology focused R&D businesses. He has driven value and transformation throughout his executive career which will further reinforce the ability of Smith+Nephew to grow and develop into new and existing markets. Rick brings significant financial and risk management expertise as a well-regarded former FTSE 100 Chief Financial Officer, NED and Audit Committee Chair. Current external appointments: – NED and member of the Audit, Risk and Compliance Committee at Datatec Ltd. – NED and Chair of the Audit Committee at Deliveroo. – NED and Chair of the Board at British Engineering Services Limited. – NED and Chair of the Board at Alaska TopCo Limited, the parent company of Nomentia Oy (the software cash and treasury solutions provider). Previous experience: Rick has had a highly successful career as a strong commercial Chief Financial Officer in the technology industry, working for a range of international FTSE 100 and NASDAQ listed businesses during periods of high growth. He has held a number of Chief Financial Officer positions throughout his career, including at NDS Group plc, Inmarsat plc and Worldpay Group plc. Rick brings a wealth of experience as a former NED and Audit Committee Chair of several technology driven businesses, such as Sophos Group plc, Edwards Vacuum, and Thus plc. Rick was also previously Chair of BluJay Solutions Ltd, Chair of Momondo Group and Chair of the Audit Committee for LoveFilm UK Limited. Nationality: British Key skills and competencies: Jez has extensive financial experience across a diverse range of industries and sectors. Jez brings more than 15 years of global experience both as a FTSE Chief Financial Officer and as a Non-Executive Director on boards of companies addressing strategic and operational challenges across a number of different industries, including life-sciences and healthcare. He has had oversight of large operations in the US, Europe and Asia in highly regulated industries. Current external appointments: – Senior Independent Director, Travis Perkins plc. – Non-Executive Director and member of the Audit Committee at Intertek Group plc. Previous experience: Jez retired in 2023 as Group Finance Director at Croda International plc, the FTSE 100 global speciality chemicals company, and previously held similar roles at National Express Group plc and Northern Foods Limited. He has served as the Senior Independent Director at Synthomer PLC and at both PZ Cussons plc and Synthomer PLC he chaired the Audit Committee and served on the Remuneration Committee. He is a fellow of the Chartered Institute of Management Accountants. Nationality: British A C R N 92 Smith+Nephew Annual Report 2023

GRAPHIC

Key skills and competencies: Helen is a qualified Solicitor admitted in England & Wales and a Chartered Governance Professional. She also serves as the Chief Risk Officer for Smith+Nephew. Previous experience: Helen started her career with Allen & Overy LLP and prior to joining Smith+Nephew held senior legal roles at WPP plc and Nomura International plc. Nationality: British John Rogers Chief Financial Officer Designate Joining the Board as Chief Financial Officer in Q1 2024 Key skills and competencies: John has extensive financial and commercial leadership experience across a range of sectors and on a global basis, as well as a track record of delivering complex international transformation programmes. Current external appointments: – Non-Executive Director of Grab Holdings Limited. Previous experience: He has served as the Chief Financial Officer at WPP plc, where he successfully led the implementation of their global transformation programme, and as Chief Financial Officer at J Sainsbury plc where he also served as Chief Executive Officer of Argos, Habitat and Sainsbury’s clothing and general merchandise businesses. Nationality: British Directors who have joined the Board since 31 December 2023 Simon Lowth Independent Non-Executive Director Appointed as Independent Non-Executive Director on 1 January 2024 Key skills and competencies: Simon has extensive experience in finance, accounting, risk, corporate strategy as well as mergers and acquisitions and brings a wealth of expertise across a wide range of sectors, including within regulated industries. Having served as the CFO in four FTSE 100 companies, he has deep experience of capital markets, implementing strategic change, cost transformation and performance improvement programmes as well as understanding how technology can be used to transform a business. Current external appointments: – Group Chief Financial Officer of BT Group. Previous experience: Simon was previously Group Chief Financial Officer at AstraZeneca and Scottish Power. Before joining Scottish Power, he led the Industrial Practice of McKinsey in the UK. He previously served as a Non-Executive Director on the Board of Standard Chartered. Nationality: British A N Helen Barraclough Group General Counsel and Company Secretary Appointed Company Secretary in April 2022 Board member whose tenure ceased during the year Roberto Quarta, Chair, stepped down from the Board on 15 September 2023. STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION Smith+Nephew Annual Report 2023 93

GRAPHIC

» See page 90 for CEO and CFO biographies Mizanu Kebede Chief Quality & Regulatory Affairs Officer Nationality: American Location: Georgia, US Mizanu brings more than 20 years of leadership experience in Quality and Regulatory Affairs. Prior to Smith+Nephew, Mizanu held senior roles at Avanos Medical, Life Technologies Corporation, Johnson & Johnson and STERIS Corporation. Phil Cowdy Chief Corporate Development & Corporate Affairs Officer Nationality: British Location: Watford, UK Prior to joining Smith+Nephew, Phil served as a senior Director at Deutsche Bank AG for 13 years specialising in corporate finance and equity capital markets. Phil serves as the representative of Smith+Nephew on the Board of Bioventus Inc. Rohit Kashyap President Advanced Wound Management and Global Commercial Operations Nationality: American Location: Fort Worth, US Rohit brings more than 20 years’ experience across wound care, surgical management, business development and global commercial leadership. Prior to joining Smith+Nephew, Rohit worked at Acelity, a global advanced wound care company, most recently as President, Global Commercial and at MIMEDX as President of the Wound and Surgical business and as Chief Commercial Officer. Executive Committee The CEO, with support from the CFO, leads the Executive Committee of Smith+Nephew which is responsible for the day-to-day operational management of the Group and executing its strategy. Brad Cannon President Orthopaedics & Americas Nationality: American Location: Andover, US Brad brings more than 25 years of experience across medical devices and medtech. Prior to Smith+Nephew, Brad worked in Medtronic plc’s Spine and Biologics division and previously served as Chief Marketing Officer and President of Europe and Canada at Smith+Nephew. Paul Connolly President Global Operations Nationality: American/Irish Location: Andover, US Paul brings more than 30 years of global manufacturing and supply chain experience at multinational companies with a strong track record in delivering operational excellence and transformation programmes. Prior to joining Smith+Nephew, Paul held senior roles at Goodyear, DePuy, Inc., and other Johnson & Johnson family companies. Board leadership and Company purpose continued 94 Smith+Nephew Annual Report 2023

GRAPHIC

Vasant Padmanabhan President Research & Development and ENT Nationality: American Location: Andover, US Vasant has over 25 years of global med-tech leadership experience. Prior to Smith+Nephew, Vasant held senior roles at Thoratec Corporation and Medtronic plc as Vice President of Connected Care R&D and Operations and Vice President of Product Development for the Implantable Defibrillator Business. Helen Barraclough Group General Counsel and Company Secretary Nationality: British Location: Watford, UK Prior to joining Smith+Nephew, Helen started her career at Allen & Overy LLP and held senior roles at WPP plc and Nomura International plc. She is a qualified Solicitor admitted in England & Wales and a Chartered Governance Professional. She also serves as the Chief Risk Officer for Smith+Nephew. Alison Parkes Chief Compliance Officer Nationality: British Location: Hull, UK Prior to moving into her current role, Alison served as the Compliance Officer for the Global Advanced Wound Management business, APAC and Emerging Markets and established and led the Global Compliance Programme Effectiveness & Improvement team. Scott Schaffner President Sports Medicine Nationality: American Location: Austin, US Scott has more than 30 years experience across the medical device industry, including cardiac rhythm management, neuromodulation, spine, and sports medicine. Prior to moving into his current role, Scott served as Executive Vice President, Global Marketing and US Commercial, Sports Medicine, Senior Vice President, Global Marketing, Sports Medicine and Vice President, Sports Medicine. Elga Lohler Chief HR Officer Nationality: American/South African Location: Fort Worth, US Prior to joining Smith+Nephew, Elga held Human Resources roles at Transnet SOC Ltd, Sensormatic (now Tyco International plc) and Advanced Tissue Sciences, Inc. (acquired by Smith+Nephew in 2002). Executive Officers whose tenures ceased and recent appointments Simon Fraser, President Advanced Wound Management and Global Commercial Operations, served until 2 June 2023. Myra Eskes, President APAC Region, served until 1 November 2023. Brad Cannon, President Orthopaedics & Americas, served until 4 March 2024. Craig Gaffin was appointed President Orthopaedics effective as of 4 March 2024. STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION Smith+Nephew Annual Report 2023 95

GRAPHIC

Company Secretary Helen Barraclough – Supports the Chair and ensures Board members have access to the information required to perform their duties. – Advises the Board on legal and corporate governance matters and supports the Board in applying the 2018 Code and complying with UK listing obligations, and other statutory and regulatory requirements. – Provides a channel for Board and Committee communications and a link between the Board and management. Chief Financial Officer Anne-Françoise Nesmes – Supports the Chief Executive Officer in developing and implementing Group strategy. – Responsible for ensuring effective financial reporting, investor relations, tax, treasury and financial controls are in place within the Group. – Provides information and participates in Board discussions regarding financial matters. – Leads global finance function, developing key finance talent and succession planning. Chief Executive Officer Deepak Nath – Responsible for delivering and implementing Group strategy and management of the organisation as a whole. Provides information and participates in Board discussions regarding Group management and operational matters. – Leads the Executive Committee and ensures its effectiveness in managing the overall operations and resources of the Group. – Sets tone at the top with regard to culture, compliance and sustainability matters. – Ensures the Chair and Board are updated regularly regarding key matters and maintains relationships with shareholders, advising the Board accordingly. Senior Independent Director Marc Owen – Acts as a sounding board for the Chair and as an intermediary for other Directors and stakeholders as necessary. – As a member of the Nomination & Governance Committee, leads the Board evaluation process and searches for Chair and Independent Non-Executive Directors to ensure effective succession. – Acts as an alternative contact for stakeholders to raise concerns (in addition to Chair and senior management). Chair Rupert Soames – Responsible for the effective leadership and operation of the Board and for facilitating the review of its composition, effectiveness and development. – Promotes effective board relationships, encouraging constructive challenge and facilitating effective communication between Board members and supporting a culture of openness, challenge and debate. – Ensures that the Board understands the views and needs of the Company’s stakeholders and facilitates effective communication and dialogue, whilst maintaining an appropriate balance between stakeholders. – Leads relations with shareholders in order to understand their views on governance and performance against strategy. – Responsible for promoting high standards of governance by the Board and its Committees. The Chair achieves this through effective chairing of Board meetings; setting a board agenda which focuses on strategy, performance, value creation, risk management, culture, stakeholders and accountability; enabling an annual review of Board effectiveness; holding discussions with Board members both inside and outside the boardroom and ensuring appropriate Board induction and development programmes are in place. Division of responsibilities Roles and composition of the Board Independent Non-Executive Directors Jo Hallas, John Ma, Katarzyna Mazur-Hofsaess, Erik Engstrom, Jez Maiden, Rick Medlock, Angie Risley and Bob White – Comprise more than half of Board membership in order to meet the independence criteria set out in the 2018 Code. – Ensure that no individual/ small group can dominate the Board’s decision making. – Provide constructive challenge, give strategic guidance, offer specialist advice and hold executive management to account. 96 Smith+Nephew Annual Report 2023

GRAPHIC

At the opening and close of each Board meeting, the Full Board meets for a short closed session discussion. At the end of each Board meeting, the Chair meets with Non-Executive Directors in the absence of the Executive Directors. The Chair also holds one to one discussions with each Board member throughout the year. Independence of Directors We require our Non-Executive Directors to remain independent from management so that they are able to exercise independent oversight and effectively challenge management. We therefore continually assess the independence of each of our Non-Executive Directors. The Executive Directors have determined that all our Non-Executive Directors are independent in accordance with both UK and US requirements. None of our Non-Executive Directors or their immediate families has ever had a material relationship with the Group. None of them receive additional remuneration apart from Directors’ fees, nor do they participate in the Group’s share plans or pension schemes. None of them serve as directors of any companies or affiliates in which any other Director is a director. The Board considers all external directorships prior to appointment, reviewing any potential conflict of interests and time commitment for both Executive Directors and Non-Executive Directors. Management of conflicts of interest None of our Directors or their connected persons, has any family relationship with any other Director or Officer, nor has a material interest in any contract to which the Company or any of its subsidiaries are, or were, a party during the year or up to 16 February 2024. Each Director has a duty under the Companies Act 2006 to avoid a situation in which they have or may have a direct or indirect interest that conflicts or might conflict with the interests of the Company. This duty is in addition to the existing duty owed to the Company to disclose to the Board any interest in a transaction or arrangement under consideration by the Company. If any Director becomes aware of any situation which might give rise to a conflict of interest, they must, and do, inform the rest of the Board immediately and the Board is then permitted under the Company’s Articles of Association to authorise such conflict. This information is then recorded in the Company’s Register of Conflicts, together with the date on which authorisation was given. In addition, each Director certifies on an annual basis that the information contained in the Register of Conflicts is correct. When the Board decides whether or not to authorise a conflict, only the Directors who have no interest in the matter are permitted to participate in the discussion and a conflict is only authorised if the Board believes that it would not have an impact on the Board’s ability to promote the success of the Company in the long term. Additionally, the Board may determine that certain limits or conditions must be imposed when giving authorisation. No actual conflicts have been identified, which have required approval by the Board. However, the situations that could potentially give rise to a conflict of interest have been identified and duly authorised by the Board and are reviewed at least on an annual basis. Outside directorships We encourage our Executive Directors to serve as Non-Executive Directors of external companies. We believe that the work they do as Non-Executive Directors of other companies has benefits for their executive roles with the Company, giving them a fresh insight into the role of a Non-Executive Director. Anne-Françoise Nesmes is the Senior Independent Director and Chair of the Audit Committee at Compass Group plc which is listed on the London Stock Exchange. Re-appointment of Directors In accordance with the 2018 Code, all Directors offer themselves to shareholders for re-election annually, except those who are retiring immediately after the Annual General Meeting. Each Director may be removed at any time by the Board or the shareholders. Board support Together with the Chief Executive Officer and the Group General Counsel and Company Secretary, the Chair ensures that the Board is kept properly informed. Each Director has access to the Group General Counsel and Company Secretary, who helps to ensure that Board procedures and good corporate governance practices are followed. Directors are permitted to take independent professional advice at the Company’s expense if required in order to enable them to fulfil their duties. Each Director is covered by appropriate directors’ and officers’ liability insurance and there are also Deeds of Indemnity in place between the Company and each Director. These Deeds of Indemnity mean that the Company indemnifies Directors in respect of any proceedings brought by third parties against them personally in their capacity as Directors of the Company. The Company would also fund ongoing costs in defending a legal action as they are incurred rather than after judgment has been given. In the event of an unsuccessful defence in an action against them, individual Directors would be liable to repay the Company for any damages and to repay defence costs to the extent funded by the Company. STRATEGIC REPORT GOVERNANCE ACCOUNTS OTHER INFORMATION Smith+Nephew Annual Report 2023 97

GRAPHIC

Division of responsibilities continued Corporate governance framework Our Board The Board is accountable to shareholders for the performance and long-term sustainable success of the Company. It approves the strategy of the Group, evaluates and monitors the management of risk, and oversees the implementation of the strategy in order to achieve sustainable growth. The Board delegates certain matters to the Audit, Remuneration, Nomination & Governance and Compliance & Culture committees which support the Board in carrying out its responsibilities. Full details of the Matters Reserved to the Board can be found on the Company’s website. www.smith-nephew.com Finance & Banking Committee A Committee comprising senior executives which approves banking and treasury matters, guarantees and Group structure changes relating to mergers, acquisitions and disposals. Disclosures Committee A Committee comprising senior executives which oversees and approves public announcements and communications to investors and Stock Exchanges. Reviews communications and reporting requirements in respect of market sensitive information. Compliance & Culture Committee »pages 111–113 Reviews and monitors and has oversight of ethics and compliance, quality and regulatory, culture, sustainability matters and metrics, stakeholder relationships and related legal matters across the Group. Audit Committee »pages 114–120 Ensures the integrity of the Company’s financial reporting, systems and controls. Oversight of risk management process. Reviews and monitors climate change disclosures and related ESG financial reporting obligations. Monitors the Group’s cyber resilience. Ensures effectiveness of internal and external audit functions. Nomination & Governance Committee »pages 102–110 Reviews size, skills, experience, knowledge and composition of the Board, succession planning, diversity and governance matters. Remuneration Committee »pages 121–154 Determines Remuneration Policy and packages for Executive Directors and senior management, having regard to pay across our workforce. Ensures reward strategy aligns with our purpose, values and long-term strategy. Executive Committee »pages 94–95 The Board delegates the day-to-day operational management and implementation of Group strategy to the Chief Executive Officer and Executive Committee). The Executive Committee recommends, and following Board approval, implements strategy, budget and three-year strategic plan within the Group. It ensures cross-functional alignment in order to deliver on strategy and reviews major investments, divestments and capital expenditure proposals. The Executive Committee also focuses on people and organisational culture, reviewing recruitment, attrition and development initiatives within the Company and developing and monitoring succession planning and talent pipeline below Board level. The Executive Committee meets at least 10 times per year to review commercial and operating results against budget, key initiatives, KPIs and performance metrics aligned to deliver Group strategy. The Executive Committee forms sub-committees including those listed below: Group Ethics & Compliance Committee ESG Operating Committee Mergers & Acquisitions Investment Committee Global Benefits Committee 12-Point Plan Steering Committee Global Crisis Management Team New Product Development Review Committee Inclusion, Diversity and Equity Council Security and Privacy Steering Committee 98 Smith+Nephew Annual Report 2023

GRAPHIC

Board and Committee attendance Total meetings Board WIP Audit Remuneration Nomination & Governance Compliance & Culture Attendees Appointed 8 7 9 6 4 Roberto Quarta1 December 2013 4/5 – 4/5 3/4 – Rupert Soames2 April 2023 6/6 – 6/6 4/5 – Deepak Nath April 2022 8/8 – – – – Erik Engstrom3 January 2015 8/8 7/7 – 5/6 – Jez Maiden4 September 2023 3/3 3/3 4/4 – – John Ma5 February 2021 7/8 – – – 4/4 Katarzyna Mazur-Hofsaess6 November 2020 7/8 – – – 3/4 Rick Medlock7 April 2020 7/8 7/7 – – – Anne-Françoise Nesmes July 2020 8/8 – – – – Marc Owen October 2017 8/8 7/7 – 6/6 4/4 Angie Risley8 September 2017 7/8 – 9/9 6/6 4/4 Bob White May 2020 8/8 – 9/9 – 4/4 Jo Hallas February 2022 8/8 7/7 – – – 1 Roberto Quarta stepped down from the Board on 15 September 2023 and of the five meetings held during his tenure in 2023, he was unable to attend the Board meeting in April as he was recuperating from a surgical procedure. Roberto was unable to attend the Nomination & Governance Committee meeting in August and the Remuneration Committee Meeting in February due to travel disruption. 2 Rupert Soames was appointed as an Independent Non-Executive Director and Chair Designate on 26 April 2023. Rupert was unable to join the Nomination & Governance Committee in July due to a pre-existing commitment prior to appointment as Chair Designate. 3 Erik Engstrom retired from the Board on 31 December 2023. Erik was unable to join the Nomination & Governance Committee in October due to executive management commitments. 4 John Ma was unable to attend the July Board meeting due to travel disruption. 5 Jez Maiden was appointed to the Board as an Independent Non-Executive Director and a member of the Audit and Remuneration Committees on 14 September 2023. 6 Katarzyna Mazur-Hofsaess was not in attendance at the December Board meetings due to a prior statutory commitment. She provided comments to the Chair in advance of the meeting. 7 Rick Medlock was not in attendance at the January Board Meeting due to a prior professional commitment. He provided his comments to the Chair in advance of the meeting. 8 Angie Risle